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GENERAL INTRODUCTION
Congenital diaphragmatic hernia or CDH is a developmental defect of the dia-
phragm that allows abdominal organs, such as intestines and liver, to herniate into 
the thoracic cavity during lung development. CDH has a prevalence of 1 in 2000 
– 3000 newborns and accounts for approximately 8% of the known major congenital 
anomalies 1. In humans, three different types of hernia can be distinguished: a pos-
terolateral Bochdalek-type (~70% of the cases), an anterior Morgagni-type (~27% 
of the cases) and a central hernia, septum transversum-type (~2 – 3% of the cases). 
Eighty-fi ve percent of the hernias occur on the left side, 13% on the right and only 2% 
bilateral (reviewed in 2-4). Children with a CDH suffer from a substantial amount of 
morbidity and mortality due to the associated abnormal pulmonary development 
resulting in two clinical problems, pulmonary hypoplasia and persistent pulmonary 
hypertension of the neonate (PPHN). Characteristics of pulmonary hypoplasia in 
CDH are thickened alveolar walls, an increase in interstitial tissue, reduced alveolar 
air spaces and reduced gas-exchange surface area. Apart from the gas exchange 
layer, well-documented changes are present in the vascular components consisting 
of media hyperplasia, peripheral muscularization of pre-acinar vessels and adventi-
tial thickening. Both conditions are present in patients with CDH to a variable extent 
and despite the fact that recent progress in the care of these children has resulted in 
survival rates of up to 90% in some tertiary care centers, these measures have not led 
to a lower morbidity 5-7. In contrast, due to the absence of suffi cient lung-protective 
strategies, most of the newer treatment modalities have replaced mortality for a 
higher morbidity in these babies. The problem with these new treatment modalities, 
such as high frequency oscillation (HFO) and/or inhaled nitric oxide (NO) and ex-
tracorporeal membrane oxygenation (ECMO), is that they are designed for treating 
the sequelae of CDH, pulmonary hypoplasia and PPHN and do not contribute to the 
prevention of these conditions. Prenatal modulation by minimal invasive techniques 
such as tracheal occlusion may potentially lead to diminished need of supportive 
care postnatally by inducing lung growth 8. However, a sound understanding of 
the etiology and pathogenesis of CDH is necessary in order to prevent the severe 
morbidity or the anomalies altogether. Essential elements required for a better 
understanding, such as how the different clinical problems relate to each other, are 
still lacking. A basic understanding of CDH together with pulmonary hypoplasia and 
PPHN is fundamental in our quest for new answers to protect these children from the 
sequelae of this anomaly.
Consequently, the aim of this dissertation was to improve our understanding of the 
pathogenesis of pulmonary hypoplasia in CDH, to eventually aid in fi nding ways to 
modulate the natural course in a prenatally diagnosed child.
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OUTLINE OF THE DISSERTATION
As stated above, the pathogenesis and etiology of CDH and its associated anomalies 
are still largely unknown despite all research efforts over the past years. Several 
animal models are available to study CDH, including the nitrofen rodent model, a 
surgical lamb or rabbit model and multiple genetic mouse models. In Chapter 2 we 
discuss the strengths and limitations of these three main models, and their relevance 
to the human situation.
Previously, the associated pulmonary hypoplasia was interpreted as a result of the 
‘compression’ of the developing lung by herniated abdominal organs. A decade ago, 
pulmonary hypoplasia was found to be present before the closure of the diaphragm, 
which prompted the foundation of the dual-hit hypothesis 9, 10: pulmonary hypopla-
sia was not solely caused by the herniated organs but also present due to an intrinsic 
defect of the lung itself. Subsequently, research focused on the intrinsic defect. One 
of the main questions of this intrinsic pulmonary defect is which of the two major 
tissue layers, epithelium or mesenchyme, is affected? In Chapter 3 we utilize an in 
vitro recombinant model for pulmonary hypoplasia to answer this question.
In order to decipher the exact pathogenesis of developmental diseases, it is neces-
sary to understand the physiology of normal, healthy development. In Chapter 4 we 
describe the infl uence of developmental stage on epithelial-mesenchymal interac-
tions during normal fetal rat lung development.
In Chapter 3 we established that fi broblasts are the primary malfunctioning tissue 
layer, which disturbs the normal epithelial-mesenchymal interactions necessary for 
proper lung development. The origin of these cells however is unknown. Recently, 
a new theory involving cell transformations has arisen to explain both normal mor-
phogenesis and the development of diseases such as fi brosis and malignancies 11-15. 
Epithelial-mesenchymal transition (EMT) is the transformation of an epithelial cell 
into a mesenchymal (fi broblast) cell. One explanation for the origin of the defective 
fi broblasts could be this process (pilot study in Chapter 5).
Translational research is necessary to validate the results of fundamental research in 
the clinical setting. While CDH animal models have generated new hypotheses of 
human CDH and its associated anomalies, tissue availability to test these hypotheses 
has decreased dramatically 16-19. Both the improved survival and decrease in permis-
sion to perform full autopsy can be accounted for this. In 2001 a new protocol was 
instituted in our hospital to increase the accrual of CDH lung tissue via a quick and 
minimal invasive method: postmortem lung biopsy through a mini-thoracotomy. In 
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Chapter 6 we describe how we were able to quadruple the accrual of human lung 
tissue for both diagnostic and translational research.
CDH consists of two major defects: the diaphragmatic hernia itself and the associ-
ated lung anomalies. It is very likely that these two defects share the same original 
insult: the ‘two defects, one origin’-theory. The retinoic acid pathway has been 
implicated in the pathogenesis of CDH. Several transcription factors involved in the 
retinoic acid pathway have been described in both the diaphragm and lungs, such 
as COUP-TFII and GATA4. In addition, these factors are located on chromosome 
regions commonly deleted in individuals with CDH, which supports a similar orginal 
insult 20-22. In normal organogenesis, vessel development is a prerequisite. The Von 
Hippel-Lindau (VHL) pathway is a pathway important for angiogenesis and vessel 
function. In human CDH lungs, disruptions in the VHL pathway were observed 
previously 23-26. To investigate this pathway in the human diaphragmatic situation, 
we investigated the VHL pathway in diaphragmatic tissues from patients with CDH 
(Chapter 7).
In Chapter 8 we discuss our major fi ndings and future perspectives, and Chapter 9 
summarizes this dissertation in both English and Dutch.
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INTRODUCTION
Congenital diaphragmatic hernia (CDH) occurs in one in 3000 newborns. Mortal-
ity and morbidity are due to the amount of pulmonary hypoplasia, the response to 
artifi cial ventilation and the presence of therapy resistant pulmonary hypertension. 
The pathogenesis and etiology of CDH and its associated anomalies are still largely 
unknown despite all research efforts over the past years. Several animal models have 
been proposed to study CDH. The main animal models available to study CDH are 
the surgical rabbit or sheep model, the pharmacological (nitrofen) rat or mouse 
model, and the genetic (knockout) mouse model. In this chapter we will describe 
these three models and discuss their strengths and limitations to study pulmonary 
hypoplasia, and we will address their differences and discuss the relevance for hu-
man CDH.
SURGICAL MODELS
One of the hypotheses of the pathogenesis of pulmonary hypoplasia in CDH is that 
intrathoracic herniation of the abdominal viscera results in compromised pulmo-
nary development. Fetal breathing movements are impaired and, therefore, normal 
development of the lungs is hampered. Based on this idea, the fi rst surgical animal 
models were created to study both lung pathogenesis and rescue options. The most 
commonly used surgical models are in sheep and rabbits.
The sheep model was introduced by Delorimier in 1967 1. The hernia is surgically 
created at gestational day 72 – 75 (term is 145 – 149 days). The abdominal bowel is 
positioned into the chest to optimally mimic human CDH. Gestational day 72 – 75 in 
sheep is equivalent to a gestational age of 10 weeks in humans. This is the pseudo-
glandular stage of lung development: the moment of pleuroperitoneal canal fusion 
during diaphragmatic development 2. Later, a similar surgical model was developed 
in rabbits. Advantages of the rabbit model over sheep are its shorter gestational 
period (term is 31 days, the hernia is created at day 23), the larger litter size, easy 
availability and lower costs 3, 4.
Surgical models are mainly suitable to investigate interventional strategies in CDH. 
Examples of investigated interventions are the administration of corticosteroids, 
retinoic acid or growth factors, in utero repair of the diaphragmatic defect and fetal 
tracheal occlusion or a combination of the two 5-10. In utero repair has been attempted 
with either closure of the defect by using a patch (immediate reduction) or by using 
the slow ‘silo’ reduction technique in which the opening gradually reduces as the 
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fetus grows 11-13. After successful in utero repair of induced CDHs in animal models, 
including in non-human primates, Harrison et al. performed the fi rst human surgical 
repair in utero. Unfortunately, it quickly became clear that there was no improve-
ment in survival and moreover, an increase in premature delivery was observed 12.
Later, tracheal ligation or clipping was developed with the aim to gradually reposi-
tion the abdominal viscera back into the abdomen 14-16. The rationale was based on 
the observation that children with a prenatal airway obstruction have hyperplastic 
lungs 17. Preventing lung fl uid effl ux exerts a build-up pressure in the thoracic cavity 
that repositions the abdominal viscera back in the abdomen. Di Fiori et al. demon-
strated that tracheal ligation reversed the effects of surgically induced pulmonary 
hypoplasia in the sheep model 15. Unfortunately, results of human trials on this ex-
utero intrapartum treatment (EXIT) technique with clipping were disappointing even 
when a minimal invasive approach was used. Again premature delivery appeared 
to be the problem 18-20. Later the ‘plug the lung until it grows’ (PLUG) method was 
developed in lambs. Endoscopically an infl atable balloon is inserted through the 
fetal mouth in the trachea through a catheter, which then is fi lled with saline and 
kept in place for various days 21-26. This demonstrated improved lung morphogenesis 
and function 27. A tracheal occlusion trial in humans in North-America demonstrated 
no differences in survival when compared to controls. The authors blamed this on an 
improvement in survival in the control group due to the increased care in a special-
ized center 20. However, Deprest et al. stated that a great part of the enrolled patients 
were likely to have survived without treatment based on the ‘lung area to head cir-
cumference ratio’ (LHR) risk assessment 28, 29. Therefore, in the European programme 
(FETO task force), only the most severe CDH cases (LHR < 1.0) were enrolled and 
underwent the Fetoscopic Endoluminal Tracheal Occlusion (FETO)-procedure. This 
study demonstrated up to 64% survival in comparison to 8% survival of non-treated 
comparable CDH patients, and thus appeared very promising 28, 30-32. The same group 
demonstrated similar results in a more homogeneous group a year later 33. Premature 
prelabor rupture of the membranes, with the risk of premature delivery, appeared 
to be a common complication, but in a more recent study it was shown that there 
was an increase to 69% of deliveries after 34 weeks when FETO was performed 
due to improved experience 34. The most recent publication comparing FETO trials 
demonstrated a survival rate of up to 58%, in a study of 16 patients and, likely more 
accurate, an overall survival of 49% in the largest study which contained data from 
210 FETO-patients 35. Optimal timing of prenatal removal of the balloon was set at 34 
weeks; a longer duration had a negative effect on type II pneumocyte development 
in the surgical sheep model 25, 36-38. Prior to FETO, observed-to-expected lung volume 
was the single most important predictor for survival; post-FETO the contralateral 
lung vascularization index at four weeks has been the best neonatal outcome predic-
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tor in one uncontrolled study 39. In postmortem studies of non-survivors of CDH 
with tracheal occlusion increased fetal lung growth has been observed. In contrast, 
no improvement of parenchymal structure or the muscularization of pulmonary 
arterioles was observed 40. Ruano et al. however demonstrated the contralateral 
lung vascularization index to improve signifi cantly in CDH survivors 39. At this mo-
ment, the Tracheal Occlusion To Accelerate Lung growth (TOTAL)-trial is conducted 
to investigate late FETO for moderate pulmonary hypoplasia and validate previous 
results 35.
Tracheal occlusion in surgical models has not only shown to improve pulmonary 
hypoplasia, but also pulmonary vascular abnormalities benefi t from this procedure. 
For instance, tracheal occlusion studies in fetal sheep with a surgically induced 
diaphragmatic hernia demonstrated thinning of the pulmonary artery, correction 
of the abnormal muscularisation of pulmonary arterioles, and a decrease in vessel 
resistance in the left pulmonary artery with maternal hyperoxia as seen in normal 
fetal sheep at term 41-43. In fact, the sheep model has been used on many occasions 
to study pulmonary vascular abnormalities in CDH, but this is beyond the scope of 
our review 44, 45. Similar results of (treatment of ) pulmonary vascular abnormalities in 
CDH have been demonstrated in the rabbit model as well 26, 46, 47.
Surgical models are based on a surgical intervention making a diaphragmatic defect 
relatively late in gestation in both rabbits and sheep 48, 49. This model has been proven 
especially useful in investigating interventional therapies, such as the administration 
of corticosteroids, in utero repair of the diaphragmatic defect and tracheal occlu-
sion, but also to compare different tissue substitutes for hernia repair 10,  50-53. Due 
to the fact that the diaphragmatic defect is created late in gestation after a period 
of normal lung and diaphragm development, we have to take into consideration 
that certain pathogenetic changes in human CDH might have occurred during lung 
development before this phase. Therefore, pulmonary hypoplasia in these models 
might have different characteristics and information about the cause and early 
pathogenesis of this hypoplasia cannot be obtained. Another disadvantage is that 
the investigated interventional therapies might not react in a similar manner, as they 
should in the human situation, because we are comparing a uni-hit versus a more 
severe dual-hit pulmonary hypoplasia 54. On top of that, a lot of the other associated 
anomalies (such as heart defects) cannot be studied in this model.
In summary, surgical animal models are useful in investigating interventional thera-
pies but are less instructive in studying the etiology and pathogenesis of CDH. Inter-
ventional studies in this model have resulted in the incorporation of new prenatal 
techniques in human fetuses, with very promising results so far.
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NITROFEN MODEL
The nitrofen model has been used for the past two decades to investigate the 
anomalies in CDH. Originally, nitrofen (2,4-diclorophenyl-p-nitrophenyl ether) was 
used as a herbicide. In toxicology screens on adult rats no apparent problems were 
observed, though administration to pregnant dams during midgestation appeared 
to cause developmental anomalies to the heart, lungs, diaphragm, and skeleton of 
the embryos 55, 56. Based on the latter fi ndings, nitrofen has been investigated for its 
usefulness to simulate the anomalies of CDH in rodents. Numerous groups including 
ours demonstrated that nitrofen induced diaphragmatic hernias that were strikingly 
similar to the human condition. The specifi c location and extent of the diaphrag-
matic defects were very comparable, but also the similarities in the CDH-associated 
anomalies, including pulmonary hypoplasia and persistent pulmonary hypertension, 
and cardiovascular and skeletal defects as well, were impressive 57-60. When nitrofen 
is administered to pregnant rat dams on day 9 of gestation when normal lung (day 
11 of gestation) and diaphragm development (day 13 of gestation) are just about to 
begin, approximately 70% of the offspring will have a CDH and 100% pulmonary 
hypoplasia. Therefore, the nitrofen animal model, taking into account the obvious 
disadvantages of being a toxicological (animal) model, can serve as a good tool to 
investigate the pathogenesis and therapeutical options in CDH and its anomalies 
in rodents. Despite the extensive use of nitrofen as a herbicide in agriculture, its 
possible teratogenetic effects have never been proven to play a role in human CDH.
In 2000, the dual-hit hypothesis was introduced. It explained pulmonary hypopla-
sia in CDH as a result of two insults 54. There is an early bilateral nitrofen-induced 
pulmonary hypoplasia observed prior to closure of the diaphragm (fi rst insult) 61, 62. 
The second insult is caused by herniation of the abdominal viscera into the thorax 
due to disrupted closure of the diaphragm and affects the ipsilateral lung only by 
interference with fetal breathing movements. The etiology of both human CDH and 
nitrofen-induced CDH in rodents has been connected to perturbations in the reti-
noid signaling pathway (Figure 1), although the exact underlying mechanism remains 
to be elucidated. The fi rst evidence that CDH could be connected to perturbations 
in the retinoid signaling pathway was obtained already in 1941 by Andersen who 
noted diaphragmatic hernias in embryos of pregnant rats on a vitamin A-defi cient 
diet 63. This effect of maternal vitamin A defi ciency was confi rmed by Wilson et al. in 
1953 64. More modern approaches using genetic manipulation in mice have shown 
that ablation of retinoic acid receptor (RAR) signaling during development indeed 
results in diaphragmatic hernias, pulmonary hypoplasia and/or lung agenesis 65. In 
humans, newborns with CDH had lower levels of plasma retinol and retinol binding 
protein (RBP) in cord blood than controls 66, 67. Nitrofen-treated rats demonstrated 
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decreased protein levels of both transport proteins RBP and transthyretin in lungs 68. 
In addition, CDH has been observed in patients with deletions on the 15q chromo-
some, which contains the encoding gene for a cellular retinoic acid binding protein 
(CRABP1), although so far mutation analysis in isolated CDH cases are negative 69-71. 
Administration of retinoic acid (RA) to nitrofen-treated lung explants demonstrated 
an increase in lung growth and partially rescued the hypoplasia 72. This observation 
was supported by Thebaud et al. who demonstrated an improvement in lung matu-
ration and growth in nitrofen-treated embryos when the pregnant dam was treated 
with vitamin A either before, during or after the nitrofen administration 73, 74. In addi-
tion, survival of the fetuses improved in the vitamin A-treated group 74. Subsequently, 
administration of RA and vitamin A were compared in their effectiveness to reduce 
the number of hernias. The untreated group had 54% hernias. With vitamin A treat-
ment, the number of hernias was reduced to 32%. RA demonstrated a reduction 
to 15%, and with continuation of the RA feedings up to 5 days, a percentage less 
than 10% was even reached 75. This supports the concept that both the diaphrag-
matic hernia and the pulmonary hypoplasia are resulting from a disruption in the 
retinoid signaling pathway. In vivo prenatal treatment of RA to nitrofen-treated rats 
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Figure 1. Schematic representation of the retinoid signaling pathway. Retinol binds STRA6 and is 
transferred into the cytoplasm. Retinol can either be stored as retinyl ester (RE) by lecithin : retinol 
acyltransferase (LRAT) or be converted into retinal by retinol dehydrogenase (ROLDH). Retinal is 
converted into retinoic acid (RA) by retinal dehydrogenase (RALDH). RA can either remain in the 
cytoplasm to be metabolized by cytochrome p450 (Cyp) 26 enzymes, or bind to retinoic acid receptor 
(RAR) or retinoid X receptor (RXR) to activate the retinoic acid response element (RARE) and thereby 
alter gene transcription. Pathways that might be infl uenced by the effects of nitrofen are indicated by 
dashed arrows.
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improved alveolization 76. In these fetuses, acceleration of type I alveolar epithelial 
cell proliferation was demonstrated, a process important for lung development 77. 
The improvement in alveolization after RA treatment could be explained by the 
upregulation of several genes involved in this process 78-82.
Retinal dehydrogenase (RALDH) 2 is perceived to be the key enzyme in the RA 
synthetic pathway 83-85. In vitro experiments have demonstrated that several agents 
(including nitrofen) responsible for the induction of diaphragmatic hernias, in-
hibit RALDH2 activity 86, 87. In contrast, Kling et al. demonstrated the decline in RA 
in nitrofen-treated Hek-293 cells to be independent of RALDH inhibition 88. The 
authors attributed the decline in RA to nitrofen-induced cell toxicity, as they ob-
served increased cell death. Others have proposed that nitrofen interferes with the 
uptake of retinol by lung cells. Nitrofen-treated lungs have lower retinol levels while 
circulating retinol levels are increased in comparison to controls, in agreement with 
the idea of a disturbed uptake of retinol 89. Recently, STRA6 has been identifi ed as 
the membrane receptor for serum retinol and mutations in STRA6 result in diaphrag-
matic hernias and pulmonary hypoplasia amongst a variety of other anomalies 90-92. 
However, nitrofen does not block the uptake of retinol by STRA6 87. Nitrofen treat-
ment has been reported to downregulate the pulmonary retinol storage enzyme, 
lecithin : retinol acyltransferase (LRAT), and the RA-degrading enzyme Cyp26, while 
not affecting RALDH2 (42). Since vitamin A defi ciency experiments have shown simi-
lar decreases in RA-degrading enzymes and -storage enzymes 93, 94, it is thought that 
this downregulation is due to low pulmonary retinol levels. The exact mechanism by 
which nitrofen infl uences RA signaling remains to be elucidated. Recently, Goumy 
et al. proposed STRA6, LRAT, COUP-TFII, and nine other retinoic-related genes as 
potential candidate genes for human CDH 95. It has also been suggested that nitrofen 
may compete with RA to bind to the RAR during embryogenesis, thereby impairing 
lung and diaphragm development 74, 96. In a two-hybrid yeast-assay nitrofen inhibited 
RAR and RXR association only when very high, embryonic lethal dosages were used 
87. In contrast, Chen et al. demonstrated that nitrofen inhibits the activation of reti-
noic acid response elements (RARE) in lacZ mice 97. RAR expression is not affected 
in CDH. Rajatapiti et al. reported that it was normal in human CDH lungs and in 
nitrofen-induced rat CDH lung tissue 98.
In summary, the retinoid signaling pathway is complex and it appears that a disrup-
tion anywhere in the pathway might be responsible for the morphological changes 
including pulmonary hypoplasia seen in CDH. An interesting novel perspective to 
investigate the RA pathway in patients with CDH is the use of fetal skin fi broblasts, in 
which the RALDH2 and Cyp26 gene expression were altered 99.
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Besides the retinoid signaling pathway, another pathway implicated in CDH is the 
thyroid hormone signaling pathway (Figure 2) 100. Nitrofen has a similar chemical 
structure as triidothyronine (T3) and thyroxine (T4). All three are halogenated di-
phenyl ethers 101-103. Thyroid hormones are important in lung morphogenesis 104-106. 
Thyroid hormone receptors (TRs) are mostly expressed after gestational day 13 in 
the rat 107, but it has been demonstrated that very low levels of message are present 
at day 11 in the embryo 108. Both T3 and T4 can cross the placenta during embryo 
morphogenesis in the rat from gestational day 9 onwards 109-111. Therefore, it is pos-
sible that nitrofen infl uences both diaphragm formation and lung development by 
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Figure 2. Schematic representation of the thyroid signaling pathway. Thyroid hormones thyroxine 
(T4) and the triiodothyronine (T3) are produced in the thyroid gland. The hypothalamus produces 
thyrotropin-releasing hormone (TRH), which stimulates the pituitary gland to release thyroid-
stimulating hormone (TSH). TSH directly acts on the thyroid gland to stimulate T4 and T3 synthesis. 
At the target cells, membrane passage is either carrier-mediated by thyroid hormone transporters 
(THT) or by diffusion. In the cell T4 is converted to T3 by deiodinases and binds to the nuclear thyroid 
hormone receptors (TRs) TRα and TRβ. Through activation of the thyroid response element (TRE) gene 
expression is altered. Pathways that might be infl uenced by the effects of nitrofen are indicated by 
dashed arrows.
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interfering with the thyroid hormone signaling pathway 87. However, nitrofen-treated 
adult mice have decreased T4 levels while T3 levels remain normal 101. In addition, 
fetuses of pregnant rats treated with nitrofen have lower circulating T3 and T4 lev-
els, but pulmonary levels of T3 and T4 are not changed when compared to control 
fetuses 102, 112, 113. If nitrofen exerts its action due to structural similarities with thyroid 
hormones (thyromimetica), it would be in a competitive manner. Nonetheless, 
Brandsma et al. demonstrated that nitrofen inhibits binding of T3 to TRα1 and TRβ1 
in a non-competitive manner by reducing the maximal binding capacity in vitro 103. 
In contrast, Noble et al. found no perturbation in TR binding in the presence of ni-
trofen 87. When nitrofen and T4 were administered simultaneously to thyroidectomy 
pregnant rats, the incidence of congenital anomalies in embryos dropped with 70% 
102. Despite this observation, co-administration of T4 and nitrofen did not reduce the 
percentage of CDHs 87.
Similar to RAR, TRα1 and TRβ1 belong to the steroid/thyroid/retinoid receptor su-
perfamily. Noble et al. demonstrated that TRα1 and thyroid response element (TRE) 
activity were not infl uenced by nitrofen in vitro 87. In vivo, however, nitrofen reduced 
the expression of TRα1 and TRβ1 in CDH rat lungs 114 without changing their cellular 
localization 98. A similar decrease in TRα1 expression was noted in human CDH re-
lated hypoplastic lungs 98. This decrease in TRα1 could lead to a diminished response 
to maternal thyroid hormone (TH) and later on (from gestational day 18 in rats) to 
the hormones produced by the fetus itself. In this way lung morphogenesis might 
be affected by nitrofen 114. As described earlier, Montedonico et al. demonstrated 
a partial rescue by RA treatment in nitrofen-induced hypoplastic lung explants. The 
authors suggested that this might be only partial because downregulation in the thy-
roid hormone signaling pathway might also contribute to the pulmonary hypoplasia 
72. However, we should bear in mind that the role of thyroid hormones appears to 
be limited since in TR null mutant mice no apparent lung and diaphragm problems 
were observed and, therefore, antenatal lung growth does not seem to be impaired 
by a lack of thyroid hormones 115. Van Tuyl et al. demonstrated that both maternal and 
fetal hypothyroidism in transgenic mice did not alter prenatal lung development 116. 
However, Pei et al. showed repression of TR by knock-in mutations of the nuclear 
co-repressor Silencing Mediator of Retinoid and Thyroid hormone receptors (SMRT) 
was linked to a respiratory distress syndrome with premature type I pneumocytes 117.
In summary, TRα1 expression is reduced in both CDH lungs of nitrofen treated rats 
as in human hypoplastic CDH lungs, which might suggest a role of TRs in the lung 
pathogenesis of CDH. However, the lack of both lung and diaphragm defects in TR 
null mice makes this less likely. Even though nitrofen has a similar structure as the 
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thyroid hormones, a clear relation between the thyroid signaling pathway and lung 
or diaphragm defects has not been demonstrated so far.
Recently the scope of the nitrofen model has broadened from purely pathogenetic 
research to a combination with surgical treatment. Tracheal occlusion was investi-
gated in the nitrofen model, which is necessary to investigate the infl uence of this 
prenatal treatment onto the ‘dual-hit’-affected lung. Tracheal occlusion improved 
lung branching, as observed in the surgical sheep and rabbit model 118, 119.
Not only pulmonary hypoplasia has been investigated in the nitrofen model but, 
as in the surgical models, vascular development in CDH has also been used for this 
purpose. An example is the study of vascular muscle tone in vitro by Belik et al. 120. 
However, this is beyond the scope of our review.
The nitrofen model is based on the administration of the herbicide before the onset 
of lung and diaphragm formation. Although this model appears to be the best model 
available since the timing of the developmental insult is similar to that in humans, 
a large disadvantage is that the signifi cance of the potential teratogenic effects of 
nitrofen in rodents has never been proven in humans. Increasing evidence about the 
etiology of CDH is pointing towards a disturbance in the retinoid signaling and/or 
thyroid signaling pathway, but this model has not yet led to a clear explanation of the 
pathogenesis of CDH and the associated pulmonary hypoplasia.
GENETIC MODELS
Since the fi rst knockout mice were produced at the end of the eighties, they have 
been widely employed by molecular biologists to investigate the function of the 
gene that is made inoperable. In this way several expected and unexpected genes 
have been linked to CDH.
Wilm’s Tumor 1 (Wt1)
The original paper describing the phenotype of Wilm’s Tumor 1 (Wt1) null mutant 
mice focused on the role of this tumor suppressor gene in urogenital development 
121. In the same paper the authors briefl y describe the incomplete formation of the 
diaphragm in the mutants resulting in the herniation of the lungs into the abdomi-
nal cavity, whereas in human CDH abdominal contents normally herniate into the 
thorax. However, in a recent publication Clugston et al. describe a more classical 
picture of abdominal contents herniating into the thorax in a comparative study on 
diaphragm development in three animal models for CDH including Wt1 null mutant 
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mice 122. In addition, the authors observe a ‘real’ posterolateral (Bochdalek) hernia 
based on the malformation of the pleuroperitoneal folds (PPFs) as opposed to differ-
ent diaphragmatic defects observed in other knockout mice. An accurate indication 
of the incidence of CDH could not be calculated because of the small numbers of 
fetuses investigated. In addition, in the nitrofen rat model a downregulation of Wt1 
gene and protein expression was observed in the PPF of diaphragms 123. Despite the 
‘true’ Bochdalek phenotype of the Wt1 null mutant mice, a translation to the human 
situation of CDH has not been made. Besides a few reports of mutations of WT1 in 
human case reports on syndromic CDH such as WAGR and Denysh Drash, no rela-
tionship between the presence of the WT1 mutation and isolated CDH was found 
124-127. In a Swedish series of 27 children with isolated CDH no WT1 gene mutations 
could be detected 128.
Sonic Hedgehog (Shh) and Gli2/Gli3
Sonic Hedgehog (Shh) and Gli2 and Gli3 are members of a highly conserved morpho-
genetic family known as the Shh-signaling pathway 129. In the original publications on 
the functions of Shh and Gli2 and Gli3 no mention was made on the diaphragmatic 
defects some of the null mutant mice displayed. These papers focused on the fore-
gut anomalies, such as abnormal branching morphogenesis of the lungs, tracheal-
esophageal fi stula and esophageal atresia, respectively 130-132. In Shh null mutants 
there is a failure of tracheo-esophageal separation and, in addition, the lungs have 
undergone less branching morphogenesis, making them hypoplastic 130, 132. Nitrofen-
treated mice however, did not demonstrate any differences in spatial transcript 
distribution and gene expression levels in early lung development compared to 
controls 133. In addition, in wildtype mice Shh was not expressed in normal primor-
dial PPF diaphragms but was strongly present in developing E11.5 lungs. Dispatched 
Homolog 1 (Disp1), which is required for Shh function, was specifi cally expressed in 
the PPF 134. Interestingly, Shh expression is decreased in human hypoplastic lungs of 
CDH patients 135, and recently, DISP1 sequencing revealed a de novo mosaic point 
mutation in a patient with non-isolated left-sided Bochdalek diaphragmatic hernia 
134.
Studies from Gli2 and Gli3 double knockout mice demonstrated a similar phenotype 
of foregut abnormalities, but a more severe phenotype of disturbed branching mor-
phogenesis. Gli2-/- mice have only one lobe on the right side (instead of four) indicat-
ing that lungs are formed, but primary branching is affected. In Gli2-/-/Gli3-/- mice no 
lungs are formed at all. In Gli2-/-/Gli3+/- mice there is ectopic branching and fusion of 
lung lobes 131. However, none of the fi rst studies described a CDH in these mice. In a 
more recent publication, the same group demonstrated that the single null mutant 
mice for both Gli2 and Gli3 as well as the double mutant Gli2-/-/Gli3+/- mice have 
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diaphragmatic defects 136. No description of the type of hernia was given for either 
Shh or Gli null mutant mice. No relationship between a mutation in GLI genes and 
CDH has been demonstrated in humans so far.
Slit3
Slit3 belongs to the family of Slit guiding proteins that are highly conserved through-
out evolution. Especially Slit1 and Slit2 have been investigated for their role in axon 
guidance and cell migration (reviewed in 137). Approximately 70% of Slit3 null mutant 
mice have a CDH 138, 139. In contrast to other animal models for CDH, most of these 
mice do not die after birth. The mice display a defect in the central tendon of the 
diaphragm, which fails to detach from the liver on the right side, thereby making it 
a good model of the human central (septum transversum) type of hernia. The origin 
of the defect lies in a defective connective tissue formation in the central septum 
transversum. The innervation of the phrenic nerve to the diaphragm was found to be 
normal in the knockout mice. No primary lung phenotype was observed in the mice. 
However, mice with end stage CDH were short of breath due to atelectasis and 
intrapulmonary hemorrhage. In addition, hypoplastic lungs of nitrofen-treated rats 
exhibit increased Slit3 expression 140. Altogether, these data suggest that Slit3 might 
play a role in a small subgroup of CDH cases. Recently, a case report of a newborn 
with CDH with a hernia sac attached to the liver was published 141. The left side of the 
liver formed a part of the sac of the CDH. Liver tissue including vessels were seen in 
the sac, as seen in Slit3-/- mice 139. This is the fi rst time that presence of hepatocytes 
within the sac itself was observed in a patient with CDH.
Fog2 (Friend of GATA2)
Employing an elegant approach of high throughput mutagenesis analysis using the 
chemical mutagen N-ethyl-N-nitrosourea (ENU), Ackerman et al. identifi ed a mouse 
line with respiratory failure at birth 142. This phenotype was based on pulmonary 
hypoplasia, disturbed heart development and a diaphragmatic defect and could 
be linked to a mutation in the gene Fog2 (Friend of GATA2). In contrast to the other 
models these mice displayed severe pulmonary hypoplasia in the absence of a hole 
in the diaphragm. Instead a posterolateral muscularization defect was observed. As 
such, this phenotype correlates better to the human situation of CDH with regards to 
the existence of pulmonary hypoplasia. Interestingly, the authors demonstrated that 
pulmonary hypoplasia occurs independently from defi cient diaphragm develop-
ment. This is a situation that can also be observed in unilateral agenesis of the lung 
with an intact diaphragm. We and others have demonstrated that the same holds 
true for lung development in the nitrofen model of CDH 54, 143, 144. However, a clear 
relationship between disturbed lung development and diaphragmatic development 
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has not been shown. It is more likely that both lungs and diaphragm are disturbed in 
their development separately.
Subsequently, the authors searched for FOG2 mutations in a series of 30 autopsy 
specimens of CDH patients and found a nonsense mutation in a female patient with 
severe bilateral pulmonary hypoplasia and a posterior diaphragmatic eventration on 
the left side. The authors suggested that this was the fi rst reported gene mutation in 
a patient with CDH and pulmonary hypoplasia. More recently, Bleyl et al. reported 
novel FOG2 sequence variants in two isolated CDH patients, but could not identify 
them as mutations 145.
Gata4 and Gata6
Fog2 can interact with many different transcription factors such as the Gata zinc fi nger 
transcription factors Gata4 and Gata6. Null mutant mice for both Gata4 and Gata6 
die early in embryonic development because of their essential roles in ventral mor-
phogenesis (including heart development) and differentiation of visceral endoderm, 
respectively 146-148. Therefore, these models could not be used to evaluate their roles 
in lung or diaphragm development that occur later in gestation. However, we and 
others demonstrated that Gata6 is essential for normal branching morphogenesis of 
the lung and late epithelial cell differentiation using a chimeric mouse mutagenesis 
approach 149-151. So far Gata6 has not been implicated in diaphragm development. 
Jay et al. recently observed a role for Gata4 in lung or diaphragm development 152. 
They noticed disturbed heart, lung and diaphragm development in approximately 
70% of heterozygous Gata4 knockout mice that were generated in a different genetic 
background 152. The mutation resulted in a mortality of up to 40%. The defect in the 
diaphragms consisted of a ventral hernia covered with a sac that was not attached 
to the liver, but allowed abdominal viscera to protrude. The incidence of CDH 
was approximately 30%. Pulmonary development in the mutant mice was not very 
disturbed, although the authors describe some airway dilatation and altered expres-
sion of certain genes in the most affected mice. In addition, another study recently 
demonstrated that Gata4 is important for normal pulmonary lobar development 
153. Interestingly, a microdeletion on human chromosome 8p23.1 that includes the 
GATA4 gene, has been linked to isolated human cases of CDH especially in com-
bination with cardiac anomalies 154-157. A recent report discussed a patient with an 
8p23.1 deletion with pulmonary hypoplasia and an anterior diaphragmatic defect, 
similar to the location of the defect reported in heterozygous Gata4 mice 152, 158.
COUP-TFII
Another transcription factor that is a binding partner of Fog2 is COUP-TFII, which 
belongs to a nuclear steroid/thyroid/retinoid hormone receptor superfamily and 
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has been shown to be essential for embryonic mouse development 159. Mice lack-
ing COUP-TFII show defects in cardiovascular development and die around day 
10.5 of gestation. Conditional mutagenesis of COUP-TFII in mice using the Cre-lox 
conditional knockout system to ablate COUP-TFII function in the mesenchyme only 
resulted in a Bochdalek-type diaphragmatic defect on the left side 160. However, the 
authors did not fi nd a defi cient lung phenotype in these mice, although this might be 
due to the tissue-specifi c ablation of the gene in the mesenchyme. In line with the 
latter idea, the authors describe that COUP-TFII expression is markedly decreased 
in the structures contributing to the developing diaphragm such as the PPF, but the 
expression was only slightly reduced in the developing lung. However, in lungs and 
the PPF of diaphragms of nitrofen-treated rats, gene expression of COUP-TFII was 
signifi cantly increased 161, 162. These results are even more interesting in the light of the 
location of COUP-TFII on human chromosome 15q26. Our group has identifi ed this 
region as a potential candidate region for human patients with isolated CDH 163, 164. 
However, following an evaluation of over 130 cases of isolated CDH from different 
hospitals, no mutations in the coding regions of COUP-TFII have yet been identifi ed.
PDGFRα
Very recently, the platelet-derived growth factor receptor alpha (PDGFRa) gene has 
been identifi ed as an important factor in the formation of the diaphragm and lung 
development 145. This gene is known for its role in tumorigenesis of gastrointestinal 
and neural tumors 165-168. In Pdgfra null mice, Bleyl and colleagues observed pul-
monary hypoplasia and a range of diaphragmatic defects including posterolateral 
diaphragmatic hernias 145. Interestingly, Dingemann et al. demonstrated upregulated 
gene and protein expression in nitrofen-treated fetal rat lungs 169. This and the other 
phenotypical characteristics observed are similar to the human Fryns syndrome 
(non-isolated CDH) 170. Hence PDGFRa might be a candidate gene for non-isolated 
CDH. Moreover, in one patient with non-isolated CDH a novel sequence variant 
of PDGFRa was identifi ed. The authors did not prove the variant to be a mutation 
145. Interestingly, successful treatment of a patient with CDH-associated pulmonary 
hypertension with a PDGFR-antagonist was recently described 171.
Retinoid signaling pathway in knockout mice
Increasing evidence from data obtained with the nitrofen model and knockout mice 
points towards perturbations in the retinoid signaling pathway as we described 
above. For example, COUP-TFII has been shown to be a downstream target of 
retinoid signaling (reviewed in 172), and different Gata transcription factors have 
been demonstrated to interact with RA receptors 173. In addition, prenatal treatment 
of RA in nitrofen-treated fetal rats upregulated COUP-TFII, Fog2, and Gata4 gene 
expression 161. Therefore, we also want to review the role of members of the retinoid 
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signaling pathway in knockout mice. The fi rst evidence from knockout mice that 
RA is involved in the pathogenesis of CDH came from retinoic acid receptor (RAR) 
double knockout mice, as described earlier. Single RAR null mutant mice did not 
show the expected anomalies that were observed in the vitamin A defi cient rats 
indicating that there is a high redundancy between the different types of receptors 
174-177. However, when the function of multiple receptors was abolished, multiple 
congenital abnormalities were observed including right-sided CDH in RARαβ2 and 
left-sided CDH in RARαβ2+/-. In addition, these mice displayed severe pulmonary 
hypoplasia 65. A more recent study of a pan-RAR antagonist (BMS493) demonstrated 
a very high induction rate of CDH, including the observation of apparent smaller 
ipsilateral lungs 178. Despite the convincing data from animal studies, the results in 
humans have been limited. Until now the only described mutations in CDH patients 
related to the RA pathway are in STRA6 and CRABP1 on chromosome 15 69-71, 90-92. Our 
group demonstrated signifi cantly lower retinol and retinol-binding protein levels in 
cord blood of CDH newborns in a case-control study of 56 patients 67.
Despite the growing amount of evidence that certain genes are involved in the 
pathogenesis of different types of CDH, until now only a mutation in FOG2 has been 
demonstrated in a single patient with non-syndromic CDH. This might be due to 
several factors. First, as described for the Gata4 gene, the genetic background of 
the species carrying the mutation is of importance to the phenotype that is related 
to the mutation. The diaphragmatic defects were only observed in heterozygous 
C57Bl/6 Gata4 mutant mice. This is also true for the rodent model based on the 
teratogenic effects of nitrofen. When nitrofen is administered to Sprague-Dawley 
rats, the percentage of the offspring having CDH is higher than following administra-
tion to Wistar rats. The same phenomenon has been observed in different mouse 
strains. Second, the pathogenesis of CDH might be explained by the necessity of 
multiple developmental insults to happen during development of the diaphragm 
and the lung. We and others demonstrated this scenario for pulmonary hypoplasia 
in the nitrofen model for CDH 54, 144. We named this the dual-hit hypothesis. Finally, 
the observed phenotype in CDH is so diverse that it is potentially not due to a single 
gene mutation, but the result of multiple gene mutations. Different genes involved 
in different signaling pathways that have been shown to be important for normal 
embryonic development might be involved. In addition, as has been suggested 
for the nitrofen model, there maybe a disturbed interaction of certain genes with 
environmental factors.
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CONCLUSIONS
Surgical models have been of great importance for validating new interventions 
in CDH. Many new approaches used today in CDH patients, for example the fe-
toscopic endoluminal tracheal occlusion, were fi rst optimized in surgical animal 
models. However, these models are less suitable than either nitrofen or genetic 
models in elucidating the pathogenesis of CDH, since the diaphragmatic defect is 
created rather late in fetal development. Combining two models might improve our 
understanding 179. Nitrofen has never been demonstrated to cause CDH in humans, 
despite its massive use as a herbicide. Nevertheless, the nitrofen rodent model has 
great similarities with human CDH. The most plausible pathogenetic explanation for 
CDH and its associated anomalies is a general genetic defect that causes the cardio-
vascular, lung and diaphragm defects. However, this particular genetic defect has 
not been identifi ed, although some mice models come close to resembling human 
CDH, as discussed previously. A new approach to discover changes in the genetics 
of CDH in human cases is the genome-wide array. Genome-wide arrays are useful to 
compare the genetic changes between CDH patients to search for the existence of 
CDH-related genes. Until now this has only been done in non-isolated (syndromic) 
human cases, mainly for the Fryns sydrome 164, 180, 181.
Although none of the animal models have been perfect in mimicking human CDH 
and its associated anomalies, they have all shed a light on the underlying pathogen-
esis and pathology, and eventually prenatal modulation, of the disease. Increasing 
evidence from studies in both human CDH and animal models of CDH (nitrofen and 
knockout mice) suggest that a disturbance in the retinoid signaling pathway might 
be responsible for the anomaly. However, not all fi ndings can solely be explained by 
disturbances in this pathway. Based on the spectrum of defects in heart, lungs and 
diaphragm, it is likely that there is a general defect in mesenchymal signaling in all 
involved organs in CDH with a variable genetic involvement in individual patients. 
This changing effect between epigenetic and genetic factors contributes to the highly 
variable phenotypic expression in the newborn. Our understanding of normal and 
abnormal diaphragm and lung development in relation to CDH is still incomplete. 
Eventually, such investigations will help in the design of new treatment modalities to 
better treat, modulate the natural course or even prevent this anomaly.
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ABSTRACT
Background Despite modern treatments, congenital diaphragmatic hernia (CDH) 
remains associated with variable survival and signifi cant morbidity. The associated 
pulmonary hypoplasia is a major determinant of outcome. To develop better treat-
ment modalities, improved comprehension of the pathogenesis of pulmonary 
hypoplasia is warranted. We developed an in vitro cell recombinant model to mimic 
pulmonary hypoplasia and specifi cally investigate epithelial-mesenchymal interac-
tions and decipher which tissue layer is primarily defective in nitrofen-induced 
CDH-associated pulmonary hypoplasia.
Methods Epithelial cells (E) and fi broblasts (F) were isolated from E19 control (C) and 
nitrofen-induced hypoplastic rat lungs (N). Cells were recombined and cultured as 
either homotypic [(FC)(EC) and (FN)(EN)] or heterotypic [(FC)(EN) and (FN)(EC)] recombi-
nants. 
Results Recombinants containing FN fi broblasts had a thickened fi broblast tissue 
layer and there were fewer organized alveolar-like epithelial structures compared to 
control (FC)(EC) recombinants. These FN recombinants exhibited a decrease in TUNEL 
and cleaved caspase-3-positive cells. Cell proliferation was arrested in recombinants 
containing FN fi broblasts, which also exhibited increased p27
Kip1 and p57Kip2 expres-
sion.
Conclusions Fibroblasts, and not epithelial cells, appear to be the defective cell type 
in nitrofen-induced hypoplastic lungs due to a decreased ability to undergo apopto-
sis and maintain overall proliferation. This may explain the characteristic pulmonary 
interstitial thickening and hypoplasia observed in both nitrofen-induced hypoplastic 
lungs as well as human hypoplastic CDH lungs.
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INTRODUCTION
Congenital diaphragmatic hernia (CDH) is a developmental defect of the diaphragm 
that allows abdominal organs to herniate into the thoracic cavity during lung devel-
opment. CDH occurs in 1 in 2500 live births 1,  2. Despite modern treatments CDH 
remains associated with variable survival and signifi cant morbidity, mainly due to the 
associated anomalies of the lung 3, 4. Although the exact pathogenesis is unknown, 
pulmonary hypoplasia is a major associated anomaly. Characteristics of human 
pulmonary hypoplasia in CDH are thickened alveolar walls, an increase in interstitial 
tissue, reduced alveolar air spaces and reduced gas-exchange surface area 2, 5-7. Apart 
from the gas exchange layer, well documented changes are present in the vascular 
components consisting of medial hyperplasia, peripheral muscularization of pre-
acinar vessels and adventitial thickening 8. It has been demonstrated that the lung in 
itself is defective, and that pulmonary hypoplasia is not caused by compression of 
the lungs by herniated abdominal organs alone 9. However, which of the two major 
tissue layers (epithelial or fi broblast/mesenchyme) in the lung is defective has never 
been addressed in detail. Such knowledge is required to design tissue-specifi c treat-
ment modalities that can exclusively target the defective tissue layer in pulmonary 
hypoplasia, and thereby modulate or potentially prevent pulmonary hypoplasia in 
CDH.
Several animal models have been utilized to study CDH and/or the associated 
pulmonary hypoplasia such as the nitrofen rodent model, a surgical lamb or rab-
bit model and multiple genetic mouse models. The nitrofen model however, is the 
preferred model to study the pathogenetic aspects of CDH. This model was dem-
onstrated to interfere with the retinoic acid (RA) signaling pathway (RA hypothesis), 
which was recently proven relevant in human CDH patients as well. 10-12. Previously 
we utilized this nitrofen model to demonstrate that CDH-associated pulmonary 
hypoplasia is a result of two hits: an intrinsic problem in the hypoplastic lungs it-
self before development of the diaphragmatic defect, and interference with fetal 
breathing movements and competition of space of the lungs due to herniation of 
abdominal organs through the diaphragmatic defect 9. In the present study, we were 
interested in the primary cause of the pulmonary hypoplasia, and therefore merely 
focused on ‘the fi rst hit’, the intrinsic lung defect of the nitrofen model. Previous 
studies have demonstrated abnormal patterns in proliferation, apoptosis and cell 
differentiation in hypoplastic nitrofen-lungs, but the defective tissue layer has not 
been identifi ed 9, 13.
Already 40 years ago it was shown that interactions between the different tissue 
layers are crucial for proper embryonic lung development 14. Since then, many stud-
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ies have contributed to the analysis of molecular determinants of lung growth 15, 16. 
Previously we have demonstrated that fetal lung epithelial cells recombined with 
fetal lung fi broblasts reorganize in alveolar-like structures in vitro and that fi broblasts 
direct epithelial morphogenesis 17. In addition, distal lung embryonic mesenchyme 
has been shown to induce expression of distal epithelial markers in proximal 
(tracheal) lung epithelial cells 18. Thus, lung fi broblasts are essential for proper lung 
organogenesis. Consequently, a defective fi broblast layer could result in abnormal 
lung formation.
Knowing the defective tissue layer in CDH-related pulmonary hypoplasia is critical 
for designing improved treatment modalities specifi cally targeted at this defective 
tissue layer. To determine which lung tissue layer is defective in CDH, we used the 
above mentioned in vitro cell recombinant model 17. Since the access to human (hy-
poplastic) lungs to perform such experiments is at best very limited, we utilized the 
nitrofen rodent model to develop a novel in vitro model for pulmonary hypoplasia 
to address this question.
Epithelial cells and fi broblasts isolated from control and nitrofen-treated lungs were 
recombined as either homotypic (control epithelial cells plus control fi broblasts or 
nitrofen epithelial cells plus nitrofen fi broblasts) or heterotypic (nitrofen epithelial 
cells or fi broblasts with healthy control fi broblasts or epithelial cells, respectively) 
recombinants (Figure 1). This approach enabled us to investigate the actual tissue 
interactions and the effects of a healthy opposing layer on a ‘diseased’ tissue layer, 
thereby gaining new insights into the pathogenesis of pulmonary hypoplasia in CDH 
and the potential role for epithelial-mesenchymal interactions. These recombina-
tion studies demonstrated that the fi broblast (mesenchymal) layer is the defective 
tissue layer in hypoplastic lungs due to a decreased ability to undergo apoptosis and 
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
Figure 1. Schematic representation of the formation of the homotypic and heterotypic recombinants.
Black represents control cells (C), and grey nitrofen-treated cells (N). The arcs denote fi broblasts (F), 
and the circles represent epithelial cells (E). Model 1 (FC)(EC) (control) and model 2 (FN)(EN) (nitrofen) are 
homotypic recombinants, while model 3 (FC)(EN) and model 4 (FN)(EC) are heterotypic recombinants.
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maintain overall proliferation. This may explain the characteristic nitrofen-induced 
pulmonary interstitial thickening and hypoplasia as well as similar features noted in 
hypoplastic lungs in children with CDH.
METHODS & MATERIALS
Animals
The animal care committee of the Hospital for Sick Children approved all experi-
mental procedures. Timed-pregnant Sprague-Dawley rats (Rattus Norvegicus) were 
ordered from Charles River (St. Constant (QC)).
Nitrofen treatment
Congenital diaphragmatic hernia and pulmonary hypoplasia were induced in preg-
nant rats using 2,4-dichlorophenyl-p-nitrophenyl ether (nitrofen) (Cerilliant, Round 
Rock (TX)) as described previously 9. E19 embryos (term = 22 days) were collected by 
Caesarian section under aseptic conditions. Thoracic contents were removed and 
collected per group in ice-cold Hanks’ Balanced Salt Solution (HBSS) (Invitrogen, 
Burlington (ON)). Lungs were microscopically separated from all other tissues in-
cluding removal of the major airways. In nitrofen-treated embryos, lungs from both 
hernia-positive and hernia-negative embryos were used, as pulmonary hypoplasia is 
present in 100% of these embryos. In a control experiment, lungs from embryos with 
a hernia were separated from embryos without a hernia to investigate differences in 
the severity of hypoplasia in our recombinant model. We did not observe any obvi-
ous differences between recombinants of lung cells isolated from hernia-positive or 
hernia-negative embryos (results not shown). E19 whole lungs from nitrofen-treated 
and control rats served as in vivo controls for the recombinants.
Cell isolation and recombinant culture
Fetal epithelial cells and fi broblasts were isolated by primary culture as described 
previously 19. After overnight culture, cells were washed, trypsinized and collected 
by centrifugation. Cells were counted and recombined (3.0x106 epithelial cells with 
3.0x106 fi broblasts in solution) in four different combinations, as depicted in Figure 
1. Subsequently, recombined cells were spun down, and supernatant was removed. 
Cells were lightly stirred and incubated for one hour, and transferred onto inserts 
(Millipore, Etobicoke (ON), Canada). The recombined cells were cultured according 
to Deimling et al. 17. After fi ve days of culture, recombinants were fi xed in 4% para-
formaldehyde overnight at 4°C, dehydrated and embedded in paraplast, and 5μm 
sections were cut. To ensure that isolated cells did not differ between the groups 
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prior to recombination with respect to differentiation markers and number of apop-
totic cells, freshly isolated cells were grown on coverslips for immunocytochemical 
analysis.
Hematoxylin and Eosin (H&E) staining
Sections were rehydrated and stained with hematoxylin (Sigma, Oakville (ON)). 
Slides were rinsed with warm tap water for 30 minutes and dehydrated to 95% etha-
nol. Subsequently, the sections were stained with 0.5% eosin (Sigma, Oakville (ON)) 
in 95% ethanol, dehydrated, and mounted with 70% permount (Fisher, Pittsburgh 
(PA)) in xylene.
Immunofl uorescence
Immunofl uorescence (IF) analysis was performed as described previously 17. Briefl y, 
tissue sections were rehydrated and antigen retrieval was performed in 10mM pH 
6.0 sodiumcitrate using a pressure cooker in a microwave for 15 minutes at maxi-
mum wattage. Slides were incubated with blocking solution consisting of 10% (w/v) 
normal goat serum (NGS) and 1% (w/v) bovine serum albumin (BSA) in phosphate 
buffered saline (PBS) for one hour. Subsequently, the primary antibody in block-
ing solution was added and sections were incubated overnight at 4°C. Following 
3 washes with PBS containing 0.05% (v/v) Tween-20 (PBST), slides were incubated 
with a secondary antibody in blocking solution for one hour. The slides were then 
washed and the samples were mounted with 4,6-diamidino-2-phenylindole (DAPI) 
hard mounting medium (Vector, Burlington (ON)). Primary antibodies were: 1:500 
rabbit anti-cytokeratin (Dako, Mississauga (ON)), 1:50 mouse anti-vimentin (Dako, 
Mississauga (ON)), 1:400 mouse anti-α-smooth muscle actin (αSMA) (NeoMarkers, 
Fremont (CA)), 1:200 rabbit anti-pro-surfactant protein-C (pro-SFTPC) (Abcam, Cam-
bridge (MA)), 1:200 rabbit anti-clara cell secretory protein (CCSP) (SantaCruz, Santa 
Cruz (CA)), 1:1000 rabbit anti-platelet endothelial cell adhesion molecule (PECAM) 
(SantaCruz, Santa Cruz (CA)). Secondary antibodies (dilution of 1:200) were fl uores-
cein isothiocyanate (FITC)-labelled anti-mouse IgG (Calbiochem, San Diego (CA)) 
for vimentin and αSMA, rhodamine-labelled anti-mouse IgG (Invitrogen, Eugene 
(OR)) for vimentin, rhodamine-labelled anti-rabbit IgG (Invitrogen, Eugene (OR)) 
for cytokeratin, pro-SFTPC, CCSP and PECAM. Whole lungs of E19 rat embryos were 
used as positive controls for immunofl uorescence.
Immunohistochemistry
Following antigen retrieval, slides were treated with 3% (v/v) hydrogenperoxide in 
methanol to block endogenous peroxidase activity. Blocking solution, containing 
avidin (Vector, Burlington (ON)), was added for one hour according to the manufac-
turer’s instructions. Primary antibody in blocking solution containing biotin (Vector, 
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Burlington (ON)) was added and slides were incubated overnight at 4°C. The follow-
ing day a biotinylated secondary antibody was added for one hour in blocking solu-
tion. Subsequently, ABC-complex (Vector, Burlington (ON)) was added for 30 min-
utes. Slides were developed using ImmPACT 3,3'-Diaminobenzidine (DAB) (Vector, 
Burlington (ON)), and counterstained with hematoxylin. Slides were mounted with 
70% permount in xylene. Primary antibodies used for DAB staining were 1:100 rabbit 
anti-cleaved caspase-3 (Cell signaling, Danvers (MA)), 1:2000 rabbit anti-ki67 (Dako, 
Mississauga (ON)), 1:1000 mouse-anti-cyclin D3 (Abcam, Cambridge (MA)), 1:1000 
rabbit anti-cyclin E (Abcam, Cambridge (MA)), 1:400 rabbit anti-phosphohistone 
H3 (pH3) (Upstate, Atlanta (GA)) and 1:100 rabbit anti-thyroid transcription factor-1 
(TITF-1) (NeoMarkers, Fremont (CA)) in blocking solution. Biotinylated anti-mouse 
IgG (Vector, Burlington (ON)) (for cyclin D3) and anti-rabbit IgG (Calbiochem, San 
Diego (CA)) (for cleaved caspase-3, ki67, cyclin E, pH3, TITF-1) were used as second-
ary antibodies in a dilution of 1:200. Whole lungs of E19 rat embryos were used as 
positive controls for immunohistochemistry.
TUNEL
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-assay 
(Roche, Toronto (ON)) was carried out according to the manufacturer’s instructions. 
Rehydration and antigen retrieval were performed as described above. Slides were 
washed twice with PBS. TUNEL solution was added to the slides and the slides were 
incubated for an hour at 37°C. Slides were washed three times with PBS and coun-
terstained with DAPI mounting medium.
EdU-uptake
5-ethynyl-2’-deoxyuridine (EdU)-incorporation assay was carried out according to 
the manufacturer’s instructions (Invitrogen, Burlington (ON)). Briefl y, recombinants 
were incubated for two hours with 10μM EdU component A on day fi ve of culture 
prior to fi xation. Sections were incubated with 0.5% (v/v) Triton X-100 for 20 minutes 
to permeabilize the samples. EdU detection was performed by incubation with a 
freshly prepared reaction cocktail of FITC-labelled anti-EdU antibody for 30 min-
utes. Slides were washed with 3% (w/v) BSA in PBS and counterstained with vimentin 
and DAPI.
Immunocytochemistry
Cells on coverslips were permeabilized with 0.2% Triton-X100 (Sigma Life Science, 
St Louis (MO)) in 1% BSA for fi ve minutes. Subsequently, IF analysis for cytokeratin, 
vimentin, pro-SFTPC, αSMA, and PECAM was performed and apoptosis measured 
using the TUNEL-assay as described above.
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Quantifi cation
Mitotic index was quantifi ed by counting pH3-positive cells for each type of recom-
binant. Per recombinant fi ve different randomly selected areas with alveolar-like 
structures were counted. Simultaneously, we determined cell origin (epithelial cell 
or fi broblast). Volocity4 software (Quorum Technologies Inc., Guelph (ON)) was used 
to quantify the surface area of cytokeratin (epithelial cells) and vimentin (fi broblasts)-
positive cells in all four types of recombinants. In each group, recombinants from at 
least four separate experiments were analyzed with an average of eight pictures per 
recombinant.
Western blot analysis
Fibroblasts from nitrofen-treated and control lungs were isolated at E19 and cultured 
for 24 hours. Cells were collected in RIPA buffer and sonicated. Western blot analysis 
was performed as previously described 20. Primary antibodies (1:1000 dilution) were 
rabbit-anti-p27Kip1, rabbit-anti-p57Kip2, and mouse-anti-p21Waf/Cip1 (all from Cell signal-
ing Technology, Danvers (MA)). Anti-rabbit and anti-mouse secondary antibodies 
(Vector, Burlington (ON)) were used in a concentration of 1:5000.
Data analyses and statistics
All recombination experiments were repeated at least four times. Data are presented as 
mean ± standard error of the mean. For statistical analyses we used an ANOVA and Bon-
ferroni multiple comparisons test to compare fi broblast and epithelial cell area fractions 
and ratios, and the pH3-positive cells per fi eld. Subsequently, a Student’s t-test was used 
for pairwise comparison of the four recombinant groups and the p-values were adjusted 
for multiple comparison error. Signifi cance was defi ned as p-value < 0.025.
RESULTS
Organogenesis
In all four types of recombinants (Figure 1), cells spontaneously organized in alveolar-
like structures (Figure 2A – D). IF staining for cytokeratin (epithelial cell marker) and 
vimentin (fi broblast marker) revealed fewer organized alveolar-like epithelial struc-
tures and a thickened fi broblast (mesenchymal) tissue layer in FN containing recom-
binants versus FC containing recombinants (Figure 2F,H vs 2E,G). Area measurements 
of the four types of recombinants demonstrated signifi cant differences between FC 
containing recombinants and (FN)(EN) recombinants in the epithelial and fi broblast 
surface areas (Figure 3A). Fraction of fi broblasts were signifi cantly different between 
(FC)(EC) and (FN)(EN) recombinants (Figure 3B).
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Freshly isolated epithelial cells and fi broblasts from nitrofen-treated and control 
lungs separately grown on coverslips did not differ in differentiation markers and 
number of apoptotic cells (results not shown).
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  (Fc)(Ec)              (FN)(EN)         (Fc)(EN)    (FN)(Ec)
Figure 2. Organogenesis in homotypic and heterotypic recombinants. Alveolar-like structures 
developed spontaneously in all four types of recombinants (A – D). IF staining of the recombinants 
for cytokeratin (epithelial cells; red) and vimentin (fi broblasts; green) and counterstained with 
DAPI (nuclei; blue) (E – H) revealed tissue layer-specifi c morphological differences. In FN containing 
recombinants (F,H) the fi broblast layer appeared thickened and epithelial structures were less 
organized in comparison to FC containing recombinants (E,G). The scale bar represents 50μm.
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Figure 3. Quantitative analysis of epithelial cells versus fi broblasts surface area in recombinants. To 
quantify the observed differences in Figure 2E – H, the surface area of epithelial cells and fi broblasts was 
measured using Volocity software. The epithelial : fi broblast (E : F)-ratio (A) and fraction of fi broblasts 
(B) in the recombinants were determined. The E : F ratio was signifi cantly decreased while the number 
of fi broblast increased in (FN)(EN) recombinants in comparison to FC containing recombinants. Both the 
E : F ratio and number of fi broblasts trended to either decrease or increase in (FN)(EC) recombinants, 
respectively. *Indicates a signifi cant difference (p-value < 0.025); the bars represent the standard error 
of the mean.
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Apoptosis
To determine if the observed differences were due to apoptotic changes we per-
formed TUNEL-assays and immunohistochemistry for cleaved caspase-3. Both 
analyses revealed less apoptosis, primarily in the fi broblast (mesenchymal) layer, in 
FN containing recombinants when compared to FC containing recombinants (Figure 
4B,D,F,H vs 4A,C,E,G). Freshly isolated FN and FC cultures were analyzed for TUNEL-
positive cells, but no differences between the cultures were observed prior to 
recombination (results not shown). E19 nitrofen-treated rat lungs also demonstrated 
less apoptosis compared to E19 control rat lungs (results not shown).
Proliferation
We then assessed cell proliferation by immunohistochemical analyses of ki67 (gen-
eral proliferation marker), cyclin D3 (‘fi rst gap’ G1-phase marker), cyclin E (G1/S-phase 
marker) and pH3 (mitosis marker). In addition, we measured the uptake of EdU into 
DNA (S-phase). Immunoreactivity for cyclin D3 (Figure 5E – H) and cyclin E (results not 
shown) were similar in all four types of recombinants. However, EdU-incorporation 
assays showed less cells in the S-phase of the cell cycle in (FN)(EN) recombinants com-
pared to (FC)(EC) recombinants (Figure 5J vs 5I). Ki67 (Figure 5A – D) and pH3 (Figure 
5K – N) immunohistochemistry corroborated the fi nding of less proliferating/divid-
ing cells in FN containing recombinants versus FC containing recombinants (Figure 
5B,D,L,N vs 5A,C,K,M, Figure 6). The ratio of proliferating cell types (epithelial versus 
fi broblast) remained the same in all four groups. No differences in total cell amount 
for each type of recombinant were observed. Western blot analysis demonstrated 
increased protein levels of cyclin-dependent kinase (Cdk)-inhibitors p27Kip1 and 
Figure 4. Nitrofen-treated fi broblasts exhibit reduced apoptosis in recombinants. Immunofl uorescent 
TUNEL (green)-analysis on recombinants counterstained with vimentin (fi broblasts; red) and 
DAPI (nuclei; blue) showed less TUNEL-positive fi broblasts of both FN containing recombinants in 
comparison to FC containing recombinants (B,D vs A,C). Cleaved caspase-3 (brown) immunoreactivity 
was less in both FN containing recombinants in comparison to FC containing recombinants (F,H vs E,G) 
as well. Scale bar represents 50mm.
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p57Kip2 in nitrofen-treated fi broblasts in comparison to control fi broblasts (Figure 7). 
These inhibitors are known to inhibit the transition from the G1- to S-phase of the cell 
cycle. The other Cip/Kip family member of Cdk-inhibitors, p21Waf1/Cip1, was not de-
tectable in either fi broblast population (results not shown). E19 nitrofen-treated rat 
lungs had less ki67- and pH3-positive cells but equal numbers of cyclin D3-positive 
cells when compared to E19 control rat lungs (results not shown).
Cell differentiation
To determine if the recombinants demonstrated differences in cell differentiation 
besides the reduced proliferation and apoptosis in vitro, we performed IF for αSMA 
(marker for myofi broblasts), TITF-1 (marker for lung epithelial cells), pro-SFTPC 
(marker for epithelial type II cells), CCSP (marker for clara cells) and PECAM (marker 
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Figure 5. Arrest in proliferation induced by nitrofen-treated fi broblasts in recombinants.
Immunohistochemistry for ki67 (brown) demonstrated less proliferation in FN containing recombinants 
(B,D) in comparison to FC containing recombinants (A,C). Cyclin D3 (brown) demonstrated no signifi cant 
differences between all four types of recombinants (E – H). EdU-uptake (green) by recombinants 
counterstained with vimentin (fi broblasts; red) and DAPI (nuclei; blue) showed a decrease in cells 
in the S-phase in (FN)(EN) recombinants (J) in comparison to (FC)(EC) recombinants (I). PH3 (brown) 
staining showed less cells undergoing mitosis in FN containing recombinants (L,N) in comparison to FC 
containing recombinants (K,M). The scale bar represents 50μm.
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for endothelial cells). αSMA IF staining was similar in myofi broblasts in all four types 
of recombinants (Figure 8A – D). In addition, IF staining for TITF-1 (results not shown), 
pro-SFTPC (Figure 8E – H), and CCSP staining (results not shown) was comparable in 
all types of recombinants. No PECAM-positive cells were present in recombinants. 
Freshly isolated epithelial cells and fi broblasts from nitrofen-treated and control 
lungs separately grown on coverslips did not differ in differentiation markers (results 
not shown).
DISCUSSION
Combining the well-established rodent model for CDH based on the teratogenic ef-
fects of nitrofen with our previously developed cell recombinant model, we created 
a new pulmonary cell recombinant in vitro model that resembles human CDH-asso-
ciated pulmonary hypoplasia. This cell recombinant model enabled us to investigate 
p27Kip1
β-actin
p57Kip2
β-actin
(Fc) (FN)
Figure 7. Increased expression of Cdk inhibitors in nitrofen-treated fi broblasts. Western blot analysis 
demonstrated that cultured fi broblasts from nitrofen-treated embryonic lungs have increased amounts 
of p27Kip1 and p57Kip2 proteins compared to fi broblasts from control embryonic lungs.
(Fc
)(E
c)
(Fn
)(E
n)
(Fc
)(E
n)
(Fn
)(E
c)
0
10
20
30
Recombinant groups
Av
er
ag
e 
nu
m
be
r o
f p
os
iti
ve
 c
el
ls
 p
er
 fi
el
d
Figure 6. Decrease in mitosis in affected recombinants. To quantify the mitotic index of Figure 5K – 5N, 
pH3-positive cells were counted in 20 slides per type of recombinant. The number of pH3-positive 
cells was signifi cantly decreased in (FN)(EN) and (FN)(EC) recombinants in comparison to both (FC)(EC) and 
(FC)(EN) recombinants. 
*p-value < 0.0001.
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epithelial-mesenchymal interactions in nitrofen-induced pulmonary hypoplasia into 
more detail and resulted in the following observations. Recombinants containing 
in vivo nitrofen-treated fi broblasts (FN) exhibited decreased apoptosis and a late G1 
cell cycle arrest. We therefore postulate that fi broblasts are the defective cells in 
CDH-associated hypoplastic lungs.
Adequate in vitro model for pulmonary hypoplasia
Obvious morphological differences between recombined normal lung cells ((FC)(EC) 
recombinants) and recombined nitrofen-treated lung cells ((FN)(EN) recombinants) 
were a thickened fi broblast (mesenchymal) layer and fewer organized epithelial 
structures (alveolar-like structures) in the (FN)(EN) recombinants. Similar structural 
abnormalities have been observed in hypoplastic lungs of nitrofen-treated rodents 
and children with CDH 5-7, 21-24. Hence, we believe the pulmonary cell recombinant 
model is an adequate in vitro model for pulmonary hypoplasia in CDH. More im-
portantly, the in vitro model enabled us for the fi rst time to recombine a ‘healthy’ 
with a ‘diseased’ tissue layer and investigate the unique crosstalk between the two 
tissue layers. After establishing a functional model for homotypic recombinants 
(recombining epithelial cells and fi broblasts from the same treatment lung group), 
we created heterotypic recombinants (recombining epithelial cells and fi broblasts 
from opposing treatment lung groups) to decipher which layer was malfunctioning 
and, simultaneously, to investigate potential rescue of the malfunctioning layer, by 
evaluating cell-cell interactions. Morphologically, the heterotypic recombinants 
containing control fi broblasts (FC) mimic the control (FC)(EC) recombinants whereas 
recombinants containing nitrofen fi broblasts (FN) are similar to the nitrofen (FN)(EN) 
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  (Fc)(Ec)              (FN)(EN)         (Fc)(EN)    (FN)(Ec)
Figure 8. Nitrofen exposure does not alter cell differentiation in recombinants. IF for αSMA (smooth 
muscle cells; green) and cytokeratin (epithelial cells; orange) in recombinants counterstained with 
DAPI (nuclei; blue) showed a similar pattern of myofi broblast staining in all four types of recombinants 
(A – D). Pro-SFTPC (type II epithelial cells; red) counterstained with DAPI (nuclei, blue) demonstrated 
also a similar pattern of staining in all four types of recombinants (E – H). The scale bar represents 50μm.
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recombinants, suggesting a defect in the nitrofen-treated fi broblast layer. Previous 
studies hypothesized that the mesenchymal tissue layer was defective in nitrofen-
treated diaphragm primordia, based on the observed morphology of a thickened 
fi broblast tissue layer 25. We hereby, for the fi rst time, provide evidence that the 
fi broblast tissue layer is also the defective tissue layer in nitrofen-induced pulmonary 
hypoplasia. More importantly, this defect was intrinsic to the fi broblasts and not 
infl uenced by epithelial-mesenchymal interactions.
Decrease in apoptosis of fi broblasts
Apoptosis is one of the developmental entities essential to the formation of a 
healthy lung 26. Immunohistochemical (TUNEL and cleaved caspase-3) analyses 
demonstrated less apoptosis in FN containing recombinants in comparison to FC 
containing recombinants. In addition, E19 whole lungs of the nitrofen-treated em-
bryos demonstrated less apoptosis versus control embryos. Apoptotic cells were 
mainly fi broblasts, as expected from previous studies 26, 27. Diminished apoptosis of 
fi broblasts could explain the thickened fi broblast tissue layer seen in FN containing 
recombinants. Diminished apoptosis could also explain the fewer alveolar-like 
structures observed due to this increase in fi broblasts. Furthermore, inhibition of 
apoptosis of the fi broblast layer has been reported to reduce epithelial branching, 
which could also contribute to decreased formation of alveolar-like structures 27. To 
our knowledge, this is the fi rst time a decrease in apoptosis has been demonstrated 
in nitrofen-treated lung cells and E19 whole lungs. In previous reports, TUNEL analy-
sis did not demonstrate differences between control and nitrofen-exposed explants 
9 nor in whole lungs after nitrofen treatment in vivo 13, 28. Similar to our recombinant 
fi ndings, TUNEL-positive cells were mainly detected in the fi broblast layer of lung 
explants 9. In vitro exposure to nitrofen increased apoptosis of NIH 3T3 and HEK-
293 cells, and rat fetal lung explants 28, 29. An explanation for these confl icting results 
could be that in our study whole lungs and lung cells from the recombinant experi-
ments were exposed to nitrofen in vivo at E9 and harvested at E19. All other studies 
investigated E12 – E16.5 rat lungs and it appears that pulmonary apoptosis is more 
pronounced later in gestation 26. In addition, E19 lungs of nitrofen-treated rats are 
subjected to mechanical compression and lack proper fetal breathing movements 
(due to herniation of abdominal contents into thorax), which negatively impacts cell 
growth 9, 30 and may have an infl uence on apoptosis as well. It is also possible that 
exposure to nitrofen in vitro as opposed to exposure in vivo could generate different 
results. An overview of the literature is shown in Table 1.
Proliferative arrest
In the present study, we found a late arrest in the G1-to-S-phase transition of the cell 
cycle in FN containing recombinants. Similar amounts of cyclin D3- and E-positive 
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cells were seen in all four types of recombinants. In contrast, signifi cantly less ki67- 
and pH3-positive cells were detected in FN containing recombinants. Also, fewer 
EdU-positive cells were noted in (FN)(EN) recombinants (heterotypic recombinants 
were not assessed). Thus, FN containing recombinants appear to have a late G1 ar-
rest and are unable to continue the proliferation cycle. The exact mechanism of 
this G1 arrest remains to be elucidated. Similar to our observation with E19 lungs, 
previous studies have reported decreased proliferation in nitrofen-treated rat lungs 
9,  13. Jesudason et al. (2000) showed reduced lung cell proliferation 24 hours prior 
to diaphragm closure (E15.5) in nitrofen-treated rats, while we found a diminished 
fi broblast proliferation in nitrofen-exposed lung explants 9,  13. In addition to lung, 
Clugston et al. (2009) demonstrated a decrease in cellular proliferation of the 
pleuroperitoneal fold (diaphragm) in nitrofen-treated rat embryos 28. None of these 
studies addressed the specifi c phase of the cell cycle involved and the present 
study is the fi rst one to report a proliferative arrest in the G1-to-S-phase transition in 
nitrofen-induced pulmonary hypoplasia. Quantitative analyses of pH3-positive cells 
demonstrated a more than two-fold decrease of proliferation in both epithelial and 
fi broblast tissue layers. Western blot analysis demonstrated increased expression of 
Cdk inhibitors, p27Kip1 and p57Kip2, in nitrofen-treated fi broblasts. Although the in-
crease in Cdk inhibitors agrees with the proliferative arrest in the late G1-phase in the 
FN containing recombinants, it does not explain the overall increase in fi broblasts. 
One possibility is that the reduction in apoptosis of fi broblasts in the FN containing 
recombinants outbalances the decrease in proliferation. The decrease in proliferat-
ing epithelial cells likely explains the fewer alveolar structures observed in the FN 
containing recombinants. An intriguing insight into the late G1-phase arrest is the 
link to RA. RA has been connected to the etiology of nitrofen-induced abnormalities 
and the human CDH lung since 1941 by Andersen 11, 12, 31 reviewed in 11. RA treatment 
has demonstrated to reduce the number of hernias and to induce lung growth in 
nitrofen-treated embryos 23, 32, 33. It has been shown that RA protects alveolar epithe-
lial cells from a late G1-phase arrest induced by hyperoxia 
34. Cells exposed to oxygen 
did form less cyclin E-Cdk complexes but these complexes regained normal values 
when oxygen-exposed cells were pretreated with RA. Interestingly, we observed a 
late G1-phase arrest in the FN containing recombinants. Several treatment options 
have been aimed at increasing proliferation in CDH-associated pulmonary hypopla-
sia but none has specifi cally targeted a G1-phase proliferative arrest 
35, 36. An overview 
of the literature is shown in Table 1.
Differentiation not altered
Four investigated cell differentiation markers (TITF-1, CCSP, αSMA, pro-SFTPC) were 
present and not differently distributed among isolated cells and the recombinants. 
PECAM was absent in freshly isolated cells prior to recombination and in the recom-
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binants, which indicates no endothelial cells were isolated during primary culture. 
The standard primary culture techniques we utilized to obtain epithelial cells and fi -
broblasts did not allow us to isolate endothelial cells. In addition, differentiation into 
endothelial cells during the culture period did not occur. Endothelial cells in human 
fetal hypoplastic lungs did not appear to be different from healthy lungs 37. αSMA 
was present in all four groups, but no apparent differences were observed. Smaller 
pulmonary vessels, which are normally not muscularized, contain smooth muscle 
cells in CDH hypoplastic human lungs 38, 39. Furthermore, the hypoplastic CDH hu-
man lung contains a decrease in interstitial and bronchial smooth muscle cells 37. In 
previous studies, differences between normal lungs and nitrofen-treated lungs have 
been reported for these differentiation markers 9,  21,  24,  40-43. This discrepancy could 
be due to the use of isolated cells in our experiments instead of using whole lungs. 
Whole lungs are exposed to mechanical forces from lung liquid and fetal breathing 
movements that contribute to lung growth and maturation by inducing stretch and 
expansion 30, 44. Due to a defect in the diaphragm in CDH and herniation of abdomi-
nal organs into the thorax, contractions for fetal breathing movements are disturbed, 
which makes the lung liquid expanding forces in nitrofen-induced lungs less effi cient 
than in normal fetal lungs. This may lead to a disturbance in cell differentiation in vivo 
that is too subtle (or not present at all) to be detected in isolated lung cells in vitro. An 
overview of the literature is shown in Table 1.
Fibroblasts are the defective tissue layer in nitrofen-induced pulmonary 
hypoplasia
Based on our fi ndings, we postulate that lung fi broblasts are the primary mal-
functioning layer in the nitrofen model (Figure 9). As cell markers were similar in 
nitrofen-treated and control cells just after isolation of the cells and prior to making 
the recombinants, all observed differences in recombinants are considered to be 
due to the intrinsic qualities of the cells and their cellular interactions. Interest-
ingly, various CDH rodent models have shown a defective fi broblast (mesenchymal) 
compartment of the pleuroperitoneal fold as the underlying mechanism resulting in 
diaphragmatic defects 25, 45, 46. The fact that we observed similar structures in FC con-
taining recombinants can be explained by the postulated hypothesis, as there are 
no malfunctioning FN cells in these recombinants present which makes them appear 
like normal lungs. The abnormal structures of FN containing recombinants may be 
explained by the presence of a malfunctioning FN tissue layer. ‘Rescue’ of diminished 
apoptosis through recombination with a healthy epithelial layer EC did not occur. (FC)
(EC) and (FC)(EN) recombinants had a comparable phenotype, supporting the concept 
of EN being unaffected. The observed thickening of the fi broblast tissue layer in FN 
containing recombinants could be the result of the observed diminished apoptosis 
in this tissue layer. Epithelial cells EC and EN were unable to rescue this defect, imply-
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ing that the diminished apoptosis was intrinsic to the nitrofen-exposed fi broblasts. 
The decrease in proliferation in FN but not FC containing recombinants was equally 
notable in epithelial cells and fi broblasts. Therefore the diminished proliferation in 
the epithelial cells must be due to the infl uence of the defective FN fi broblasts since 
we did not observe such an effect in the FC containing recombinants. Taken together, 
the diminished proliferative capacity probably refl ects in the smaller size of the lungs 
(pulmonary hypoplasia), while the diminished apoptosis of the fi broblasts causes 
the thickening of the fi broblast tissue layer. Identifi cation of the timing and, eventu-
ally, targeted modulation of the defect in the fi broblasts during lung development 
warrants more research.
Limitations of our model
We are aware of the limitations of our study. First of all, we are dealing with an animal 
model for pulmonary hypoplasia in CDH based on the teratogenic effects of the 
herbicide nitrofen; a role of herbicides such as phenyl ether compounds in the etiol-
ogy of human CDH has never been found. Nitrofen was found to inhibit RALDH2, 
an enzyme involved in the RA pathway 47, and, recently, lower levels of retinol and 
retinol binding protein were documented in human umbilical cord blood 12. This 
Normal lung 
development
CDH hypoplastic 
lung development
Apoptosis 
fibroblasts
Proliferation
Apoptosis 
fibroblasts
Proliferation
Figure 9. Schematic representation of the hypothesis. A schematic representation of our hypothesis 
of the pathogenesis in pulmonary hypoplasia: the lung fi broblasts are the malfunctioning layer. Both 
a defect in mesenchymal apoptosis and a proliferative arrest generate the characteristic image seen in 
hypoplastic CDH lungs such as thickening of the fi broblast (mesenchymal) tissue layer and reduced 
alveolar spaces.
64
Chapter 3
suggests a possible epigenetic role of RA metabolism in the pathogenesis of human 
CDH. However, despite its shortcomings, the pharmacological nitrofen model is the 
preferred model to investigate pathogenetic aspects of (pulmonary hypoplasia in) 
CDH as it has very similar characteristics to human CDH 22, 48. The surgical model, 
another model for human CDH, is mainly suitable to investigate interventional 
strategies in CDH. In this model a hernia is surgically created in the diaphragm and 
abdominal organs are positioned in the thoracic cavity of either fetal sheep or rab-
bits to optimally mimic human CDH. Limitations of this model are the creation of 
pulmonary hypoplasia by mechanical interference while lungs in itself are normal, 
the relatively late creation of the defect during lung development, and the almost 
completed alveolization in sheep while in humans only 20% of adult alveolization 
is achieved at that timepoint. Genetic mouse models have also been used to study 
pulmonary hypoplasia in CDH. However, no knockout mouse model is presently 
available that mimics the human phenotype with isolated left posterior CDH (Boch-
dalek’s hernia) and pulmonary hypoplasia suffi ciently. Recently, common expres-
sion of transcription factor (regulator)s such as CoupTFII, GATA-binding protein 4 
(GATA4), and Friend of GATA2 (FOG2) have been identifi ed in both the developing 
lung and diaphragm, and are located on chromosome regions commonly deleted in 
individuals with CDH 46, 49, 50. However, no single gene mutation has been identifi ed 
to date, and, as the CDH phenotype is so variable, it is unlikely to be caused by 
a single gene mutation but more a result of multiple gene defects. Therefore the 
use of genetic mice models was deemed unfeasible to address our study objec-
tive. An overview of CDH models has been elaborately reviewed in 10,  11. Another 
argument that supports the signifi cance of the nitrofen model is the link to the RA 
signaling pathway. Nitrofen has been demonstrated to interfere with the RA pathway 
in several ways and consequently with the before mentioned transcription factor 
(regulator)s (GATA4, CoupTFII, etcetera) 10, 11. The so-called retinoic acid hypothesis 
was recently supported by our human studies, which showed that human newborns 
with CDH had signifi cant lower retinol and retinol binding protein levels in umbilical 
cord blood 12.
Secondly, our recombination model is an in vitro cell culture model based on an 
experimental approach. Even though the hernia and pulmonary hypoplasia were 
induced in vivo, the recombinants were cultured in vitro. We realize that our re-
combinants mimic lung development under unnatural conditions, and we cannot 
exclude that this infl uences certain developmental processes. For example, in our 
experiments we recombined equal numbers of fi broblasts with epithelial cells. We 
did not take into consideration that hypoplastic (nitrofen) lungs contain less cells, 
or that the ratio of fi broblasts and epithelial cells might not be 1:1 during in vivo lung 
development. However, as was previously demonstrated, alveolar-like structures 
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did form and important structural differences between recombinant groups became 
apparent following recombination with different sources of fi broblasts 17. In addition, 
previous experiments by our group also demonstrated no differences between using 
recombinants in a 1:1 or 1:3 (Fibroblasts : Epithelial cells) ratio (results not shown). 
Consequently, since our goal was to investigate the interactions between different 
tissue layers during (ab)normal lung development, this in vitro model was deemed 
appropriate. In order to translate the obtained results of this nitrofen rat-model to 
human CDH, the obvious next step would be to use this in vitro model using human 
CDH lung samples. However, given the limited availability of fresh pulmonary tis-
sues from terminated pregnancies, such an approach is nearly impossible due to 
ethical and logistical problems.
Relevance for human pulmonary hypoplasia in CDH
Our hypothesis of fi broblasts being the defective tissue layer in hypoplastic CDH-
lungs becomes more interesting when we relate it to the abnormalities observed 
in human CDH-associated pulmonary hypoplasia. Characteristics of human pul-
monary hypoplasia in CDH are thickened alveolar walls, an increase in interstitial 
tissue, reduced alveolar air spaces and reduced gas-exchange surface area 2,  5-7. A 
malfunctioning fi broblast layer could basically explain all these features. A decrease 
in apoptosis of fi broblasts prevents the thinning of the interstitial fi broblast layer nor-
mally seen during later lung development 51, 52. The increase in alveolar wall thickness 
likely results in more primitive alveolar saccules. In addition, the proliferative arrest 
of epithelial cells may contribute to reduced air spaces and, therefore, a reduction 
in the gas-exchange area 5-7, 21. Our fi ndings do not support an immature state of CDH 
lungs, as reported by others 53, 54. The idea that the CDH hypoplastic lung is immature 
remains controversial since to date no studies have reported primary surfactant de-
fi ciencies in human and nitrofen-induced CDH lungs 55, 56, neither a decreased pool 
size of surfactant 57. Oligohydramnios due to obstructive uropathy, another cause 
of human pulmonary hypoplasia, has different morphological features and might 
therefore not be associated with the pathogenesis for pulmonary hypoplasia in CDH 
58. Further research is warranted to investigate whether this defect in the fi broblast 
tissue layer is present in human CDH lungs as well. Unfortunately, as mentioned ear-
lier, the recombinant approach cannot easily be applied to human CDH lungs. Even 
in whole human postnatal CDH lungs experimental results should be interpreted 
carefully, as it is diffi cult to distinguish if observed differences are due to the underly-
ing cause of the hypoplastic CDH lungs or secondary to treatment modalities such 
as ventilation and extracorporeal membrane oxygenation (ECMO).
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Future directions
Utilizing this cell recombinant in vitro model, we demonstrated the malfunctioning 
fi broblast tissue layer to exhibit decreased apoptosis and an arrest in proliferation. 
Future experiments need to address the mechanism by which these processes are 
infl uenced. Several fi broblast growth factors (FGFs) are known to play an important 
role in lung development 59, 60. For instance FGF2 plays a role in lung cell apoptosis, 
while FGF1 is an example of a growth factor with proliferative qualities 61, 62. In ad-
dition, in the nitrofen model both FGF7 and FGF10, and FGF receptor L1 (FGFRL1) 
were downregulated, while recently LopezJimenez et al. demonstrated a CDH 
patient with a 4p16.3 deletion that included the FGFRL1 region 63-65. The next step 
to elucidate the pathogenesis and work towards innovative therapeutic strategies 
would be to investigate FGFs and their receptors in this model. Also the effect of 
RA given the strong link with the pathogenesis in humans as documented before is 
worth investigating 23.
CONCLUSIONS
We demonstrated that the fi broblast tissue layer is malfunctioning in nitrofen-
induced pulmonary hypoplasia. Knowing the malfunctioning tissue layer will aid 
to develop targeted treatments inducing apoptosis in fi broblasts and annulling the 
proliferative arrest. An example of a treatment modality that could induce these 
two components is tracheal occlusion. In both surgically- and nitrofen-induced 
diaphragmatic hernia models, tracheal occlusion induces fi broblast apoptosis and 
accelerates cell proliferation 35, 66-69, the main defects according to our recombinant 
model. Thus, this treatment modality appears to have great potential.
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ABSTRACT
Background It is well established that lung morphogenesis is dependent on epithe-
lial-mesenchymal interactions; however, the exact molecular mechanisms guiding 
lung organogenesis have yet to be determined. Cell proliferation has been recog-
nized as a crucial modulator of lung development. Apoptosis is another important 
mechanism involved in remodelling of both the prenatal and postnatal lung; for 
instance late gestational thinning of the fi broblast tissue layer through apoptosis is 
important to optimize postnatal gas exchange in the lungs. The aim of our study was 
to investigate the infl uence of gestational stage on epithelial-mesenchymal interac-
tions through cell proliferation and apoptosis during lung morphogenesis utilizing 
an in vitro cell recombinant model.
Methods Embryonic day (E)13 endodermal and mesenchymal cells and E19 epithelial 
cells and fi broblasts were isolated from fetal rat lungs using standard primary culture 
techniques. The cells were then recombined in various combinations and cultured. 
In these recombinants, proliferation and apoptosis were investigated using PCNA 
immunohistochemistry and TUNEL-assay, respectively.
Results We observed more proliferating cells in homotypic E13 recombinants than 
in homotypic E19 recombinants. The proliferation characteristics of the different tis-
sues appeared to be intrinsic to those tissues, and were not altered by heterotypic 
recombination. Homotypic E19 recombinants and E19 fetal lungs demonstrated 
more apoptosis in fi broblasts than homotypic E13 recombinants and E13 fetal lungs, 
respectively. To our surprise, apoptosis of E19 fi broblasts was abolished, when the 
fi broblasts were recombined with E13 endodermal cells.
Conclusions Our results suggest that apoptosis of the fi broblast tissue layer late 
in pulmonary development is regulated by the surrounding epithelial cells, and 
consequently is not intrinsic to the fi broblasts itself. With our study we are a step 
closer to understanding the physiology of normal lung development, which will aid 
in deciphering the pathogenesis of, and ultimately design targeted treatments for, 
developmental lung diseases such as pulmonary hypoplasia in CDH and oligohy-
dramnios.
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INTRODUCTION
Organogenesis of the lung is highly dependent on epithelial-mesenchymal interac-
tions as well as cell-matrix interactions 1-3. Several tissue recombination studies have 
demonstrated that for normal branching morphogenesis of the lung to occur, inter-
action between lung epithelium and lung mesenchyme is a prerequisite 4-7. It has 
long been recognized that branching morphogenesis of lung epithelium is guided 
by instructions from the surrounding mesenchyme. Interestingly, proximal tracheal 
epithelium, which is normally not able to branch, can in this manner be forced to 
undergo branching morphogenesis when recombined with distal lung mesenchyme 
8. In contrast, recombining proximal tracheal lung mesenchyme with distal lung 
epithelium, which is normally undergoing extensive branching morphogenesis dur-
ing pulmonary development, inhibits branching 9. Additional experiments demon-
strated that epithelial differentiation is dependent on the type of mesenchyme used 
for recombination 6, 10 (for review see 5). These epithelial-mesenchymal interactions 
are modulated by a well-orchestrated interplay between hormones, growth factors 
and extracellular matrix proteins (for review see 1-3,  5,  11). Various factors have been 
revealed by experiments with isolated mesenchyme-free pulmonary epithelium. In 
this system isolated epithelium could be stimulated to undergo branching morpho-
genesis when it was cultured in the presence of a specifi ed mix of certain growth 
factors and extracellular matrix proteins 12. All these experiments have demonstrated 
an important role for the mesenchyme in instructing the developing epithelium in 
lung development. However, the infl uence of epithelium on development of the 
mesenchyme is less well understood.
The aim of our study was to investigate the infl uence of gestational stage on 
epithelial-mesenchymal interactions through cell proliferation and apoptosis dur-
ing lung morphogenesis utilizing an in vitro cell recombinant model. Apoptosis 
and proliferation are a crucial part of epithelial-mesenchymal interactions in lung 
development. Cell proliferation has been recognized as a crucial modulator not only 
for lung growth, but also for branching morphogenesis 3, 13-16. Outgrowth of terminal 
lung buds is associated with higher numbers of proliferating cells. Programmed cell 
death, apoptosis, is another important mechanism involved in remodelling of both 
the prenatal and postnatal lung 17-20. Apoptosis was demonstrated to occur predomi-
nantly in the mesenchyme, in particular during the pseudoglandular phase and peri-
natally 18-20. Perinatally a huge thinning of the pulmonary mesenchyme has to occur 
in order to enable gas exchange over the pulmonary epithelium. During this process, 
apoptosis is known to play a signifi cant role 17-19. Taken together, a balanced interplay 
between cell proliferation and apoptosis, is required to help the primary lung bud to 
become the postnatal gas exchanging organ. Herein, we investigated apoptosis and 
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proliferation in normal fetal rat lungs and, more specifi cally, studied the infl uence 
of gestational stage on epithelial-mesenchymal interactions utilizing a previously 
established in vitro cell recombinant model 10, 21. We demonstrate that apoptosis of 
the fi broblasts late in pulmonary development is regulated by surrounding epithelial 
cells in this in vitro cell recombinant model.
METHODS & MATERIALS
Animals
The animal care committee of the Hospital for Sick Children approved all experi-
mental procedures. Female (200 - 250 g) and male (250 - 300 g) Wistar rats were 
obtained from Charles River (St. Constant (QC)). The animals were kept in a con-
trolled light-dark cycle and food and water were supplied ad libitum. Rats were 
mated overnight and the fi nding of a sperm-positive vaginal smear was designated 
embryonic day (E)0. At E13 and E19 (term = E22), timed-pregnant rats were sacrifi ced. 
The fetuses were delivered by Caesarian section using aseptical surgical techniques.
Cell isolation
Using microsurgical techniques, lungs were dissected from embryos at E13 and 
transferred to Hanks Balanced Salt Solution (-) from Gibco (Grand Islands (NY)). E13 
lungs were divided into two groups: to be used as whole fetal lungs or as isolated 
cells for the cell recombinants. To obtain E13 isolated cells, we treated E13 lungs with 
20% (v/v) dispase and 100mg/ml DNAse for 45 minutes at 37°C in order to aid in 
the surgical separation of the tissue layers. Following neutralization of enzyme activ-
ity with fetal calf serum (FCS), the epithelial and mesenchymal components were 
separated under a dissection microscope, using microsurgical techniques. Single 
cells were isolated from the endodermal and mesenchymal cell layers by gentle 
mechanical agitation.
Simultaneously, lungs were isolated from E19 embryos. E19 lungs were divided into 
two groups for the use of E19 whole fetal lungs and to isolate E19 cells to be used for 
recombinants. To obtain E19 isolated cells, epithelial cells and fi broblasts were iso-
lated using standard primary culture techniques, as previously described 10. Isolated 
epithelial cells and fi broblasts were evaluated for purity as described previously 21. 
E13, E16, E19, E21 and postnatal day (P)1 lungs were isolated to investigate the spatial 
and temporal changes of proliferation and apoptosis during development.
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Formation of recombinants
Recombinants were formed as previously described 10,  21. Briefl y, E13 endodermal 
cells were recombined with either E13 mesenchymal cells or E19 fi broblasts; E19 epi-
thelial cells were recombined with either E13 mesenchymal cells or E19 fi broblasts 
(Figure 1), and transferred to 4mm porous membranes (Millipore, Bedford (MA)). The 
cell recombinants were cultured at 37°C in an atmosphere of 5% CO2 in air for fi ve 
days. During the culture period, medium was changed daily. E13 endodermal and 
mesenchymal cells as well as E19 epithelial cells and fi broblasts were cultured alone 
as well.
Tissue preparation
All lungs, epithelial cells and fi broblasts alone, and the recombinants were fi xed in 
4% (v/v) paraformaldehyde in phosphate buffered saline (PBS) overnight at 4°C, de-
hydrated and embedded in paraplast (Oxford Labware, St. Louis (MO)). Sections of 
5μm were cut and mounted on Superfrost slides (Fisher Scientifi c, Unionville (ON)).
Immunohistochemistry
Immunohistochemistry was carried out as described previously 22. Following pre-
treatments including antigen retrieval, sections of the recombinants were incubated 
with primary antibodies at 4°C overnight. Primary antibodies used were 1:5 mouse 
anti-pan cytokeratin (Boehringer Mannheim, Laval (QC)), undiluted mouse anti-
vimentin (Serotec, Missisauga (ON)) and 1:1000 mouse anti-proliferating cell nuclear 
antigen (PCNA; Santa Cruz Biotechnology, Santa Cruz (CA)). Sections were washed 
                        
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Figure 1. Schematic representation of recombination experiments. Schematic representation of 
the various combinations that were used in the recombination experiments. Following separation of 
lung cell layers, E13 endodermal cells (black circles) and E13 mesenchymal cells (black half circles) 
were recombined in homotypic recombinants (model 1). The same procedure was used in making 
the homotypic recombinants of E19 epithelial cells (grey circles) and E19 fi broblasts (grey half circles) 
(model 2). In heterotypic recombinants, E13 endodermal cells (black circles) were recombined with 
E19 fi broblasts (grey half circles) (model 3) and E19 epithelial cells (grey circles) were recombined with 
E13 mesenchymal cells (black half circles) (model 4).
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and incubated for one hour at room temperature with 1:200 biotinylated anti-mouse 
IgG (Calbiochem, LaJolla (CA)). Sections were washed and incubated for two hours 
at room temperature with Vectastain (avidin-biotin peroxidase-kit) (Vector Labora-
tories, Burlingame (CA)). Subsequently, sections were washed, and developed in 
3,3’-diaminobenzidine. Hematoxylin was used to counterstain sections. Sections 
were dehydrated and mounted with Permount. Terminal Deoxyribonucleotidyl 
Transferase dUTP Nick-End labeling (TUNEL)-assay was carried out as described 
previously 22. 4’,6-diamidino-2-phenylindole (DAPI) was used to counterstain the 
nuclei of cells.
RESULTS
Morphogenesis of the recombinants
E13 and E19 lungs were used for the recombination studies. At the saccular stage 
(E19) of lung development there is a peak in prenatal apoptosis and E13 lungs are the 
smallest lungs to isolate cell layers with a reasonable yield 19, 20. After approximately 
72 hours of culture of the recombinants, morphogenesis started to occur spontane-
ously in all previously unorganized clumps of cells (results not shown). After fi ve 
E13endo / E13mes    E19epi / E19fib
E13endo / E19fib          E19epi / E13mes
A B
DC
A B
C D
Figure 2. Cell proliferation in recombinants. An antibody against PCNA was used to investigate 
cell proliferation in the recombinants. Highest numbers of proliferating cells (endodermal and 
mesenchymal cells) were observed in E13 homotypic recombinants (A). In E19 homotypic recombinants 
(B) proliferating cells were mainly observed in the epithelial cell layer and much less in the fi broblast 
tissue layer. In the heterotypic recombinants of E13 endodermal cells and E19 fi broblasts, proliferating 
cells were predominantly localized in the endodermal cell lining (C). In the heterotypic recombinants 
of E19 epithelial cells and E13 mesenchymal cells, proliferation was less pronounced, but evenly 
distributed over both cell layers (D). The scale bar represents 100μm.
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days of incubation, the E13 homotypic recombinants (E13 endodermal cells with E13 
mesenchymal cells) developed large airspaces with a lining of cuboidal endodermal 
cells surrounded by mesenchymal cells. These resembled the E13 fetal lungs (Figure 
3A). In the E19 homotypic recombinants (E19 epithelial cells with E19 fi broblasts), 
alveolar-like structures formed containing a circle lining of epithelial cells and a thin 
layer of fi brobasts. Again, this resembled the situation observed in the E19 fetal lungs 
(Figure 3B).
In the heterotypic recombinants with E13 endodermal cells and E19 fi broblasts large 
airspaces with a thick lining of cuboidal endodermal cells were formed (Figure 2C). 
Fibroblasts surrounded the endodermal lining. The structures of these recombinants 
resembled the structure of the E13 homotypic recombinants (Figure 2A) and E13 fetal 
lungs (Figure 3A).
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Figure 3. Cell proliferation in fetal lungs and cells alone. In a series of control experiments, cell 
proliferation (PCNA) was investigated in fetal lungs, cells of endodermal / epithelial origin alone and 
mesenchymal cells or fi broblasts alone. In E13 fetal lungs extensive proliferation was observed in both 
the endodermal cell layer and mesenchyme (A). As in the E19 homotypic recombinants, in E19 fetal 
lungs more proliferating cells were observed in the epithelial cell layer than in the fi broblast layer (B). 
In isolated E13 endodermal (C) and mesenchymal (E) cells high amounts of proliferating cells were 
present. Isolated E19 epithelial cells (D) had more proliferating cells than E19 fi broblasts (F). The scale 
bar represents 100μm.
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In the heterotypic recombinants of E19 epithelial cells and E13 mesenchymal cells 
more alveolar-like structures were observed (Figure 2D), albeit smaller than observed 
in the E19 homotypic recombinants (Figure 2B) or the E19 fetal lungs (Figure 3B).
Proliferation
Using an antibody against PCNA, a cell cycle associated protein, we investigated 
patterns of proliferation in the different types of recombinants 23. Extensive cell 
proliferation was observed in endodermal and mesenchymal cells in E13 homotypic 
recombinants (Figure 2A) as well as in the E13 lungs (Figure 3A). In contrast, in the E19 
TUNEL     DAPI
E1
9e
pi
/E
13
m
es
 
  E
13
en
do
/E
19
fib
 
   
   
 E
19
ep
i/E
19
fib
 
   
   
E1
3e
nd
o/
E1
3m
es
   A B
C D
E F
G H
Figure 4. Apoptosis in recombinants. Apoptosis was determined in the recombinants using TUNEL-
assay (A,C,E,G). Nuclei were stained with DAPI to visualize the structure of the recombinants (B,D,F,H). 
In the E13 homotypic recombinants only a few TUNEL-positive cells were observed in the mesenchymal 
cells (A). The same holds true for both the heterotypic recombinants of E13 endodermal cells and E19 
fi broblasts (E) and the heterotypic recombinants of E19 epithelial cells and E13 mesenchymal cells (G). 
In contrast, extensive apoptosis was observed in the E19 fi broblasts in the E19 homotypic recombinants 
(C). The scale bar represents 100μm.
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homotypic recombinants proliferating cells were mainly observed in the epithelial 
lining and much less so in the fi broblasts (Figure 2B). A similar pattern was observed 
in the E19 lungs (Figure 3B). The distribution of PCNA-positive cells changed from be-
ing abundantly present in both tissue layers at E13 to mainly present in endodermal/
epithelial lining at P1 (Figure 6: left column).
In the heterotypic recombinants, a similar pattern of proliferation was observed. 
In the recombinants of E13 endodermal cells and E19 fi broblasts (Figure 2C), pro-
liferating cells were predominantly localized in the endodermal cells, whereas 
proliferation appeared to be attenuated in the fi broblasts when compared to the E13 
homotypic recombinants (Figure 2A). In the recombinants of E19 epithelial cells and 
E13 mesenchymal cells, proliferation appeared to be less pronounced, but evenly 
distributed between epithelial cells and mesenchymal cells (Figure 2D). In isolated 
E13 endodermal and mesenchymal cells high amounts of proliferating cells were 
present (Figure 3C,E). Isolated E19 epithelial cells had more proliferating cells than 
E19 fi broblasts (Figure 3D vs 3F). Results are summarized in Table 1.
Apoptosis
Using the TUNEL-assay, apoptosis was investigated in all recombinants. Apoptotic 
cells were only observed in the mesenchymal cells and fi broblasts. In the E13 ho-
motypic recombinants TUNEL-positive cells were sporadically observed in the 
fi broblast tissue layer (Figure 4A). In contrast, almost every fi broblast was TUNEL-
positive in the E19 homotypic recombinants (Figure 4C). Similarly, we observed more 
apoptosis in the fi broblast tissue layer in E19 fetal lungs in comparison to E13 (Figure 
A B E F
 TUNEL          DAPI               TUNEL     DAPI
E1
3 
M
es
en
ch
ym
e 
   
   
   
E1
3 
Fe
ta
l L
un
gs
E1
9 
Fi
br
ob
la
st
s 
   
   
   
   
 E
19
 F
et
al
 L
un
gs
I   J
HGC D
J
Figure 5. Apoptosis in fetal lungs and cells alone. In control experiments, apoptosis was investigated 
in fetal lungs and isolated cell cultures. In E19 fetal lungs (E) more apoptosis was observed compared to 
E13 fetal lungs (A). E13 mesenchymal cells (C) and E19 fi broblasts (G) had a minimal amount of TUNEL-
positive cells. The scale bar represents 50μm.
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5E vs 5A), E16 and E21 fetal and P1 postnatal lungs (Figure 6: right column). In both 
heterotypic recombinants, a similar pattern as in the E13 homotypic recombinants, 
was observed: hardly any mesenchymal cell or fi broblast was TUNEL-positive, and 
no TUNEL-positive endodermal or epithelial cells were observed (Figure 4E,G). The 
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Figure 6. Proliferation and apoptosis during fetal lung development. In a control experiment, 
spatial and temporal changes of proliferation (PCNA: left column) and apoptosis (TUNEL-assay: right 
column) during fetal rat lung development were assessed. Proliferation changed from abundantly 
present in both tissue layers to mainly present in the epithelial lining of the lungs. Apoptosis was most 
pronounced in the saccular phase (E19) of fetal rat lung development. The black scale bar represents 
100mm; the white scale bar represents 50μm.
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same was seen in the E13 mesenchymal cells (Figure 5C) and E19 fi broblasts (Figure 
5G) when cultured alone: only a few cells were TUNEL-positive. Only non-specifi c 
background staining was observed in the E13 endodermal cells and E19 epithelial 
cells (results not shown). DAPI was used to visualize the nuclei (Figure 4B,D,F,H and 
Figure 5B,D,F,H). Results are summarized in Table 1.
DISCUSSION
Morphogenesis of the lung has long been recognized to be highly dependent on 
epithelial-mesenchymal interactions 1,  3,  24. Most studies focussed on branching 
morphogenesis and demonstrated epithelial-mesenchymal interactions in one 
direction: pulmonary epithelial branching morphogenesis is regulated by factors 
produced by its surrounding mesenchyme 1, 3, 11. Using a cell recombinant model of 
fetal rat lung we provide evidence for regulation of mesenchymal morphogenesis by 
its surrounding epithelium in a gestational stage-dependent manner.
Apoptosis of E19 fi broblasts was demonstrated to be developmentally regulated by 
epithelial cells. Apoptosis of E19 fi broblasts occurred when they were recombined 
with E19 epithelial cells, but not when E19 fi broblasts were recombined with E13 
endodermal cells. On the other hand, E13 mesenchymal cells could not be forced 
to undergo apoptosis by recombining them with E19 epithelial cells. Therefore, we 
Table 1. Summary of proliferation and apoptosis in all cultures
Proliferation Apoptosis
Type of culture Endodermal or 
epithelial cells
Mesenchymal cells 
or fi broblasts
Endodermal or 
epithelial cells
Mesenchymal cells 
or fi broblasts
E13 fetal lungs +++ +++ - +
E13 endo only +++ n/a - n/a
E13 mes only n/a +++ n/a ++
E13 endo/E13 mes +++ +++ - +
E19 fetal lungs +++ + - ++
E19 epi only ++ n/a - n/a
E19 fi b only n/a + n/a +
E19 epi/E19 fi b ++ + - +++
E13 endo/E19 fi b +++ + - +
E19 epi/E13 mes ++ ++ - +
+++ indicates high number of cells; ++ indicates medium number of cells; + indicates low number of 
cells; - indicates no cells; n/a indicates not applicable. E indicates embryonic day; endo indicates 
endodermal cells, epi indicates epithelial cells, fi b indicates fi broblasts, mes indicates mesenchymal 
cells.
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believe that thinning of the pulmonary mesenchymal tissue layer through apoptosis 
(as observed in E19 fetal lungs) is regulated by its surrounding epithelial cells, and is 
not intrinsic to the fi broblast tissue layer itself. The distribution of apoptotic cells is in 
accordance with what has been reported in vivo during rat pulmonary development, 
and what we observed in E19 fetal rat lungs 18. Apoptotic cells were only observed in 
the mesenchymal cell layer, and predominantly during the later stages of pulmonary 
development 18, 19.
Apoptosis characteristics appeared to be extrinsic to the cells, since they changed 
depending on the gestational age of the cells that was used for recombination. An in-
crease in apoptosis occurs during normal prenatal lung development, as confi rmed 
in the E19 fetal lungs. This could have several explanations. Logically, this could be 
the result of a cell’s intrinsic induction of apoptosis. However, in our experiments, 
E19 fi broblasts did not undergo apoptosis when recombined with E13 endodermal 
cells or when cultured alone, which rules out this possibility. Consequently this 
means that surrounding epithelial cells regulate the apoptosis in the fi broblast tis-
sue layer observed late in gestation. Epithelial cells could do this in different ways. 
First, E19 epithelial cells could directly send pro-apoptotic signals to E19 fi broblasts 
to induce apoptosis. E13 mesenchymal cells are most likely too immature –lacking 
pro-apoptotic signal receptors– and therefore do not respond to these apoptosis-
inducing signals of the E19 epithelial cells. This possibility is in agreement with the 
minimal apoptosis observed when E19 fi broblasts were cultured alone. However, we 
cannot rule out another possible explanation, namely that lung fi broblasts intrinsi-
cally have an anti-apoptotic phenotype due to a balance favouring pro-survival over 
death-inducing molecules. This balance maybe disturbed due to paracrine (soluble, 
matrix or cell contact) signals from E19 epithelial cells later in gestation. This second 
possibility would also agree with the minimal apoptosis seen in E19 fi broblasts cul-
tured alone.
Apoptosis is considered to be a physiological phenomenon, which is required 
for normal thinning of mesenchymal tissue layer in late pulmonary development. 
In addition, apoptosis was demonstrated to play an important role during the 
postnatal structural maturation of the lung 25. The amount of apoptosis observed in 
homotypic E19 recombinants, however, was more extensive than what we observed 
in the control experiment using E19 fetal rat lungs. We and others observed much 
less apoptosis in vivo than in vitro during late gestation 18-20. This can be explained by 
the unnatural conditions under which the cells in our experiments were cultured. 
We recombined equal amounts of epithelial cells and mesenchymal cells whereas 
in vivo there are much less mesenchymal cells than epithelial cells at the investi-
gated stage of pulmonary development (E19). Another ‘in vitro’-limitation is the 
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two-dimensional growth of the cells. Several groups have demonstrated that fetal 
breathing movements (and thereby stretching of the alveolar wall) are a vital part of 
lung development processes, such as late term apoptosis 26-28. However, despite the 
use of our two-dimensional model, we did observe obvious differences between 
the four groups in terms of apoptosis. As all other circumstances remained equal 
between groups, we feel that the differences we observed are attributable to the 
epithelial-mesenchymal interactions.
Our results indicate that proliferation in both pulmonary epithelial cells and mesen-
chymal cells occurs in a cell autonomous manner during pulmonary development. 
Highest numbers of proliferating cells were observed among E13 endodermal and 
mesenchymal cells. Recombining these cells with E19 epithelial cells or fi broblasts 
did not alter the distribution and number of proliferating cells. Proliferation ap-
peared to be an intrinsic feature of both epithelial and mesenchymal cells when 
they were cultured in close contact to each other. E13 endodermal cells remained 
in a high proliferative state when recombined with E19 fi broblasts that proliferated 
much less. On the other hand, the E19 fi broblasts could not be induced to proliferate 
more when recombined with the E13 endodermal cells. Proliferation characteristics 
of heterotypic recombinants of E19 epithelial cells and E13 mesenchymal cells 
also did not change when compared to their homotypic counterparts. Thus, E13 
endodermal and E19 epithelial cells and E13 mesenchymal cells and E19 fi broblasts 
all displayed intrinsic proliferation characteristics, which were not infl uenced by 
heterotypic recombination. This result is in contrast to results obtained from stud-
ies using conditioned medium from epithelial cells, which were demonstrated to 
elaborate a hydrophobic polypeptide that inhibits fetal and adult lung mesenchymal 
cell proliferation in vitro 29, 30. However, in those studies mesenchymal cells were not 
in close contact to the epithelial cells, and this might be an essential condition for 
normal proliferation to occur.
Future research is warranted to determine which epithelial paracrine signals 
(soluble, matrix or contact) regulate fi broblast apoptosis. For instance, prostaglandin 
E2 (PGE2) has been shown to induce fi broblast apoptosis 31. Both epithelial cells and 
fi broblasts as well as other cells produce PGE2 32-34. Therefore, it is conceivable that 
epithelial cells regulate late term fi broblast apoptosis by excreting such prostanoids 
or other soluble factors. However, the exact mechanism remains to be determined.
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CONCLUSIONS
Our results indicate that epithelial cells regulate the thinning of the surround-
ing mesenchymal (fi broblast) cell layer late during pulmonary development. To 
our knowledge this is the fi rst study providing direct evidence of modulation of 
mesenchymal morphogenesis (through apoptosis) by its surrounding epithelium. 
This adds to the already extensive literature on the infl uence of mesenchyme on 
branching morphogenesis of the epithelial cell layer 2-4, 6-9, 24. In addition, our study 
demonstrated once more the essential role of epithelial-mesenchymal interactions 
in lung morphogenesis through a balanced interplay between cell proliferation 
and mesenchymal apoptosis. With our study we are a step closer to understand-
ing the physiology of normal lung development, which will aid in deciphering the 
pathogenesis of, and ultimately design targeted treatments for, developmental lung 
diseases such as pulmonary hypoplasia in CDH and oligohydramnios. Future stud-
ies revealing the signals involved in these epithelial-mesenchymal interactions, in 
particular in modulating mesenchymal apoptosis by its surrounding epithelium, are 
warranted.
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ABSTRACT
Background Despite years of research, the pathogenesis of pulmonary hypoplasia 
in congenital diaphragmatic hernia (CDH) remains elusive. Previously, we demon-
strated fi broblasts to be the ‘defective’ pulmonary tissue layer in the nitrofen model 
for CDH. Epithelial-mesenchymal transition (EMT) is involved in both normal organo-
genesis as well as the pathogenesis of several diseases, such as lung fi brosis. In this 
preliminary study we investigated EMT in nitrofen-induced pulmonary hypoplasia.
Methods Epithelial cells and fi broblasts were isolated from lungs of nitrofen-treated 
rats at embryonic day (E)19, and analyzed with immunocytochemistry for the simul-
taneous presence of pancytokeratin (epithelial cells) and vimentin (fi broblasts). 
Transgenic mice containing an infi nite fl uorescent labeling of epithelial cells (GNZ 
ROSA26-SPCrtTA-tetO-cre mice) were treated with nitrofen at E8.5 to induce pul-
monary hypoplasia and CDH. At E18 lungs were isolated and immunohistochemical 
analysis was performed for GFP and mesenchymal markers vimentin and aSMA. 
Co-localization was determined by confocal microscopy.
Results Isolated cells from nitrofen-treated lungs contained both cytokeratin and 
vimentin. Control cells from untreated lungs were either cytokeratin- or vimentin-
positive. In nitrofen-treated transgenic mice we observed cells positive for both GFP 
and mesenchymal markers; these were not present in control mice.
Conclusions These preliminary results suggest that EMT might be (partially) respon-
sible for the thickened fi broblast layer observed in nitrofen-induced hypoplastic 
lungs.
EMT in Nitrofen-Induced Pulmonary Hypoplasia
91
INTRODUCTION
Despite years of research, the mystery around the pathogenesis of congenital 
diaphragmatic hernia (CDH) and its associated pulmonary anomalies remains un-
raveled. The main concern of CDH is the severe morbidity due to the associated 
lung anomalies pulmonary hypoplasia and persistent pulmonary hypertension of 
the neonate (PPHN). To develop preventative and new treatment strategies, detailed 
knowledge of the pathogenesis is a requirement.
Previously, utilizing an in vitro cell recombinant model, we demonstrated that the 
fi broblast tissue layer is the primary affected tissue layer in nitrofen-induced pulmo-
nary hypoplasia in CDH 1. Based on these results, we hypothesized that a similar de-
fect is present in human CDH-associated pulmonary hypoplasia as well. An intrinsic 
defect in the fi broblasts could explain the morphological characteristics observed in 
hypoplastic lungs of both the nitrofen model as human CDH. However, the origin of 
the affected fi broblasts remains elusive.
Epithelial-mesenchymal interactions have been elaborately described as a prereq-
uisite for proper lung development 2. More recently, the concept of transitional 
processes has been speculated to be involved in normal lung development. In many 
organs, transitional processes are essential during development 3, 4. Epithelial mesen-
chymal transition (EMT) is the transformation of an epithelial cell into a mesenchymal 
cell (fi broblast). EMT, and its opposite process mesenchymal-epithelial transition, 
have been described in many organs (eg. the kidney and the lung), both as a normal 
part of (embryonic) development as well as a pathological process such as carcino-
genesis and fi brosis 3-7. In lungs, EMT has been demonstrated in both the bleomycin 
rodent model for lung fi brosis and idiopathic pulmonary fi brosis in patients 8, 9. In 
this pilot study we hypothesized that the origin of the affected fi broblast tissue layer 
descents from an epithelial origin.
To test our hypothesis we fi rst isolated in vivo nitrofen-treated fi broblasts and epithe-
lial cells and observed a concomitant expression of cytokeratin (epithelium) and vi-
mentin (fi broblasts / mesenchyme), which was lacking in control lung cells. The gold 
standard to test whether EMT is present in nitrofen-induced pulmonary hypoplasia 
involves a method of infi nite labeling of epithelial cells (and thereby, consequently, 
their progeny). We created transgenic mice that contained green fl uorescent protein 
(GFP)-labeled epithelial type II cells. As these cells and their progeny will indefi nitely 
keep their GFP label, it is possible to establish whether the increase in fi broblast cells 
descends from an epithelial origin. Embryonic day (E)18 lungs of nitrofen-treated 
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mice were analyzed for the presence of cells containing both the GFP signal (cells 
from epithelial origin) and fi broblast markers such as vimentin and αSMA.
METHODS & MATERIALS
Animals
The study was conducted according to the guidelines of the Canadian Council for 
Animal Care and with approval of the Animal Care Committee of the Hospital for 
Sick Children (protocol #6834 (transgenic mice) and #4245 (rats)). The animals were 
kept in a controlled light-dark cycle and food and water were supplied ad libitum.
Rats
Timed-pregnant Sprague-Dawley rats were ordered from Charles River (St. Constant 
(QC)). The fi nding of a sperm-positive vaginal smear was designated E0.
Transgenic mice
The conditional ROSA26 GNZ knock-in mice (The Jackson Laboratory, Bar Harbor 
(ME)) contain a nuclear-localized GFP / beta-galactosidase fusion protein (LacZ) 
(GNZ) inserted into the Gt(ROSA)26Sor (ROSA26) locus. Expression of GNZ is blocked 
by an upstream loxP-fl anked STOP sequence (in the absence of Cre-recombinase 
no GNZ is expressed). When bred to cre expressing mice, offspring will have the 
STOP sequence deleted in tissues containing Cre recombinase. ROSA26 GNZ mice 
are on a C57BL/6J;129 background. Lung epithelial specifi c recombination between 
loxP sites was achieved by using the tetO-cre transgene and the surfactant protein 
C promotor-reverse tetracycline transactivator transgene (SPC-rtTA). All strains were 
backcrossed to a pure CD1 background to optimize the infl uence of nitrofen 20. Mice 
containing two copies of ROSA26 and at least one copy of tetO-cre and SPC-rtTA 
were obtained by breeding and were genotyped by polymerase chain reaction. The 
fi nding of a sperm-positive vaginal smear was designated embryonic day E0. Timed-
pregnant females received doxycyclin-containing water and food on embryonic 
days E9 – 12.
Nitrofen treatment
At E9 congenital diaphragmatic hernia and pulmonary hypoplasia were induced in 
pregnant rats by oral gavage of 100mg of 2,4-dichlorophenyl-p-nitrophenyl ether 
(nitrofen) (Cerilliant, Round Rock (TX)) in 1ml olive oil. Control pregnant rats were 
gavaged with 1ml of the vehicle. At E19 (term = E22) rats were sacrifi ced. Mice were 
gavaged at E8 with 25mg of nitrofen in 250μl olive oil. Control pregnant mice were 
gavaged with 250μl of the vehicle. At E18 (term = E19) mice were sacrifi ced.
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Isolation of fetal rat pulmonary cells
To investigate whether these pulmonary cells from nitrofen-treated fetal rat lungs 
were positive for both cytokeratin (epithelial cell marker) and vimentin (mesen-
chymal cell marker), we isolated epithelial cells and fi broblasts from E19 fetuses as 
previously described 21. Briefl y, lungs were obtained and microscopically dissected 
from all other tissues including the major airways. Subsequently, lungs were minced, 
treated with collagenase and DNAse, and incubated at 37°C twice for one hour to 
isolate fi broblasts by differential adherence. Next, the remaining cells were incu-
bated overnight to isolate epithelial cells.
Isolation of in vivo transgenic mouse lungs
We isolated nitrofen-treated lungs from transgenic mice to investigate whether these 
contained pulmonary cells positive for both epithelial and mesenchymal markers. 
The mouse fetuses were delivered by Caesarian section using aseptical surgical 
techniques. Lungs were removed from the thorax and fi xed in 4% paraformaldehyde 
overnight at 4°C, dehydrated and embedded in paraplast, and 5μm sections were 
cut.
Immunofl uorescence
Immunofl uorescence protocols were previously described 1, 22. Pulmonary cells iso-
lated from nitrofen- and vehicle-treated fetal rats were double-stained for cytokera-
tin and vimentin. Primary antibodies were: 1:500 rabbit anti-pancytokeratin (Dako, 
Mississauga (ON)), 1:50 mouse anti-vimentin (Dako, Mississauga (ON)). Secondary 
antibodies (dilution of 1:200) were fl uorescein isothiocyanate (FITC)-labelled 
anti-mouse IgG (Calbiochem, San Diego (CA)) for vimentin, and rhodamine-labelled 
anti-rabbit IgG (Invitrogen, Eugene (OR)) for cytokeratin.
Lungs from transgenic mice were triple-stained for 1:500 rabbit anti-E-Cadherin (Cell 
Signaling, Danvers (MA)), 1:1000 chicken anti-GFP (Novus Biologicals, Cambridge 
(United Kingdom)), and 1:50 mouse anti-vimentin (BD Pharmingen, Breda (the 
Netherlands)), or 1:1000 mouse anti-α-smooth muscle actin (αSMA) (Biogenex, 
The Hague (the Netherlands)). Secondary antibodies (dilution of 1:400) were FITC-
labeled anti-mouse IgG (Invitrogen, Bleiswijk (the Netherlands)), Cy3-labeled anti-
rabbit IgG (Invitrogen, Bleiswijk (the Netherlands)), and Cy5-labeled anti-chick IgY 
(Abcam, Cambridge (United Kingdom)). Nuclei were stained with Hoechst-33258, 
a kind gift from Alex Nigg (Department of Pathology, Erasmus MC, Rotterdam (the 
Netherlands)), in Vectastain (Vector Laboratories, Peterborough (United Kingdom)).
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Confocal microscopy
To analyze co-localization of epithelial / endothelial and mesenchymal markers in 
lungs, we used confocal microscopy (LSM 700 Zeiss, Sliedrecht (the Netherlands)). 
Z-stacks were made to visualize the complete cell.
RESULTS
Immunofl uorescence of isolated cells
We isolated E19 epithelial cells and fi broblasts from nitrofen-treated and vehicle-
treated fetal rat lungs to investigate whether these pulmonary cells were positive for 
both cytokeratin (epithelial cell marker) and vimentin (mesenchymal cell marker). 
Nitrofen-treated lungs contained epithelial cells with co-localization for cytokeratin 
and vimentin (Figure 1C and 1D). In contrast, vehicle-treated lungs did not contain 
epithelial cells with co-localization for cytokeratin and vimentin (Figure 1A and 1B). 
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Figure 1. Co-localization of epithelial and mesenchymal markers in nitrofen-treated cells. IF staining 
of isolated epithelial cells from control (A,B) and nitrofen-treated (C,D) fetal rat lungs. Nitrofen-treated 
lungs contain epithelial cells with co-localization of cytokeratin (Cyt) (epithelial cell marker; red) (C) 
and vimentin (Vim) (fi broblast marker; green) (D). The arrows point towards cells positive for both 
markers. No co-localization was observed in control epithelial cells (A,B). Nuclei were stained with 
Hoechst (blue). The scale bar represents 100μm.
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Isolated fi broblasts did not demonstrate co-localization for cytokeratin and vimentin 
(results not shown).
Immunofl uorescence of in vivo lungs
To investigate whether nitrofen-treated lungs from transgenic mice contained cells 
positive for both epithelial and mesenchymal markers, we performed a triple-stain 
for GFP (cells from an epithelial origin), E-Cadherin (epithelial cells), and a mesenchy-
mal marker. Mesenchymal markers that we investigated were vimentin (fi broblasts) 
and αSMA (myofi broblasts).
In nitrofen-treated lungs we observed cells triple-positive for GFP, E-Cadherin, and 
vimentin (Figure 2G – 2K). In vehicle-treated lungs we observed co-localization of 
GFP and E-Cadherin, but no co-localization of either of these epithelial markers with 
mesenchymal marker vimentin (Figure 2A – 2E).
In nitrofen-treated lungs we observed cells triple-positive for GFP, E-Cadherin, and 
αSMA (Figure 3G – 3K: upper arrow). In addition, we observed pulmonary cells that 
contained co-localization of GFP and αSMA, but no E-Cadherin (Figure 3G – 3K: 
lower arrow). These pulmonary cells from an epithelial descent might have lost 
their E-Cadherin expression (or might not have adopted their E-Cadherin expres-
sion due to reduced mesenchymal-epithelial transition). In vehicle-treated lungs we 
observed co-localization of GFP and E-Cadherin, but no co-localization of either of 
these epithelial markers with mesenchymal marker vimentin (Figure 3A – 3E).
Figure 2. Co-localization of epithelial markers and vimentin in nitrofen-treated lungs. In nitrofen-
treated lungs we observed cells triple-positive (G,H) for GFP (red) (2J), E-Cadherin (yellow) (I), and 
vimentin (green) (K). The arrow points towards a cell positive for all three markers. In vehicle-treated 
lungs (A,B) we observed co-localization of GFP (red) (D) and E-Cadherin (yellow) (C), but no co-
localization of either of these epithelial markers with mesenchymal marker vimentin (green) (E). 
Nuclei were stained with Hoechst (blue) (F,L). The scale bar represents 25μm.
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DISCUSSION
This pilot study demonstrated that nitrofen-treated lungs contain mesenchymal cells 
from an epithelial descent. These preliminary results suggest that EMT is a process 
that occurs in nitrofen-treated lungs in vivo, and may contribute to the CDH-associ-
ated pulmonary hypoplasia.
EMT has been described in pulmonary diseases such as lung cancer and lung 
fi brosis 8,  9,  23. So far, in pulmonary morphogenesis transitional processes have not 
been described. However, during kidney branching morphogenesis, mesenchymal-
epithelial transition (MET), the opposite process of EMT, is present. During kidney 
morphogenesis, a mutual induction of the (ureteric bud) epithelium and (nephro-
genic) mesenchyme occurs. As the ureteric bud grows, the nephrogenic mesen-
chyme induces the ureteric bud to branch. In addition, the ureteric bud induces 
the nephrogenic mesenchyme to form around the bud and undergo MET to form 
the renal epithelium 24, 25. As pulmonary branching morphogenesis resembles kidney 
branching morphogenesis, it seems likely that the process of MET plays a role in 
pulmonary development as well. During late pulmonary development, thinning 
of the mesenchymal tissue layer is a physiological process in order to establish an 
optimal cell layer for postnatal gas exchange. MET could play a role in this process 
during normal pulmonary development. Nitrofen disturbs normal pulmonary de-
velopment by an unknown mechanism. An explanation for nitrofen to disturb this 
process would be to interfere with (physiological) interplay between MET and EMT.
Figure 3. Co-localization of epithelial markers and a-smooth muscle actin in nitrofen-treated lungs.
In nitrofen-treated lungs we observed cells triple-positive (G,H) for GFP (red) (J), E-Cadherin (E-Cadh) 
(yellow) (I), and a-smooth muscle actin (aSMA) (green) (K) (upper arrow). In addition, we observed cells 
positive for GFP and α-smooth muscle actin, but not E-Cadherin (lower arrow). In vehicle-treated lungs 
(A,B) we observed co-localization of GFP (red) (D) and E-Cadherin (yellow) (C), but no co-localization 
of either of these epithelial markers with mesenchymal marker α-smooth muscle actin (green) (3E). 
Nuclei were stained with Hoechst (blue) (F,L). The scale bar represents 25μm.
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Additional experiments should be performed to confi rm the presence of EMT in 
nitrofen-induced pulmonary hypoplasia. Fetuses with a CDH must be included as 
these contain the most severe form of pulmonary hypoplasia. Subsequently, it would 
be interesting to quantify the number of cells co-localizing epithelial and mesenchy-
mal markers. So far, we have only investigated lungs of nitrofen-treated fetuses at a 
late gestational age. Investigating earlier lungs might increase the amount of double-
positive cells in close proximity. If the process of EMT starts in early gestation, the 
double-positive cells might become more scattered later on. The time point at which 
EMT occurs in this model is unknown. To eventually design a treatment modality 
specifi cally aimed at this process it is necessary to decipher the optimal time point 
to start treatment. Furthermore, EMT can be induced through several pathways, such 
as the Wnt/beta-catenin pathway. Also the exact role of transforming growth factor-
beta (TGF-β) in the nitrofen model should be established. TGF-β has been recog-
nized as an important inducer of EMT 10-12. There is increasing evidence that TGF-β is 
involved in negatively regulating fetal lung branching morphogenesis 13-16. TGF-β has 
been shown to be involved in the CDH lung in both the nitrofen model and human 
lungs, which encourages the hypothesis that EMT is involved in the pathogenesis of 
CDH lungs 17-19. To develop these targeted treatment strategies to prevent pulmonary 
hypoplasia, it is necessary to decipher which pathway is responsible.
Besides EMT, MET could have been an explanation for the co-localization of epi-
thelial and mesenchymal cell markers in the isolated cells. The presence of EMT in 
nitrofen-induced lungs does not necessarily exclude MET. Both EMT and MET could 
be present simultaneously, especially if one process attempts to regenerate the 
damaged lung tissue by counteracting the other.
In our transgenic mouse model, cells become fl uorescent when the SPC-promotor is 
switched on. An explanation for co-localization of epithelial and mesenchymal cell 
markers, other than EMT, is that these cells are pluripotent (progenitor) cells. Previ-
ously, cells at the bronchoalveolar junction were identifi ed as bronchoalveolar stem 
cells (BASCs) 26. These cells demonstrated co-localization of epithelial cell and clara 
cell markers in vivo. In vitro BASCs were capable of differentiation and self-renewal. 
In addition, these cells had a proliferative response to naphthalene injury instead of 
cell death. In this study, cells in nitrofen-treated lungs demonstrated the presence 
of two markers from a different lineage, and could therefore be progenitor cells. To 
test this hypothesis, co-localizing cells would have to be sorted with fl uorescence-
activated cell sorting (FACS). Subsequently, these sorted cells should be cultured 
and tested to observe whether cell differentiation into multiple lineages such as 
chondrocytes and neural cells could be induced. The limitation of FACS analysis is 
that it can only detect cell surface markers, and not cytoplasmic or nuclear markers 
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such as GFP in our transgenic mice. Therefore, only cells double-positive for epithe-
lial and mesenchymal cell markers can be FACS-sorted and cultured, which will lead 
to the loss of cells that have fully transitioned to a mesenchymal cell.
Another interesting direction for future research would be live imaging of cells in 
fetal (transgenic mouse) lung explants. Nitrofen has been demonstrated to induce 
pulmonary hypoplasia in vitro as well 27. Live cell imaging is used to study cell dynam-
ics. Frequent snapshots of cells are taken and can be turned into moving pictures of 
dynamic processes. The infl uence of nitrofen on the behavior of healthy fetal pulmo-
nary explants could be examined when cells from an epithelial origin are labeled. 
The process of EMT could be visualized as epithelial cells would disintegrate from 
the matrix, and subsequently transform to a spindle-shaped mesenchymal cell in 
the interstitium. Limitations of live cell imaging are phototoxicity and -bleaching of 
the cells, but this would be equally present in nitrofen-treated and control fetal lung 
explants.
CONCLUSIONS
EMT is present in nitrofen-induced pulmonary hypoplasia, and might (partially) 
explain the thickening of the mesenchymal tissue layer in this model. Further experi-
ments need to be performed to confi rm these results.
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ABSTRACT
Background Accrual of human tissues from autopsies for diagnostic and translational 
research has decreased signifi cantly over the last decades. The objective of this 
study was to evaluate our experience with lung biopsy through a mini-thoracotomy 
as an alternative for obtaining postmortem tissue when full autopsy is refused in 
congenital diaphragmatic hernia (CDH) patients.
Methods Within two hours of death we routinely asked parents for permission to 
perform an autopsy. Starting in 2001, parents who refused autopsy were asked per-
mission for a postmortem lung biopsy. Pathology autopsy and biopsy reports were 
compared to clinical records.
Results Between 2001 and 2009, 46 patients died from CDH. Permission for autopsy 
was granted in fi ve patients (11%). The parents of fi fteen (33%) of the remaining 41 
patients agreed to postmortem lung biopsy. In all cases, additional fi ndings were re-
ported from the autopsy or biopsy, without changing the originally reported cause of 
death. In one case, we isolated fi broblasts from the lung biopsy using standardized 
cell culture techniques. Parents were able to take their child home with a minimal 
delay following biopsy.
Conclusions Parents refusing a full autopsy frequently agree to postmortem organ 
biopsy. The quick procedure of biopsy might be helpful in the mourning process of 
parents as it prevents delay of transferring their deceased child home. This approach 
should therefore be considered as a valuable alternative to obtain human tissues 
for both diagnostic and research purposes and is potentially applicable to other 
anomalies.
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INTRODUCTION
Permission for autopsies has been declining for decades 1-4. This decline has been 
elaborately discussed by others and the main reasons are concerns from the next of 
kin about disfi gurement of the body, exposing the child to additional invasive pro-
cedures or the feeling that the patient has ‘suffered enough’, and the possible delay 
of taking their child home 5-8. In addition, media coverage of certain scandals has 
negatively infl uenced the public opinion on autopsies 9, 10. Autopsies are not merely 
necessary to obtain or confi rm the cause of death, but can also be instrumental for 
translational research to improve our understanding of diseases. As a result, we 
may create new therapeutic strategies and/or evaluate the effects of new treatment 
strategies 1,  2,  11-14. Due to the decline in permission for autopsies, less translational 
research based on human tissue samples investigating the pathogenesis of diseases 
can be performed. In this study we describe our experience with a minimally inva-
sive method of obtaining postmortem lung biopsies through a mini-thoracotomy of 
patients with congenital diaphragmatic hernia (CDH). This approach has potential 
relevance for a broader spectrum of pediatric diseases that result in death.
CDH is an example of a major congenital anomaly with an unknown pathogenesis. 
The associated lung abnormalities (pulmonary hypoplasia and persistent pulmo-
nary hypertension) observed in CDH are the major cause of either death or severe 
morbidity. Modern-day treatment modalities such as ventilation and extracorporeal 
membrane oxygenation (ECMO) may have pathological effects on lungs such as 
hemorrhage (this study), interstitial fi brosis, and alveolar calcifi cations and as a result 
of ECMO, secondary infl ammatory changes are frequently observed in these lungs 
15, 16. Understanding the pathogenesis of this disease is warranted to develop alterna-
tive (prenatal) therapeutic interventions such as tracheal occlusion to prevent or 
decrease its severe morbidity 17. However, human tissue samples for investigation are 
not readily available. Obtaining a lung biopsy from a living newborn with CDH for re-
search is unethical. The burden of such a biopsy in a very ill child is too high in terms 
of pain, risk of infection and bleeding, and loss of the already small amount of lung 
tissue due to pulmonary hypoplasia. Autopsies of children that deceased from the 
sequelae of CDH are the second best option to obtain human lung tissue samples. 
However, with permission declining for autopsies in children due to religious or 
other reasons such as negative public opinion, it is diffi cult to obtain these tissues 
for diagnostic and translational research purposes 1,  2,  18,  19. New minimally invasive 
autopsy procedures through a mini-thoracotomy might help to deter this trend.
In 2001 we instituted a new protocol for postmortem lung biopsies through a mini-
thoracotomy in our center to increase the accrual of lung samples from deceased CDH 
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children. By increasing the amount of lung tissue available for diagnostic and research 
purposes we aspired to potentially obtain better insight in the pathology of the lungs by 
performing a microscopic examination and to potentially facilitate translational research 
into the pathogenesis of CDH 20, 21. The main objective of this study was to evaluate our 
experience with minimally invasive postmortem lung biopsy as an alternative for obtain-
ing postmortem tissue when full autopsy is refused in CDH patients.
PATIENTS & METHODS
The Research Ethics Board of the Erasmus MC – Sophia Children’s Hospital approved 
the protocol for this study. We included all children with CDH admitted to the intensive 
care unit between 2001 and 2009 that died during their initial admission. Parents are 
routinely informed during prenatal counseling given the potential risk of dying in CDH 
about the procedures in case their child would die. One of the aspects mentioned was 
that permission would be asked for a postmortem investigation (without specifying full 
autopsy or mini-thoracotomy). After the patients died, parents were fi rst asked to give 
consent for a full autopsy. If parents refused the autopsy, they were asked for permission 
to perform a postmortem lung biopsy through a mini-thoracotomy for both diagnostic 
and research purposes. If parents agreed, one of the pediatric surgeons or pediatric sur-
gical fellows performed a mini-thoracotomy at the level of the fourth or fi fth intercostal 
space with an incision of approximately two centimeters through which the lung biopsy 
was taken. Biopsies were performed at the ipsilateral side unless the lung was too small 
to obtain tissue. In that case, the contralateral lung was used. Previously, we and others 
have failed to observe clear differences in histology between ipsilateral and contralateral 
lungs of CDH patients, so this approach was not considered to be a bias for the outcome 
22, 23. The specimen was divided in two equal parts and snap-frozen using isopentane 
in liquid nitrogen and processed for paraffi n embedding within two hours after death. 
In one case we attempted and succeeded in isolating fi broblasts from the lung biopsy 
using standard cell culture techniques as previously described 24. Clinical diagnoses and 
clinical causes of death were obtained from prospective and routinely available elec-
tronic medical patient records. Findings from autopsy and postmortem lung biopsy were 
obtained from pathology reports, and morphology of all lung samples was re-evaluated 
by a specialized pediatric pathologist (Ronald R. de Krijger) unaware of the treatment 
given before death. At full autopsy pulmonary hypoplasia was defi ned as a lung weight 
: body weight-ratio < 0.012. When not all information was available from the pathology 
reports or if patients were described as severely edematous at autopsy, hypoplasia was 
determined by lung weight compared to normal values based on gestational age. In lung 
biopsies, determining pulmonary hypoplasia based on weight was not feasible as only a 
part of the lung tissue was available.
Postmortem Lung Biopsy in CDH
105
RESULTS
From 2001 to 2009 46 newborns died of CDH in the intensive care unit of our 
hospital. Parents of fi ve patients (11% of all deceased children) gave consent for a 
full autopsy. Fifteen of the remaining 41 patients (33% of all deceased children and 
37% of the remaining parents) underwent a postmortem lung biopsy through a mini-
thoracotomy. In total, we were able to quadruple the accrual of lung tissue from 11% 
from autopsies alone to 44% from autopsies and biopsies combined.
Results from full autopsies
Table 1 provides an overview of the clinical fi ndings and fi ndings at full autopsy of 
the fi ve patients in which a full autopsy was performed. Two of these patients were 
female, the median gestational age (GA) at birth was 36+5 (27+5 – 38+2) weeks +  days, 
the median time of death was 6 days (1 – 16 days) postnatally, and all hernias were 
left-sided. Four patients died from therapy-resistant pulmonary hypertension of 
the neonate (PPHN, diagnosed by repeated Doppler cardiac ultrasound), and one 
patient died from thrombo-embolic complications and hemorrhage, according 
to the clinical information. The cause of death according to autopsy reports was 
denoted as ‘due to lung abnormalities’ and thrombo-embolic as well as bleeding 
complications, respectively. Two of fi ve patients did not receive ECMO therapy. In 
one patient abstaining from ECMO treatment was decided based on a combina-
tion of prolonged hypoxia, therapy-resistant pulmonary hypertension and severe 
pulmonary hypoplasia. The other patient did not receive ECMO treatment due to 
prematurity, which is an exclusion criterion to start ECMO treatment. In three cases, 
an increased wall thickness of the pulmonary arterioles consistent with PPHN was 
reported. In two patients, associated anomalies observed in the clinical setting were 
infant respiratory distress syndrome (IRDS) and aortic coarctation. In all patients, 
pulmonary hypoplasia was confi rmed. Additional fi ndings in the lungs were hemor-
rhage (4 patients), congestion (3), hyaline membrane disease (3), amniotic fl uid and/
or meconium aspiration (fetal distress) (2), extramedullary hematopoiesis (sign of 
hypoxia), fi brosis of the alveolar septa (2), lungs immature-for-age (2), thrombi in 
the arteries and arterioles (1), type II pneumocyte hyperplasia (1), and dilated lymph 
vessels at the pleural surface (1). (Extensive) hemorrhage was present in all ECMO 
patients, and in one of two non-ECMO patients. Additional fi ndings of other organs 
were cyst formation in kidneys and testes, asphyctic hemorrhages of the kidneys, 
and liver, heart, and thymus abnormalities as denoted in Table 1.
Results from postmortem lung biopsies through a mini-thoracotomy
Table 2 gives an overview of the clinical fi ndings and the postmortem lung biopsy 
fi ndings of the 15 patients. Ten of these patients were female, the median GA at 
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Chapter 6
birth was 38+2 (36+2 – 41+1) weeks + days, the median time of death was 16 days (1 – 29 
days) postnatally, and 13 (87%) of the hernias were left-sided. Clinical causes of 
death were pulmonary hypertension or sepsis and multi-organ failure (MOF). 
Fourteen of 15 patients had therapy-resistant pulmonary hypertension following 
ECMO-treatment. Two of 15 patients did not receive ECMO therapy. In one patient, 
phenotypic characteristics of Cornelia de Lange syndrome (confi rmed by genetic 
analysis) resulted in withdrawal of treatment. The other patient had a hypoplastic 
left ventricle in addition to CDH, resulting in a dismal prognosis, which was the 
reason to withdraw further treatment. Four patients had no associated anomalies. 
Associated clinical anomalies observed in the remaining 11 patients were cerebral 
hemorrhage/infarction (3 patients), pneumothorax (3), sick euthyroid syndrome (2), 
severe congenital cardiac anomalies (1), phenotypic Cornelia de Lange syndrome (1), 
hypospadias (1), hemivertebra T12 (1), and right-sided pulmonary hypoplasia (1). An 
experienced pediatric pathologist (Ronald R. de Krijger) evaluated the morphology 
of the tissue samples (Figure 1A). Arteriolar wall thickening due to PPHN was always 
confi rmed. Additional fi ndings in the lung biopsy specimens were hemorrhage (14 
patients), hyaline membrane disease (7), septal fi brosis (5), thickened alveolar septa 
(6), extramedullary hematopoiesis (sign of hypoxia) (4), thrombi (5), congestion (9), 
type II pneumocyte hyperplasia (6), centroacinary unfolding and/or atelectasis (11), 
amniotic fl uid and meconium aspiration (1), pneumonia (1), and immature paren-
chyma (10). (Extensive) hemorrhage was present in 12 of 13 ECMO patients, and in 
one of two non-ECMO patients. The morphological characteristics of lung biopsies 
resembled fi ndings observed in lungs in full autopsies. Pulmonary fi broblasts were 
successfully isolated from one of the biopsies (Figure 1B).
A                         B
Figure 1. Histology of a postmortem lung biopsy and an image of isolated fi broblasts. Microscopic 
image of hematoxylin and eosin stain of a postmortem lung biopsy through a mini-thoracotomy (A) 
and an image of fi broblasts isolated from a postmortem lung biopsy through a mini-thoracotomy (B).
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DISCUSSION
Although full autopsy remains the ‘gold standard’ for postmortem investigations as 
organs can be investigated entirely and in relationship to other organs, our experi-
ence with postmortem lung biopsies through a mini-thoracotomy demonstrates 
that this can be a good alternative to obtain tissue for diagnostic and translational 
research purposes if consent for a full autopsy is refused. Herein, we demonstrate 
that permission for obtaining postmortem lung tissue increased from 11% for conven-
tional autopsies to 44% for the combination of conventional full autopsies and lung 
biopsies through a mini-thoracotomy.
We speculate that the main reason for the high permission rate for a postmortem 
lung biopsy through a mini-thoracotomy is that disfi gurement of the body and ad-
ditional invasive procedures are not as severe as compared to a full autopsy, which 
are common reasons for declining full autopsy 5-8. Secondly, the opportunity for 
parents to take their child home within hours after demise of the child might add to 
this. From a psychological point of view, taking the child home within hours seems 
favorable as well, as it may support the mourning process. In addition, Sullivan et al. 
described that in 42% of parents full autopsy added to their grief 25.
Alternative minimally invasive autopsy approaches have previously been described 
in literature. Non-invasive techniques such as MRI or CT scan were demonstrated 
to lack accuracy and cost-effectiveness compared to full autopsy, although further 
evaluation is warranted 26-28. Non-invasive techniques in combination with organ 
needle core biopsies varied in accuracy. Depending on the study population some 
studies demonstrated a 100% false-negative rate while others demonstrated opti-
mistic results of 90% sensitivity 29-31. Obvious limitations of such approaches are the 
logistics (as MRI or CT are often not universally available for postmortem purposes) 
and additional costs of the MRI and CT scans. Laparoscopic postmortem investi-
gations have been described as well. Fan et al. reached a high accuracy with this 
method when compared to full autopsy 32. Limitations to this method are again the 
signifi cant costs and logistics, with an additional limitation of the possible spread of 
infectious diseases by CO2 leakage from the insertions 32. A common limitation of 
all of the alternative methods mentioned is the delay in performing the procedure.
Postmortem lung biopsies through a mini-thoracotomy appear to be a good alterna-
tive to increase lung tissue available for diagnostic purposes. In up to 40% of full 
autopsies additional information is uncovered that was not available in the clinical 
setting 1, 13, 33, 34. In our study, the pathology reports and morphological evaluation of 
all autopsies and biopsies demonstrated additional fi ndings to the clinical reports. 
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However, signifi cant changes in the cause of death were not identifi ed. In one full 
autopsy report no vessel abnormalities were observed while the clinical cause of 
death was PPHN. Additional fi ndings that were clinically relevant but were not 
considered the cause of death were fi ndings of pneumonia and hemorrhage. This 
emphasizes the importance of full autopsies and postmortem biopsies 1, 33, 34. Know-
ing the cause of death is also important for general knowledge of diseases and their 
complications to improve the quality of care and to enhance the accuracy of death 
statistics. In addition, full autopsies are necessary to monitor new clinical investiga-
tive techniques for accuracy and side effects and new treatment modalities for ef-
fi cacy and complications 3, 35. And, last but not least, autopsy results help the parents 
grieve, understand what happened, and whether the diagnosis was accurate and 
the treatment given appropriate. For instance, when the treatment team decides to 
withdraw further treatment, additional diagnostic insight from a lung biopsy could 
help parents cope with this decision. Simultaneously, results from an autopsy may 
provide information about obstetric or genetic risk of recurrence, and can therefore 
be important for future pregnancies or family members 1, 2, 5, 11-14, 35-39. However, we are 
aware that not all benefi ts associated with full autopsies are present in postmortem 
biopsies through a mini-thoracotomy. Evaluating a small part of, in this instance, the 
lung might not be representative for the entire organ, even though most biopsy char-
acteristics in our study did resemble full autopsy results of the lungs 30, 40. In addition, 
validation of diagnostic tools and monitoring treatments are not feasible when we 
are not able to evaluate the entire body.
Even though we agree that a postmortem lung biopsy through a mini-thoracotomy 
could never replace a full autopsy 40, there are a few advantages to a postmortem bi-
opsy through a mini-thoracotomy over full autopsy. Postmortem tissue availability is 
primarily necessary for diagnostic purposes, however can be useful for translational 
research as well. A scientifi c advantage of the biopsies is minimal delay between 
death and obtaining the tissue, which improves tissue quality 41. Van Maldegem et 
al. demonstrated that RNA quality decreased when time till fi xation of the tissue 
increased 42. We demonstrated the potential to isolate fi broblasts for cell culture 
experiments from lung tissue of a CDH patient obtained from a postmortem lung 
biopsy through a mini-thoracotomy. This provides the unique opportunity for 
pathogenetic research to translate results from in vitro animal studies to the human 
situation. Nowadays, cells such as lung fi broblasts can be stored for a prolonged 
time, so cells derived from biopsies as well as the tissues itself could, with proper 
consent, be stored to create a biobank for future research 43. Our biobank of lung bi-
opsy samples has proved to be an invaluable resourch for many translational studies 
by our group as demonstrated in literature 20, 21, 44-46. Examples of successful use of the 
biobank are Unger et al., who demonstrated that the expression of sonic hedgehog 
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is downregulated in pulmonary hypoplasia, and Rajatapiti et al., who demonstrated 
that the expression of glucocorticoid, retinoid and thyroid hormone receptors is not 
altered in lungs of patients with CDH 20,  21. These studies both contributed to our 
current knowledge on CDH. The biobank allows us to collect specimens from more 
patients and use these in the future when new investigative techniques, such as the 
recent whole genome sequencing, become available or new results from animal 
studies warrant translation to the human situation. This is especially important in 
diseases such as CDH in which survival has improved (and therefore the opportunity 
to obtain material from deceased patients has become rare) but there is still a need 
for elucidating the exact pathogenetic mechanisms. This procedure might be ap-
plicable to a broader spectrum of pediatric diseases that result in death, and does 
not have to be restricted to newborns.
CONCLUSIONS
Given the low consent rate for full autopsy, postmortem biopsies through a mini-
thoracotomy provide a valuable alternative to obtain human tissue samples for 
diagnostic and research purposes. The value of postmortem organ biopsies through 
a mini-thoracotomy for a broader spectrum of diseases that result in pediatric death 
should be evaluated in future studies.
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ABSTRACT
Background The Von Hippel-Lindau (VHL) pathway is involved in the morphogenesis 
of many organs amongst which kidneys, testes and lungs. In congenital diaphragmat-
ic hernia (CDH) both the diaphragm and lungs are affected. Recent data suggest that 
these defects are caused by a similar insult. The exact pathogenesis of CDH has not 
been elucidated so far. The retinoic acid (RA) pathway has been implicated in CDH. 
Several transcription factor (regulators) are present in both lungs and diaphragm, 
and are located on chromosomes commonly deleted in CDH patients. This encour-
ages the theory of a similar insult. Hypoplastic CDH lungs display abnormalities in 
the VHL pathway. The VHL pathway has not been investigated in the diaphragms of 
CDH patients, neither during normal diaphragm development. The objective of this 
study was to determine the expression pattern of VHL pathway proteins in healthy 
diaphragms and the diaphragm of patients with CDH and diaphragmatic eventration 
(CDE).
Methods After obtaining consent from parents, diaphragms were isolated during au-
topsies of deceased children with CDH (4), CDE (3) and children without congenital 
abnormalities (7). No chromosomal anomalies were present. In addition, diaphragm 
biopsies were collected from nine other CDH patients during operative repair. 
Standard histology and immunohistochemical staining for platelet endothelial cell 
adhesion molecule (PECAM), VHL, hypoxia-inducible factor-1α (HIF1α), vascular 
endothelial growth factor (VEGF), and endothelial nitric oxide synthase (eNOS) were 
performed. Quantitative real-time RT-PCR for eNOS was performed as well.
Results Protein expression of components of the VHL pathway in the interstitium, 
muscle, and vessel wall was similar between CDH, CDE and healthy diaphragms. 
Neither did we observe any differences at the gene expression level of eNOS be-
tween CDH and healthy diaphragms.
Conclusions The VHL proteins are present in healthy diaphragms while a disrup-
tion related to the VHL pathway appears unlikely as the common cause of lung and 
diaphragm anomalies in CDH patients.
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INTRODUCTION
The Von Hippel-Lindau (VHL) pathway is a pathway involved in embryogenesis, and 
in formation of many organs such as kidneys, testes, and the central nervous system 
1, 2. The enzyme endothelial nitric oxide synthase (eNOS), a downstream target of the 
VHL pathway, converts l-arginine to nitric oxide (NO) (Figure 1) 3. In development, 
NO is mainly involved in angiogenesis. The diaphragm is a crucial organ for breath-
ing. To our knowledge, the VHL pathway has not been studied in diaphragms so far.
Diaphragmatic defects such as congenital diaphragmatic hernia (CDH) or con-
genital diaphragmatic eventration (CDE) can severely impair oxygenation and can 
be incompatible with life. CDE, which is 7% (versus 93% CDH) of real diaphragmatic 
defects, has been proposed as a ‘milder’ form of CDH in which the diaphragm is 
affected by loss of muscle tissue without causing a ‘hole in the diaphragm’ 4. Interest-
ingly, pulmonary hypoplasia, heart and skeletal abnormalities are associated with 
both defects, which strengthens this assumption 5-11. CDE has a lower mortality rate 
(1 – 8% versus ≥ 20% depending on case selection) and is less complicated to repair 
than CDH.
HIF1_
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Figure 1. Schematic of the VHL pathway. In normoxic conditions prolyl hydroxylase (PHD) causes 
hydroxylation of hypoxia-inducible factor-1α (HIF1α) to allow Von Hippel-Lindau (VHL) protein to 
bind to HIF1α. This results in the degradation of HIF1α. In hypoxic conditions, PHD is inhibited, which 
allows HIF1α to induce gene expression of angiogenic factors such as vascular endothelial growth 
factor (VEGF) and endothelial nitric oxide synthase (eNOS). The enzyme eNOS converts l-arginine to 
nitric oxide (NO). NO is involved in angiogenesis and vessel function.
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CDH consists of two major defects: a diaphragmatic defect and lung anomalies. For 
decades, lung anomalies were thought to be solely attributable to the abdominal organs 
‘compressing’ the lungs. However, in 2000 our group demonstrated that the observed 
lung anomalies in the rat nitrofen model are due to an intrinsic defect in the lungs as 
well, the so-called dual-hit hypothesis 12. Therefore, it has become likely that these de-
fects occur through the same pathogenetic pathway. In addition, more recently, several 
transcription factor (regulators) of the retinoic acid (RA) pathway, located on chromo-
somes commonly deleted in CDH patients, are present in both organs 13-15. During lung 
morphogenesis NO is important in the formation of vessels and after birth for pulmonary 
gas exchange as it acts as a prominent vasodilator. In human CDH lungs our group 
demonstrated earlier that the VHL pathway is disrupted 16-19. We speculate this pathway 
might be disrupted in CDH diaphragms as well, as a common denominator between 
the lung and diaphragm anomalies in diaphragmatic defects. To test this hypothesis we 
investigated the expression of components of the VHL pathway in healthy diaphragms 
and, subsequently, in diaphragms from patients with CDH and CDE.
PATIENTS & METHODS
Human diaphragms
Informed consent was obtained from parents of children that succumbed from 
CDH (4), CDE (3) and other causes except congenital abnormalities in their neonatal 
period (controls) (7). Subsequently, diaphragms were isolated during autopsy. In 
CDH patients the median gestational age (GA) at birth or abortion was 40+1 (28 – 42+1) 
weeks + days; median survival time was 4 days (< 24 hours – 2 weeks). One CDH patient 
had undergone a prenatal tracheal occlusion procedure and was postnatally treated 
with extra-corporeal membrane oxygenation (ECMO), and died at the age of 14 days 
due to therapy-resistant pulmonary hypertension. The median GA of CDE patients 
was 21+1 (17+3 – 21+3) weeks; these were all terminations of pregnancy. The median 
GA of control patients was 32+1 (23+6 – 38+4) weeks. Most control patients had died 
intrauterine or immediately after birth.
Diaphragm tissue was also collected from living patients during operative hernia 
repair. Separate informed consent was obtained from parents. During the operation a 
biopsy from the diaphragm was collected (5) and tissue from the hernia sac, if present, 
was removed in four other patients (4). The median gestational age at birth was 39+1 
(35+5 – 40+3) weeks. Three patients were treated with ECMO before the hernia-repair. 
Tissues (except for biopsies) were processed for paraffi n embedding according to the 
standard pathology protocol. Biopsies were frozen in liquid nitrogen. Sections of 5μm 
were stained with hematoxylin and eosin (H&E) staining for histology.
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Genetic studies
Karyotyping was performed in 17 of 20 patients according to standard analysis meth-
ods. DNA for genomic analysis was extracted from peripheral blood or fi broblast 
cultures by the puregene DNA purifi cation kit (Gentra Systems, Minneapolis (MN)). 
Genomic DNA of ten CDH patients was hybridized to a high-resolution Illumina 
cyto-SNP bead chips version 12.2 (Illumina, San Diego (CA)). Filtering, normaliza-
tion and data analysis of each array was done using the Nexus® software programme 
(version fi ve, Biodiscovery, El Segundo (CA)) as previously described 20. To review 
functionality of each putative copy number variation (CNV), occurrence frequen-
cies in qualifi ed normal cohorts of CHOP [http://www.chop.edu/], DGV [projects.
tcag.ca/variation/] and Decipher databases [https://decipher.sanger.ac.uk/] were 
checked. Since these populations display various ethnic backgrounds, comparison 
to an in-house local reference set of 470 normal individuals was executed also. Con-
fi rmation of each putative candidate with real-time RT-PCR and/or fl uorescent in situ 
hybridization (FISH) was executed in the proband and his / her parents according to 
local standard protocols as recently described 21.
Immunohistochemistry
We used antibodies against members of the VHL pathway to determine whether they 
are differently expressed between the three groups. The VHL protein regulates the 
production of nitric oxide (NO) through hypoxia-inducible factor-1α (HIF1α) inhibi-
tion. When HIF1α is not degraded, it induces the production of vascular endothelial 
growth factor (VEGF) and endothelial nitric oxide synthase (eNOS). eNOS converts 
l-arginine into NO 22. We investigated VHL, HIF1α, VEGF, and eNOS. We used platelet 
endothelial cell adhesion molecule (PECAM) as a positive control for vessels.
Following heat-induced antigen retrieval in Tris-EDTA pH 9.0 buffer, slides were 
treated with 3% (v/v) hydrogenperoxide in phosphate buffered saline to block 
endogenous peroxidase activity. We added blocking solution of 10% normal goat 
serum and 1% bovine serum album in PBS for one hour at room temperature. 
Subsequently, we incubated slides overnight with primary antibodies at 4°C. Slides 
were developed using Envision kit according to the manufacturer’s instructions, 
and counterstained with hematoxylin. Slides were mounted with perfex (Histolab, 
Gothenburg (Sweden)). Primary antibodies used were undiluted mouse anti-VHL 
protein (Genetex, Irvine (CA)), mouse anti-HIF1α (1:200; Abcam, Cambridge (United 
Kingdom)), rabbit anti-VEGF (1:100; Abcam, Cambridge (United Kingdom)), anti-
eNOS (1:100; BD Biosciences Pharmigen, Breda (the Netherlands)), and anti-PECAM 
(1:50; Dako, Heverlee (Belgium)).
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Quantifi cation
We investigated all diaphragms for the presence of staining of the VHL pathway 
antibodies in the muscle, interstitium and vessels of the diaphragm (if present), 
and scored blinded as strong staining (+++), average staining (++), weak staining (+), 
absence of staining (-).
Real-time RT-PCR
To validate our immunohistochemical results, we performed real-time RT-PCR in 
fi ve patients (three CDH versus two controls) to compare eNOS expression at the 
RNA level. We used iScript cDNA synthesis kit (Bio-rad, Hercules (CA)) to reversely 
transcribe 2μg of total RNA sample to cDNA. Per well we used 0.6μl of each cDNA 
product, which was mixed with the KAPA-SYBR fast mastermix (KapaBiosystems, 
Woburn (MA)). Subsequently, for the quantitative RT-PCR analysis we used the 
ABI7300 Real-time PCR system. We performed each reaction in triplicate, designed 
as described by Boehm et al., with a region of the RPS18 human gene serving as a 
control 23. We designed the primers from the unique cDNA sequences of the eNOS 
gene (forward ACTGAGATCGGCACGAGGAA; reverse GTCCATGCAGACAGCCA-
CAT) with Primer Express software v2.0 (Applied Biosystems).
RESULTS
Genetic studies
All 17 patients displayed a normal 46.XX or 46.XY karyotype. Of the 11 patients in 
which genomic analysis was performed two demonstrated a known CDH related 
CNV (22q11 duplication and 15q25 deletion). No deletions or duplications were 
observed involving the VHL and related genes as prolyl hydroxylase (PHD)3, HIF1α, 
VEGFA and eNOS.
Human diaphragm morphology
H&E staining demonstrated that all eventration diaphragms did not have any 
muscularization present in the specimen (Figure 2C). CDH postmortem tissue and 
biopsy tissue did not appear different from control diaphragm tissue (Figure 2B vs 
2A). Hernia sac tissue removed during hernia surgery did not have any musculariza-
tion either; the morphology was similar to CDE tissue (Figure 2D). Vessels did appear 
to be further apart and smaller in the CDE and hernia sac tissue than in postmortem 
diaphragmatic tissue from CDH patients and controls (Figure 2C and 2D vs 2B and 
2A, respectively). However, due to the limited number of patients, we were not able 
to quantify this.
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Human diaphragm VHL pathway
PECAM, VHL, VEGF, HIF1a and eNOS staining were present in control diaphragms, 
which means the VHL pathway is part of the vessel formation, and maybe vessel func-
tion, in healthy diaphragms. Background staining was present in muscle fi bers when 
present in the sample, staining in interstitum was either weakly present or absent. 
eNOS staining was demonstrated in Figure 3, and is representative for the protein 
expression pattern of the other stainings. These fi ve markers were similar in control 
C
A B
D
Figure 2. Diaphragm morphology. An H&E staining was performed for morphological analysis of 
diaphragms of control (A), CDH (B), CDE (C), and hernia sac (D). The scale bar represents 100μm
C
A B
D
Figure 3. eNOS staining of diaphragms. Staining was performed on diaphragms of control (A), CDH 
(B), CDE (C), and hernia sac (D). No differences were quantifi ed in intensity of the staining. The scale 
bar represents 100μm.
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and CDH diaphragms (Figure 3A vs 3B, respectively). This was also similar in hernia 
sac tissue (Figure 3D). No effect of gestational age on staining pattern was observed 
as all antibodies were present in diaphragm tissue from 17+3 weeks onwards.
In CDE tissue PECAM, VEGF, and HIF1a staining were similar to controls and CDH 
tissue (data not shown). eNOS appeared slightly weaker in CDE tissue compared 
to the other groups. VHL had a weak intensity in CDE tissue compared to all other 
groups (data not shown). An overview of the intensity of staining in vessels is shown 
in Table 1.
Real-time RT-PCR
No differences were observed in eNOS expression between control and CDH. 
Differences between the two groups fell within the intra-group variability. Due to 
the relative low numbers of patient material we did not perform a statistical analysis 
(Figure 4).
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Figure 4. Relative expression of eNOS in CDH and controls. 
Real-time RT-PCR of eNOS was performed on diaphragms 
of three CDH and two control patients. No differences were 
observed between groups.
Table 1. Semi-quantifi ed data of protein expression
PECAM VHL VEGF HIF1a eNOS
Control +++ ++ +++ + +++
CDH +++ ++ +++ + +++
Hernia sac +++ ++ +++ + +++
Eventration +++ + +++ + ++
An overview of the semiquantifi ed data from immunohistochemical analyses. No apparent differences 
were observed between groups.
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DISCUSSION
In this study, we investigated components of the VHL pathway in diaphragms. We 
demonstrated that these are present during prenatal and perinatal healthy dia-
phragm development. Subsequently, we investigated these proteins in diaphragms 
of patients with CDH and CDE. We observed that these proteins were present in 
diaphragms of CDH and CDE patients. However, no differences in expression were 
found compared to healthy diaphragms. Therefore, it is unlikely that this is the 
pathogenetic pathway that results in both the diaphragmatic defect and pulmonary 
hypoplasia seen in CDH patients.
To our knowledge this is the fi rst study to investigate the VHL pathway in human 
(neonatal) diaphragms. All tested markers of the VHL pathway were present in dia-
phragms of control patients suggesting a role of the VHL pathway in normal vessel 
development and function of the diaphragm.
The second part of this study was prompted by the idea that one insult causes both 
the hypoplastic lungs and diaphragmatic defect, supported by studies that demon-
strated a common expression of transcription factors in the developing lung and 
diaphragm mainly related to the RA pathway such as COUP-TFII 13-15. Previously, our 
group demonstrated disruptions in the VHL pathway in CDH lungs 16-18, 24. Both in the 
nitrofen CDH model and in human CDH disturbances in the RA pathway have been 
demonstrated 25, 26. RA has been demonstrated to increase NO production by eNOS 
phosphorylation through activation of an RA receptor (RAR)-mediated pathway in 
endothelial cells 27,  28. As eNOS is the downstream target of the VHL pathway, we 
were interested in the VHL pathway in diaphragms of CDH cases. The intensity of 
the immunostaining, although at best semi-quantitative, of the various VHL pathway 
associated proteins did, however, not differ amongst the investigated groups. In ad-
dition, real-time RT-PCR revealed gene expression of eNOS not to be altered. There-
fore it is unlikely that a disturbance in the VHL pathway is the mutual link between 
CDH lung and diaphragm abnormalities.
The nitrofen mouse model is a well-established CDH rodent model to elucidate 
pathogenetic aspects of diaphragmatic defects and the associated pulmonary 
hypoplasia 26. In CD1 mice, nitrofen induces pulmonary hypoplasia in 100% and 
diaphragmatic hernias in approximately 30% of mice (unpublished results and 
Iritani 29). As stated previously, disruptions in the RA pathway have been observed 
in the nitrofen model. As RA has been demonstrated to increase NO production 
by eNOS phosphorylation, nitrofen causing an inhibition of RA could lead to a 
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downregulation of eNOS and as a result NO 27, 28. This might disrupt vessel forma-
tion, and therefore diaphragm formation. We observed a lower incidence of CDH 
after nitrofen treatment of Tie2eNOS CD1 mice compared to control CD1 mice (0% 
versus 21%, p-value < 0.01) (unpublished results). In these mice, endothelial nitric 
oxide (eNOS) is overexpressed in endothelial cells using the endothelial cell specifi c 
promoter Tie2. This might indicate that nitrofen acts on the VHL pathway resulting in 
a lack of eNOS. This pathogenetic pathway would explain why mice overexpressing 
eNOS are resistant to the impact of nitrofen on the diaphragm, and therefore do not 
develop diaphragmatic defects.
We did not fi nd any differences in protein expression in the residual diaphragmatic 
tissue of CDH cases. This is however residual tissue, and might therefore be unaf-
fected tissue. The CDE diaphragms and the remaining part of the CDH diaphragms 
are however the best available tissues to study the defect. A limitation of this study 
is that we are evidently never able to investigate the actual ‘missing tissue’ in CDH 
patients. The CDE diaphragms we investigated originated from patients with a severe 
form of eventration, which was diagnosed prenatally. In all three patients pregnancy 
was terminated due to its severe phenotype. Therefore the gestational age of these 
patients was lower compared to other groups.
As described in the introduction, a defect in the VHL pathway could have been a 
potential candidate for several reasons. One major reason was that our group pre-
viously demonstrated human CDH lung vessel defects in the VHL pathway 16-18,  24. 
We must however not forget that the abnormalities in lung vessels might have been 
caused by other mechanisms than the intrinsic defect. Vessels are subject to pulmo-
nary hypertension and to the iatrogenic damage from intense treatments. Whether 
the defects of the VHL pathway are cause or effect, remains to be elucidated.
CONCLUSIONS
The VHL signaling pathway is present in the developing diaphragm and likely plays a 
role in vessel development and function of the diaphragm. In addition, this pathway 
does not seem to be affected in diaphragms of CDH and CDE patients. Therefore, it 
is unlikely that this is the common pathogenetic pathway linked to RA signaling that 
results in both major abnormalities as observed in CDH patients.
VHL Pathway in Diaphragmatic Defects
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GENERAL DISCUSSION
Congenital diaphragmatic hernia (CDH) consists of two major anomalies: a dia-
phragmatic defect and pulmonary anomalies consisting of a respiratory and vascular 
component. Despite extensive research, the pathogenesis and etiology of CDH and 
the pulmonary anomalies are still largely unknown. As children with CDH primarily 
suffer from the associated pulmonary anomalies, this dissertation mainly focused on 
deciphering the pathogenesis of pulmonary hypoplasia.
Lungs consist of two major tissue layers: epithelium and mesenchyme. Interactions 
between these tissue layers (epithelial-mesenchymal interactions) are crucial for 
proper embryonic lung development 1-7. Several developmental entities such as 
proliferation, apoptosis, and differentiation, are essential to form a healthy lung 3, 8-11. 
Apoptosis, for instance, is necessary during late lung development for thinning of 
the mesenchymal cell layer to improve gas exchange and as a result the oxygen-
ation of blood in the vessels 12-15. For these processes to occur correctly, interaction 
between epithelial and mesenchymal cells (fi broblasts) is a prerequisite. Cells in 
close proximity communicate via paracrine signals (soluble factors, matrix or cell 
contact) 16, 17. To study the particular interactions between these two pulmonary cell 
types, we isolated, recombined, and cultured these cells together in different ways; 
and created ‘cell recombinants’. Previously, our group demonstrated that fetal lung 
epithelial cells recombined with fetal lung fi broblasts reorganize in alveolar-like 
structures in vitro and that fi broblasts direct epithelial morphogenesis 18.
Understanding the pathogenesis of pulmonary hypoplasia is warranted to de-
velop novel prenatal therapeutic interventions to prevent or minimize its severe 
morbidity. We utilized the recombinant model to investigate the pathogenesis of 
nitrofen-induced pulmonary hypoplasia. Obviously, the best tissue to investigate the 
pathogenesis of pulmonary hypoplasia would have been fresh lung tissue from a 
living patient instead of an animal model. However, obtaining a lung biopsy from 
a living fetus or newborn with CDH for research is unethical. The burden of such a 
biopsy in a very ill child is too high in terms of pain, risk of infection and bleeding, 
and loss of the already small amount of lung tissue (pulmonary hypoplasia). How-
ever, several animal models are available to study CDH (as discussed in Chapter 
2). The nitrofen model is best suited to investigate the pathogenesis of pulmonary 
hypoplasia. Previously our group utilized this nitrofen model to demonstrate that 
CDH-associated pulmonary hypoplasia is a result of two hits: an intrinsic problem 
in the hypoplastic lungs itself before development of the diaphragmatic defect, and 
interference with fetal breathing movements and competition for space of the lungs 
due to herniation of abdominal organs through the diaphragmatic defect 19, 20. In the 
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present study, we were interested in the primary cause of the pulmonary hypoplasia, 
and therefore we focused on the intrinsic lung defect of the nitrofen model (Chapter 
3). Which of the two major tissue layers (epithelial or fi broblast / mesenchyme) is 
defective in the lung (and what epithelial-mesenchymal interactions are responsible 
for the pulmonary morphological characteristics of this disease) has never been 
addressed in detail. Such knowledge is required to design tissue-specifi c treat-
ment modalities that can exclusively target the defective tissue layer in pulmonary 
hypoplasia, and thereby modulate or potentially prevent pulmonary hypoplasia in 
CDH. To determine which lung tissue layer is defective in CDH, we combined the 
above mentioned nitrofen rodent and in vitro recombinant model, and created an 
in vitro model for pulmonary hypoplasia. This cell recombinant model enabled us 
to investigate epithelial-mesenchymal interactions in nitrofen-induced pulmonary 
hypoplasia into more detail. These recombination studies demonstrated, for the fi rst 
time, that the fi broblast (mesenchymal) layer is the defective tissue layer in hypo-
plastic lungs due to a decreased ability to undergo apoptosis and maintain overall 
proliferation. More importantly, this defect was intrinsic to the fi broblasts and this 
fi broblast tissue layer defect was not infl uenced by epithelial-mesenchymal interac-
tions. As mentioned earlier, this newly gained knowledge is necessary to eventually 
develop fi broblast-targeted treatment strategies. Later on, we will discuss how this 
affects future research and focus on treatment modalities.
Diminished apoptosis of fi broblasts could explain the thickened fi broblast tissue 
layer seen in nitrofen lungs. Diminished apoptosis could also explain the fewer 
alveoli observed due to this increase in fi broblasts. Furthermore, inhibition of apop-
tosis of the fi broblast layer has been reported to reduce epithelial branching, which 
could also contribute to decreased formation of alveoli 15. Healthy epithelial cells 
were unable to rescue this defect, implying that the diminished apoptosis was intrin-
sic to the nitrofen-exposed fi broblasts. In addition, nitrofen-exposed epithelial cells 
did not induce the observed defect in control fi broblasts, again indicating that the 
observed defect is inherent to the nitrofen-exposed fi broblasts.
In order to decipher the exact pathogenesis of developmental diseases, it is neces-
sary to understand the physiology of normal development. We used the established 
recombination method in Chapter 4 to investigate the infl uence of developmental 
stage on epithelial-mesenchymal interactions in developing lungs, and discovered 
that apoptosis of the mesenchyme during late prenatal lung development, is or-
chestrated by the surrounding epithelial cells, and is consequently not intrinsic to 
the mesenchyme itself. However, in our cell recombinant model we observed that 
apoptosis of nitrofen-treated fi broblasts was diminished and could not be rescued 
by a healthy epithelial opposing layer (Chapter 3). These seemingly controversial 
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results can be explained by the following: apoptosis of the fi broblasts is initiated by 
the surrounding epithelial cells however in nitrofen-treated fi broblasts the apoptotic 
process cannot be maintained. The exact processes responsible for these observa-
tions remain to be elucidated. One possible explanation could be interference in 
fi broblast growth factor-2 (FGF-2), which plays an important role in apoptosis. Later 
on, we describe an experimental setup to decipher the infl uence of FGF-2 on this 
process.
In contrast to earlier observations in apoptosis in our cultures, proliferation was 
intrinsic to the cells and therefore not triggered by surrounding cells (Chapter 4). In 
nitrofen lungs the decrease in proliferation was equally notable in epithelial cells and 
fi broblasts (Chapter 3). The decrease in proliferating epithelial cells likely explains 
the observed fewer number of alveoli and airways in nitrofen lungs. The ‘fi broblast 
defect’ must have infl uenced the proliferation of epithelial cells through epithelial-
mesenchymal interactions, as no decrease was observed when healthy fi broblasts 
were used. Apparently, fi broblasts can infl uence proliferation of epithelial cells in 
nitrofen lungs in such a way that an arrest of the cell cycle occurs, while the initiation 
of proliferation remains intrinsic to the epithelial cells, as demonstrated in Chapter 4. 
The proliferative arrest however, does not explain the overall increase in fi broblasts. 
One possibility is that the reduction in apoptosis of fi broblasts outbalances the de-
crease in proliferation. A lack of retinoic acid (RA) has been demonstrated to cause 
an arrest in the transition from the G1- to S-phase of the cell cycle 
21. A link to the RA 
pathway has been described in both the nitrofen model and human CDH patients. 
Nitrofen has been demonstrated to interfere with the RA pathway in several ways, in 
particular by blocking RALDH2, and consequently interferes with transcription factor 
(regulator)s such as GATA4, CoupTFII, etcetera 22, 23. The so-called RA hypothesis was 
recently supported by human studies, which showed that in a case-control design 
human newborns with CDH had signifi cant lower retinol and retinol binding protein 
(RBP) levels in umbilical cord blood 24. No differences in serum levels were observed 
in the mothers. Whether low serum retinol and RBP were present during the early 
phase of lung development remains to be seen, as placental function is different 
at that time and free diffusion of blood between mother and child occurs. Never-
theless, it would be interesting to investigate the effect of supplementing RA to the 
recombinant cultures containing nitrofen fi broblasts to observe whether this would 
annul the cell cycle arrest. To confi rm that those results are the effect of RA on the 
fi broblasts, and not epithelial cells, cultures with RA-pretreated fi broblasts should 
be performed additionally. Another possibility would be to use isolated pulmonary 
cells from a double-knockout model of the RA receptor described by Mendelsohn 
et al. to investigate whether this creates a similar morphology as the recombinants 
containing nitrofen fi broblasts 25.
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Taken together, the diminished proliferative capacity probably refl ects in the smaller 
size of the lungs (pulmonary hypoplasia), while the diminished apoptosis of the fi -
broblasts causes the thickening of the fi broblast tissue layer in nitrofen-treated lungs.
Our in vitro recombination experiments of nitrofen-treated and control epithelial 
and fi broblast lung cells suggest a defect in the fi broblast cell layer in the nitrofen 
model of pulmonary hypoplasia in CDH. The utilized in vitro cell recombinant model 
has its limitations. Endothelial cells were not added to the culture, and therefore 
the infl uence of vascularization and pulsations could not be studied. Fetal breathing 
movements, which have been demonstrated essential for proper lung development, 
were absent. The model also lacked the physiological ratio of lung cells. However, 
to study the pure interactions between epithelial cells and fi broblasts, we deemed 
this to be an appropriate model. In future experiments it could be interesting to 
implement endothelial cells in cultures as well as to observe their infl uence on in 
vitro morphogenesis and nitrofen-treated fi broblasts. Also, to provide more spacial 
accuracy cultures could be plated on 3D scaffolds to give cells the possibility to grow 
in all directions, and to mimic fetal breathing movements cell recombinants could 
be grown on stretch plates. Human hypoplastic CDH lungs contain thickened alveo-
lar walls, an increase in interstitial tissue, reduced alveolar air spaces and a reduced 
gas-exchange surface area 26-29. The defect in the fi broblast layer as we described 
above, could be a good explanation for these observations. A decrease in apoptosis 
of fi broblasts prevents the thinning of the interstitial fi broblast layer normally seen 
during later lung development 12, 30. Identifi cation of the timing and, eventually, tar-
geted modulation of the defect in the fi broblasts during lung development warrants 
more research. However, the origin of the increase in fi broblasts is unknown, and 
would be the logical next step to address in order to elucidate the pathogenesis 
of pulmonary hypoplasia in CDH. Recently, researchers discovered that pulmonary 
fi brosis is partially due to a process called epithelial-mesenchymal transition (EMT) 
in both the bleomycin mouse model and idiopathic pulmonary fi brosis patients 31, 32. 
EMT is the transformation of an epithelial cell into a mesenchymal (fi broblast) cell. 
EMT, and its opposite process mesenchymal-epithelial transition (MET), have been 
described in many organs (eg. the kidney and the lung), both as a normal part of 
(embryonic) development as well as a pathological process 33-37. We hypothesized 
that EMT might explain the increase in fi broblasts observed in the previous cell 
recombinant experiments, but also in hypoplastic lungs in the nitrofen model and 
in human CDH. Another explanation within the concept of transitional processes 
would be a loss of physiological MET; this could explain the thickened fi broblast 
layer as well. However, even though it seems likely that EMT and MET are physi-
ological processes in the lungs, this remains to be determined. In our pilot study 
in Chapter 5 we demonstrated that nitrofen-treated lungs contain mesenchymal 
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cells from an epithelial descent. This suggests that EMT is a process that occurs in 
nitrofen-treated lungs in vivo, and may contribute to the CDH associated pulmonary 
hypoplasia. If EMT is the cause of the thickened fi broblast layer, therapeutic options 
to further pursue would be selectively blocking EMT-inducing factors such as trans-
forming growth factor-beta.
A progressive obstacle in the fi eld of research of CDH-associated pulmonary hypo-
plasia is the lack of human lung tissues available for research. As mentioned before, it 
is unethical to obtain a lung tissue biopsy, not merely due to the existing pulmonary 
hypoplasia. However, human tissue for translational research is necessary to validate 
the results from fundamental research in animal models to the clinical setting in hu-
man patients. While CDH animal models have generated new hypotheses for human 
CDH and its associated anomalies, tissue availability has decreased dramatically to 
test these hypotheses 38-41. The accrual of fresh tissue to perform sensitive investiga-
tive techniques (ie. cell cultures, RNA extraction, etc) is even more diffi cult due to 
the postmortem delay, which affects tissue quality. In Chapter 6 we described a new 
approach that was implemented in 2001 in the Sophia Children’s Hospital in Rot-
terdam to increase the accrual of human CDH lung tissue: a postmortem lung biopsy 
through a mini-thoracotomy. Parents who refused to consent for a full autopsy were 
offered the opportunity of a minimally invasive lung biopsy for pathological evalu-
ation (diagnostics) of the lung and translational research purposes. We managed to 
quadruple the amount of postmortem tissues obtained from 11% (autopsy) to 45% 
(autopsy and biopsy combined). In addition, we demonstrated that it is possible 
to isolate fi broblasts from these tissues. This is an interesting application to create 
human CDH biobanks to collect tissue and isolated cells to test future hypotheses 
and prospective investigative techniques (see ‘fi broblasts in the biobank’). Due to 
its severe phenotype, parents with a prenatally diagnosed child have the option 
to terminate the pregnancy. Especially in the presence of chromosomal anomalies 
termination of pregnancy takes place on a regular base. Also in case of a predicted 
low chance of survival (lung area to head circumference-ratio (LHR < 1.0) and liver 
present in the thoracic cavity) termination of pregnancy is regularly considered in 
the Netherlands. Tissues from these prenatally terminated children are very valu-
able for research, as they are untreated and therefore little iatrogenic damage is 
present. In addition, cord blood is a valuable source of progenitor cells. Progenitor 
cells are cells that have the ability to differentiate into different cell types. They are 
an interesting source for the repair of damaged tissues as has recently been shown 
for other organs like the heart 42. Isolated progenitor cells could be tested for their 
regenerative potential in hypoplastic lungs.
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It is likely that the two major anomalies of CDH (the diaphragmatic and pulmo-
nary defect) occur through a shared pathogenetic pathway: the ‘two defects, one 
origin’-theory. Previously, the pulmonary defect was demonstrated to be present 
in the lungs before closure of the diaphragm, and consequently, not only a result 
of herniation of the abdominal viscera through the diaphragmatic hernia 20. More 
recently, data that encourages this theory is that the chromosome regions that are 
commonly deleted in CDH patients are located in both lungs and diaphragm 43-45. 
Examples of the RA pathway related genes are COUP-TFII and FOG2. In human CDH 
lungs, expression of proteins of the Von Hippel-Lindau (VHL) pathway is disrupted 
46-49. As vascularization is important for proper embryogenesis and therefore likely in 
diaphragm formation as well, a disruption in the VHL pathway could be the mutual 
cause of both major defects in CDH patients. In Chapter 7 we performed experi-
ments to investigate the expression of proteins in the VHL pathway in the remaining 
diaphragms of patients with CDH. We did not observe any differences compared 
to control human diaphragms. However, the pitfall of performing research on the 
residual diaphragm in CDH is that this is the residual tissue. Residual tissue might 
mean that it is unaffected tissue. Whether we should actually study diaphragm tissue 
from CDH patients is discussed below.
FUTURE PERSPECTIVES
Two central points of attention for future research should be considered: 1) searching 
for the intrinsic defect of the fi broblasts, and 2) exploring new (preventative) treat-
ment modalities, both pre- and postnatal.
Fibroblasts: focus of future research
This dissertation focused on deciphering the malfunctioning tissue layer in nitrofen-
induced pulmonary hypoplasia in CDH. We demonstrated that fi broblasts are the 
malfunctioning tissue layer, and therefore, these cells should be the focus of future 
research. The fi rst step of future research should be to confi rm that the fi broblast tis-
sue layer is indeed the malfunctioning tissue layer in human hypoplastic CDH lungs. 
In addition, we should verify that these fi broblasts contain diminished apoptosis 
and a proliferative arrest. The performed recombinant experiments with healthy and 
hypoplastic isolated tissue layers have not been feasible in human CDH so far. How-
ever, in Chapter 6 we did demonstrate the application of isolating fi broblasts from 
the postmortem biopsies of approximately two hours old to create an opportunity to 
study these defective fi broblasts in cell culture. If we would be able to do the same 
for epithelial cells, and store these in the biobank, human cell recombination experi-
ments should be possible in the future. Previous attempts to isolate human epithelial 
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cells failed; therefore it is necessary to optimize these techniques. We should bear in 
mind that the interpretation of such experiments with human lung tissue should be 
done with caution, as it is diffi cult to distinguish whether the observed differences 
are due to the underlying pathogenesis or caused by the intense treatment these 
children undergo, for instance prenatal tracheal occlusion (PLUG). The best tissue 
source for unbiased results would be tissues from terminated pregnancies of chil-
dren with isolated CDH, although the level of autolysis remains a matter of concern.
Fibroblasts: deciphering the defect
Isolation of human fi broblasts is not easily established and also a labour intensive 
process. It requires a delicate infrastructure and informed consent of the parents for 
obvious reasons. However, it is worth the effort to make it common practice to do so. 
Fibroblasts from CDH lungs are a unique material, especially as it seems increasingly 
likely that these contain the defect we are searching for. With fi broblast biobanking 
we could collect and analyze fi broblasts from several CDH patients simultaneously. 
More importantly, these materials will be available for novel future investigative 
techniques. Once we have established that human fi broblasts are indeed defective, 
the next step would be to search for the cause of this malfunctioning. Recently, ad-
vanced techniques for molecular profi ling have become available such as genome-
wide association studies. These compare the DNA of patients with healthy individu-
als to fi nd abnormalities in the DNA sequence such as mutations. However, over 
the last decades no specifi c genes have been revealed that explain the phenotype 
of the group of isolated CDH patients. It seems likely that the abnormality does not 
lie within the DNA sequence itself. Hence, the next step in deciphering the intrinsic 
defect of human fi broblasts should be mRNA expression arrays. These arrays could 
demonstrate which mRNA pathways are altered in CDH fi broblasts compared 
to healthy fi broblasts. This information aids us in fi nding the affected pathway(s). 
MicroRNAs are important regulators of the expression of mRNA. MicroRNAs can 
bind to mRNA resulting in inhibition of the mRNA, and therefore determine protein 
expression. Once we know which mRNAs are abnormal in the fi broblasts, we can 
develop mRNA-specifi c treatment options, such as administrating microRNAs (to 
stop protein expression if abundant) or their antagonists (to increase the amount of 
particular proteins).
Fibroblasts and the retinoic acid signaling pathway
Another argument that supports the ‘two defects, one origin’-theory is the common 
expression of transcription factor (regulator)s such as COUP-TFII, GATA-binding pro-
tein 4 (GATA4), and Friend of GATA2 (FOG2). Both are expressed in the developing 
lung and diaphragm, and are located on chromosome regions commonly deleted 
in individuals with CDH 43-45. An interesting link is the connection to the RA signaling 
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pathway. These factors are all downstream targets of this pathway. Both human and 
nitrofen-induced CDH and pulmonary hypoplasia have been connected to pertur-
bations in the RA signaling pathway for many years 50-53. More recently this connec-
tion was supported by a study that showed that human newborns with CDH had 
signifi cantly lower retinol and retinol binding protein levels in umbilical cord blood 
24. An intriguing insight into the late G1-phase arrest we demonstrated in the nitrofen-
treated fi broblasts is the link to RA. It has been shown that RA protects alveolar 
epithelial cells from a late G1-phase arrest induced by hyperoxia 
21. Cells exposed 
to oxygen did form less cyclin E-Cdk complexes but these complexes regained 
normal values when oxygen-exposed cells were pretreated with RA. Interestingly, 
we observed a late G1-phase arrest in the recombinants containing nitrofen-treated 
fi broblasts. Several treatment options have been aimed at increasing proliferation 
in CDH-associated pulmonary hypoplasia but none has specifi cally targeted a G1-
phase proliferative arrest 54,  55. The application of prenatal tracheal occlusion was 
able to increase lung growth, branching and the gas exchange surface at least in 
nitrofen-treated lungs and larger animals such as sheep 54, 56-59. It would be interest-
ing to see whether this specifi cally targeted the G1-to-S-phase arrest, and infl uenced 
cyclin-dependent kinase inhibitors.
Several FGFs are known to play an important role in lung development 60,  61. For 
instance FGF-2 plays a role in lung cell apoptosis, while FGF-1 is an example of a 
growth factor with proliferative qualities 62, 63. In addition, in the nitrofen model both 
FGF-7 and FGF-10, and FGFRL-1 were down regulated, while recently LopezJimenez 
et al. demonstrated a CDH patient with a 4p16.3 deletion that included the FGFRL-1 
region 64-66. As we now know that fi broblasts are the malfunctioning tissue layer in 
the nitrofen model, it would be interesting to investigate FGFs and their infl uence. 
One approach would be to grow healthy fetal rat lungs in vitro together with nitrofen 
and FGFs to observe whether an abundance of FGF is able to save the hypoplasia 
nitrofen induces. Another option would be to administer FGFs in vivo to the fetus 
during nitrofen treatment. Finally, it would be interesting to investigate the effect of 
blocking FGFs in vitro and investigate the infl uence in healthy lungs. Especially the 
infl uence of adding FGF-2 and FGF-1, which play a role in apoptosis and prolifera-
tion, respectively, on the development of nitrofen lungs would be of interest. Previ-
ously, our group was able to grow organotypic cultures of human fetal lungs 67. If we 
would be able to do this for CDH lungs as well, we could investigate the infl uence of 
FGFs on hypoplastic lungs. No major differences in timeframe of the termination of 
pregnancy exist (between 16 and 22 weeks in healthy fetuses versus 16 and 24 weeks 
in CDH fetuses), but there are some other concerns to this approach. First, there is a 
difference in delay before lungs can be isolated. Fetuses from an abortion clinic are 
readily available and cultures can start with little delay. However, deceased CDH 
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fetuses may stay in the womb for a couple of days till induced delivery takes place, 
which causes delay to culture. In addition, healthy lungs might be easier to culture 
compared to hypoplastic CDH lungs. Given the suggested importance of derailment 
of the RA pathway, RA would be an important factor for further investigation.
Towards therapeutics
It will be a while before we can implement our results in the clinical setting. First, 
possible treatments have to be tested in animal (model)s. Prenatal surgery was tested 
in animal models for many years before it was implemented in the clinical setting. 
Prenatal surgery has grown in the last decade, and is potentially relevant for a few 
congenital anomalies such as meningomyelocele and selected cases of lung cysts 
68,  69. Fetal surgeons have been able to improve their skills, and certain congenital 
anomalies are waiting to be added to the standard prenatal surgery list. As individual 
children with CDH suffer and succumb from their hypoplastic lungs, for these pa-
tients one logical treatment option would be lung transplantation. Lung transplanta-
tion in newborns is rarely performed as it has many associated problems such as 
the risk of rejection, not to mention the shortage of donor organs and technical 
diffi culties in the newborn 70, 71. In addition, prenatal transplantation of an entire lung 
has never been performed but would be very challenging and risky, if even, feasible. 
Recently, the area of tissue engineering has been explored. Lungs are removed from 
the thorax and acellularized, and used as an in vitro scaffold to grow cells and create 
a new ‘lung’. Petersen et al. demonstrated that transplantation of such a recellular-
ized scaffold participated in gas exchange within two hours and up to seven days in 
adult rats 72, 73. This is a very new and promising approach to replace diseased lungs 
without the need for a donor and the associated risks of allogeneic transplantation. 
Previously, tissue engineered trachea was successfully transplanted in a patient with 
bronchomalacia. The trachea was functioning normally at four months and, despite 
not using any immunosuppressive drugs, no anti-donor antibodies were formed, 
which demonstrates that such approaches are feasible 74. Interestingly, as we dem-
onstrated that the nitrofen fi broblasts are the defective cell layer, which acts through 
cell-cell interactions, transplanting the acellularized scaffold of nitrofen-treated 
lungs might be able to solve this problem. Even before actually transplanting the 
recellularized scaffold, it would be interesting to see whether growing healthy lung 
cells onto a nitrofen-scaffold would ‘rescue’ pulmonary hypoplasia. As the inter-
stitium is acellularized and only the scaffold remains, diseased nitrofen fi broblasts 
would not be able to result in defective growth of the lung. This approach has only 
been demonstrated for an adult full-grown lung, and not for a developing lung. It is 
a precarious approach but it would be interesting to see whether it has the potential 
to grow and be used in a developing lung as well.
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Instead of transplanting an entire lung, single cells can be transplanted as well. Pro-
genitor cells can be extracted from cord blood of the newborn. These days we are 
even able to create induced pluripotent stem cells (iPS cells) from skin fi broblasts 75. 
To test the infl uence of pluripotent cells on lung growth, we could create fl uorescent-
labeled iPS cells and administer them to nitrofen-treated rodent embryos prenatally. 
The best method of administration with direct delivery of the cells to the damaged 
lungs would be to endoscopically inject the iPS cells in the trachea followed by 
tracheal occlusion. Another method would be microinjections in the right ventricle. 
We should however take into account that approximately 10% of the blood volume 
circulates through the lungs, and 90% will leave the heart through the ductus ar-
teriosus and foramen ovale straight into the general circulation, which makes this 
method less desirable. However, other options could be examined as well such as 
administration through amniotic fl uid injections, maternal circulation, or in the um-
bilical vein. Subsequently, lungs would be isolated and investigated for morphology 
and localization of the labeled iPS cells. In addition, isolated lung cells can be sorted 
by fl uorescence-activated cell sorting (FACS) to determine their differentiation pat-
tern. Another option would be to inject labeled pluripotent cells in the trachea of 
nitrofen explants. Using live imaging of cells (with confocal microscopy) it is possible 
to follow cells for a certain amount of time. Cells are photographed at regular time 
intervals over several hours and their behavior can be followed individually.
Fibroblasts in nitrofen-treated lungs and diaphragm: same intrinsic defect?
The pulmonary hypoplasia and diaphragmatic hernia are likely to have a similar 
origin. Chromosome regions that are commonly deleted in CDH patients such as 
COUP-TFII and FOG2 are located in both lungs and diaphragm. In addition, nitrofen 
blocks RALDH2 in vitro cell cultures. RALDH2 was demonstrated to be present in 
both the pleuroperitoneal fold of the rat diaphragm and lungs 76-79. Based on the 
localization of the defect of the primordial diaphragms in several CDH animal mod-
els, Clugston et al. previously hypothesized that it is the non-muscular component 
that is defective 80. In addition, we hereby, for the fi rst time, demonstrate that the 
fi broblast tissue layer is also the defective tissue layer in nitrofen-induced pulmonary 
hypoplasia. These results combined encourage the theory that fi broblasts are the 
primary affected cells caused by the same insult in the nitrofen model for CDH.
Research in CDH diaphragms and/or CDH lungs?
Even though it is very likely that both anomalies contain a defective fi broblast tissue 
layer, the question arises whether we should indeed study both human tissues. The 
major issue with diaphragmatic material from patients with an isolated congenital 
diaphragmatic hernia (both postmortem or through a biopsy obtained during hernia 
repair), is that this diaphragm material is the residual ‘healthy’ tissue, and might 
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therefore not contain any defect at all. So far, the only evidence that the residual 
human diaphragm contains abnormalities was that the residual diaphragm tissue 
surrounding the hernia was thickened in CDH patients as well as in several CDH 
animal models 80. Even though we believe that the diaphragmatic defect and pulmo-
nary hypoplasia share the same original insult, research might have to focus on the 
pulmonary hypoplasia to uncover the shared origin of the fi broblast defect.
CONCLUSIONS
The aim of this dissertation was to improve our knowledge into the pathogenesis 
of pulmonary hypoplasia in CDH, to eventually aid in fi nding ways to modulate 
the natural course in the prenatally diagnosed child with CDH. The most important 
fi nding we uncovered was that fi broblasts are the actual malfunctioning tissue layer 
in the nitrofen lung, and orchestrate the characteristic morphology we observe in 
nitrofen lungs. Therefore, fi broblasts should be the primary focus of future research. 
The next step in our quest should be to elucidate what causes the intrinsic defect of 
the fi broblasts. This knowledge is necessary to develop new (prenatal) preventative 
or therapeutic strategies. These strategies should focus on correcting the defective fi -
broblast tissue layer, so that lungs of the future prenatally diagnosed child with CDH 
can develop (near) normal, and this future child does not suffer from the current 
severe morbidity and risk of dying in the newborn period even under conditions of 
maximal supportive care.
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 ENGLISH SUMMARY
Congenital diaphragmatic hernia or CDH is a developmental defect of the dia-
phragm that allows abdominal organs, such as intestines and liver, to herniate into 
the thoracic cavity and compromise lung development. CDH has a prevalence 
of one in 2000 – 3000 newborns. Children with a CDH suffer from a substantial 
amount of morbidity and mortality due to the associated abnormal pulmonary 
development. This results in two clinical problems: pulmonary hypoplasia and per-
sistent pulmonary hypertension of the neonate (PPHN). New treatment modalities, 
such as extracorporeal membrane oxygenation (ECMO), are designed for treating 
the sequelae of CDH, pulmonary hypoplasia and PPHN, but do not contribute to 
the prevention of these conditions. The pathogenesis and etiology of CDH and its 
associated pulmonary anomalies are still largely unknown despite all research ef-
forts over the past years. A basic understanding of these anomalies is fundamental in 
our quest for new answers how to protect these children from the sequelae of this 
anomaly. Consequently, the aim of this dissertation is to improve our understanding 
of the pathogenesis of pulmonary hypoplasia in CDH, to eventually aid in fi nding 
ways to modulate the natural course in a prenatally diagnosed child (Chapter 1).
The best tissue to investigate the pathogenesis of pulmonary hypoplasia would 
be a lung biopsy from a living fetus or newborn with CDH. The burden of such a 
procedure would be unethical due to the high associated risks and loss of the al-
ready small amount of hypoplastic lung tissue. Fortunately, several animal models 
are available to study CDH, including the nitrofen rodent model, a surgical lamb 
or rabbit model and multiple genetic mouse models. In Chapter 2 we discuss the 
strengths and limitations of these three models, and their relevance to the human 
situation. Surgical models are preferred for validating new interventions in CDH. 
Genetic mouse models are necessary to study the infl uence of genes on lung and 
diaphragm development. The nitrofen model is best suited to investigate the patho-
genesis of pulmonary hypoplasia. Although none of the animal models have been 
perfect in mimicking human CDH and its associated anomalies, they all contributed 
to improve our understanding of the underlying pathogenesis and pathology of this 
disease.
Previously, the associated pulmonary hypoplasia was interpreted as a result of the 
‘compression’ by herniated abdominal organs of the developing lung. A decade ago, 
pulmonary hypoplasia was found to be present before closure of the diaphragm, 
which prompted the postulation/foundation of the dual-hit hypothesis: pulmonary 
hypoplasia was not solely caused by the herniated organs but also the results of an 
intrinsic defect in the lungs itself. Subsequently, research focused on the intrinsic de-
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fect. In Chapter 3 we utilized an in vitro cell recombinant model (a model appropri-
ate to investigate epithelial-mesenchymal interactions) for pulmonary hypoplasia to 
demonstrate that the fi broblast tissue layer (or mesenchyme) is the primary affected 
tissue layer in nitrofen-induced pulmonary hypoplasia. The fi broblast tissue layer 
has a decreased ability to undergo apoptosis and maintain overall proliferation. This 
knowledge is necessary to eventually develop fi broblast-targeted treatment strate-
gies, to prevent severe pulmonary hypoplasia in children with CDH.
In order to decipher the exact pathogenesis of developmental diseases, it is neces-
sary to understand the physiology of normal, healthy development. In Chapter 4 we 
utilized the in vitro cell recombinant model to study the infl uence of developmental 
stage on epithelial-mesenchymal interactions during normal fetal rat lung develop-
ment. Apoptosis of the fi broblast tissue layer, a physiological phenomenon during 
late prenatal lung development, appears to be orchestrated by the surrounding 
epithelial cells and is consequently not intrinsic to the mesenchyme itself.
In Chapter 5 we present data from our pilot study of epithelial-mesenchymal 
transition (EMT) in nitrofen-treated lungs. In nitrofen-treated lungs we established 
previously that the fi broblasts are the primary affected tissue layer, which disturbs 
the normal epithelial-mesenchymal interactions necessary for proper lung develop-
ment. The origin of these cells however is unknown. Recently, a new theory involving 
cell transformations arose to explain both normal morphogenesis and the develop-
ment of diseases such as fi brosis and malignancies. EMT is the transformation of an 
epithelial cell into a mesenchymal cell (fi broblast). One explanation for the origin of 
the defective fi broblasts could be this process. Our preliminary results demonstrated 
that nitrofen-treated lungs contain mesenchymal cells from an epithelial descent. 
This suggests that EMT is a process that occurs in nitrofen-treated lungs in vivo, and 
may contribute to the CDH associated pulmonary hypoplasia.
Translational research is necessary to validate the results of fundamental research in 
the clinical setting. While CDH animal models have generated new hypotheses of 
human CDH and its associated anomalies, tissue availability has decreased dramati-
cally to test these hypotheses. Both the improved survival and decrease in permis-
sion to perform full autopsy can be held responsible for this development. In 2001 
a new protocol was instituted in our hospital to increase the accrual of CDH lung 
tissue via a quick and minimal invasive method: postmortem lung biopsy through 
a mini-thoracotomy. In Chapter 6 we described that this new procedure to obtain 
human CDH lung tissue for both diagnostic and translational research quadrupled 
the amount. In addition, we were able to isolate CDH fi broblasts from one of these 
biopsies. Human CDH fi broblasts are very precious and necessary, as it seems 
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increasingly likely that these cells contain the defect we are after. These isolated 
fi broblasts are the key to eventually develop and implement fi broblast-targeted 
treatment modalities.
It is very likely that the two major defects of CDH, the diaphragmatic hernia and 
pulmonary anomalies, share the same original insult. This is confi rmed by the pres-
ence of disruptions in similar developmental pathways of both organs such as the 
retinoic acid signaling pathway. During normal organogenesis, vessel development 
is a prerequisite. The Von Hippel-Lindau (VHL) pathway is important for angiogenesis 
and vessel function. Previously, disruptions in the VHL pathway were observed in 
human CDH lungs. In Chapter 7 we investigated the VHL pathway in diaphragmatic 
tissues from healthy controls, patients with CDH and patients with congenital dia-
phragmatic eventration (CDE). We demonstrated that the VHL signaling pathway is 
present during diaphragm development at early stages of gestation, and likely plays 
a role in vessel development and function of the diaphragm. The VHL pathway does 
not appear affected in diaphragms of CDH and CDE patients. Therefore, it is unlikely 
that this is the common pathogenetic pathway linked to retinoic acid signaling that 
results in both major abnormalities as observed in CDH patients.
The general discussion in Chapter 8 describes the interpretation of the studies 
reported in this dissertation. In addition, it provides suggestions for future research 
to continue the quest for answers to eventually develop prenatal tissue-targeted 
treatment modalities
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 NEDERLANDSE SAMENVATTING
Congenitale hernia diafragmatica of CDH is een defect in de ontwikkeling van het 
middenrif dat organen van de buikholte, zoals darmen en lever, de kans geeft om 
ruimte in te nemen binnen de borstkas en zo de ontwikkeling van de longen te be-
perken. CDH komt voor bij één op de 2000 – 3000 pasgeborenen. Pasgeborenen 
met CDH lijden onder ernstige restverschijnselen en sterfte door de abnormale long 
ontwikkeling die hiermee gepaard gaat. Dit resulteert in twee klinische problemen: 
een vorm van abnormale long ontwikkeling (pulmonale hypoplasie) en abnor-
male long vaat ontwikkeling (persisterende pulmonale hypertensie van de neonaat 
(PPHN)). Nieuwe therapeutische mogelijkheden, zoals extracorporele membraan 
oxygenatie (ECMO of hart-longmachine), zijn ontwikkeld om de gevolgen van 
CDH, pulmonale hypoplasie en PPHN, te behandelen, maar dragen niet bij aan 
het voorkómen hiervan. De ontstaanswijze (pathogenese en etiologie) van CDH 
en zijn aanverwante long afwijkingen zijn nog grotendeels onbekend ondanks het 
vele onderzoek van de afgelopen jaren. Basale kennis van deze aandoeningen is 
noodzakelijk in onze strijd naar antwoorden hoe deze kinderen beschermd kunnen 
worden tegen deze gevolgen. Het doel van dit proefschrift is om de kennis van de 
pathogenese van pulmonale hypoplasie in CDH te verbeteren, om uiteindelijk het 
natuurlijke beloop van een prenataal gediagnosticeerd kind ten goede te kunnen 
beïnvloeden (Hoofdstuk 1).
Het beste weefsel voor onderzoek naar de ontstaanswijze van pulmonale hypopla-
sie zou een long biopt zijn van een levende foetus of pasgeborene met CDH. Zo’n 
procedure is echter niet ethisch verantwoord door het hoge risico dat het met zich 
meebrengt naast het verlies van het al minimaal aanwezige (hypoplastische) long 
weefsel. Gelukkig bestaan er meerdere diermodellen om CDH te onderzoeken, zo-
als het nitrofen model, het chirurgische model, en een aantal genetische modellen. 
In Hoofdstuk 2 bespreken we de sterke en zwakke punten van deze drie modellen, 
en hun relatie tot de humane situatie. Het chirurgische model verdient de voorkeur 
om nieuwe interventies te testen. Genetische modellen zijn noodzakelijk om de 
invloed van genen op de ontwikkeling van de long en het diafragma te analyseren. 
Het nitrofen model is het meest geschikte model om de pathogenese te bestuderen. 
Alhoewel geen enkel model hét perfecte model is, zijn ze belangrijk om nieuwe 
inzichten te verkrijgen ten aanzien van de pathogenese en pathologie van de aan-
doening.
In het verleden werd pulmonale hypoplasie geïnterpreteerd als het gevolg van ‘com-
pressie’ van de ontwikkelende long door de buik organen. Ruim tien jaar geleden 
werd ontdekt dat pulmonale hypoplasie aanwezig is vóórdat de fysiologische slui-
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ting van het middenrif plaatsvindt. Dit vormde de basis van de ‘dual-hit’ hypothese: 
pulmonale hypoplasie wordt niet puur door ‘compressie’ van de binnendringende 
buik organen veroorzaakt maar de long is zelf afwijkend. Zodoende verschoof de 
focus van het onderzoek naar dit intrinsieke long defect. In Hoofdstuk 3 toonden 
we aan, middels gebruik te maken van een in vitro cel recombinatie model (een 
model geschikt om interacties tussen twee weefsellagen (epitheel en fi broblasten) te 
onderzoeken), dat de fi broblasten (of het mesenchym) de weefsellaag is die primair 
is aangedaan in nitrofen-geïnduceerde pulmonale hypoplasie. Tevens liet dit model 
zien dat de defecte fi broblasten een verminderd vermogen hebben om geplande 
celdood (apoptose) te ondergaan en cel vermeerdering (proliferatie) te behouden. 
Dit is noodzakelijke kennis om uiteindelijk fi broblast-specifi eke therapeutische 
strategieën te ontwikkelen ter voorkoming van ernstige pulmonale hypoplasie bij 
pasgeborenen met CDH.
Om de exacte pathogenese van ziektes die tijdens de ontwikkeling ontstaan te 
achterhalen, is het nodig om de fysiologie van normale, gezonde ontwikkeling te 
begrijpen. Middels het in vitro cel recombinatie model onderzochten we in Hoofd-
stuk 4 de invloed van de ontwikkelingsfase op epitheliale-mesenchymale interacties 
tijdens normale foetale rat long ontwikkeling. Apoptose van de fi broblasten, een 
fysiologisch fenomeen aan het eind van de prenatale long ontwikkeling, wordt 
gereguleerd door de omliggende epitheelcellen, en is dus niet intrinsiek aan de 
fi broblasten zelf.
In Hoofdstuk 5 presenteerden we onze pilot studie naar epitheliale-mesenchymale 
transitie (EMT) in nitrofen-behandelde longen. In nitrofen longen zagen we eerder dat 
de fi broblasten de primair afwijkende weefsellaag zijn, die de normale epitheliale-
mesenchymale interacties, noodzakelijk voor normale long ontwikkeling, verstoren. 
De oorsprong van deze cellen is echter onbekend. Recent is er een nieuwe theorie 
ontstaan rondom cel transformaties die zowel normale orgaan ontwikkeling als de 
ontstaanswijze van ziektes zoals fi brose en maligniteiten verklaart. EMT is het trans-
formeren van een epitheelcel naar een mesenchymale cel (fi broblast). De oorsprong 
van de fi broblasten kan zo verklaard worden. Onze eerste resultaten laten zien dat 
nitrofen-behandelde longen mesenchymale cellen bevatten van een epitheliale 
afkomst. EMT zou plaats kunnen vinden in nitrofen-behandelde longen in vivo, en 
dus bij kunnen dragen aan de pulmonale hypoplasie bij kinderen met CDH.
Translationeel onderzoek is nodig om de resultaten van basaal wetenschappelijk 
onderzoek te vertalen naar de kliniek. Terwijl diermodellen nieuwe hypotheses over 
CDH bij de mens en de aanverwante afwijkingen teweeg hebben gebracht, is de 
hoeveelheid humaan weefsel om deze hypotheses op te testen aanzienlijk gedaald. 
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Zowel de verbeterde overlevingskans als de afname in toestemming voor obductie 
zijn verantwoordelijk voor deze ontwikkeling. In 2001 is er een nieuw protocol in 
ons ziekenhuis geïntroduceerd om een toename van het verkrijgen van weefsel te 
bewerkstelligen via een snelle en minimaal invasieve procedure: een postmortaal 
long biopt middels een mini-thoracotomie. In Hoofdstuk 6 beschreven we dat deze 
nieuwe procedure de hoeveelheid weefsel voor zowel diagnostiek als translationeel 
onderzoek verviervoudigde. Daarnaast waren we in staat om CDH fi broblasten uit 
één van de long biopten te isoleren. Humane CDH fi broblasten zijn erg waardevol en 
noodzakelijk nu het in toenemende mate duidelijk wordt dat deze cellen het defect 
bevatten waar we naar op zoek zijn. Deze geïsoleerde fi broblasten zijn de sleutel om 
uiteindelijk fi broblast-specifi eke therapeutische mogelijkheden te onderzoeken en 
toe te passen.
Het is zeer waarschijnlijk dat de voornaamste defecten van CDH, het gat in het mid-
denrif en de longafwijkingen, een zelfde oorsprong delen. Dit wordt bevestigd door 
de aanwezigheid van verstoringen in overeenkomstige pathways zoals de vitamine 
A cascade tijdens de ontwikkeling van beide organen. Vaatontwikkeling (angioge-
nese) is een vereiste tijdens normale orgaan ontwikkeling. De Von Hippel-Lindau 
(VHL) pathway is belangrijk voor angiogenese en vaatfunctie. In eerder onderzoek 
zijn verstoringen in de VHL pathway gezien. In Hoofdstuk 7 bestudeerden we de 
VHL pathway in middenrif weefsel van gezonde controle patiënten, patiënten met 
CDH, en patiënten met congenitale eventeratie van het diafragma (CDE). De VHL 
cascade was aanwezig tijdens de ontwikkeling van het diafragma en vroeg in de 
zwangerschap, waardoor het aannemelijk is dat de VHL cascade een rol speelt in de 
ontwikkeling en functie van het diafragma. De VHL pathway blijkt niet afwijkend te 
zijn in diafragmata van CDH en CDE patiënten. Daardoor is het onwaarschijnlijk dat 
dit de gemeenschappelijke pathway is, verbonden door vitamine A, van de beide 
afwijkingen in CDH patiënten.
De algemene discussie in Hoofdstuk 8 beschrijft de interpretatie van de studies 
beschreven in dit proefschrift. Daarnaast geeft het suggesties voor toekomstige 
onderzoeksprojecten in de zoektocht naar weefsel-specifi eke therapeutische mo-
gelijkheden.
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 ABBREVIATIONS
ARDS acute respiratory distress syndrome
αSMA alpha-smooth muscle actin
BASC bronchoalveolar stem cell
BSA bovine serum albumine
CCSP clara cell secretory protein
CDE congenital diaphragmatic eventration
CDH congenital diaphragmatic hernia
Cdk cyclin-dependent kinase
COUP-TFII chicken ovalbumin upstream promotor-transcription factor 2
CRABP1 cellular retinoic acid binding protein
Cyp cytochrome p450
DAB 3,3’-Diaminobenzidine
DAPI 4’,6-diamidino-2-phenylindole
Disp1 Dispatched homolog 1
E embryonic day
EC control epithelial cells
EN nitrofen epithelial cells
E-Cadh E-Cadherin
ECMO extracorporeal memebrane oxygenation
EdU 5-ethynyl-2’-deoxyuridine
EMT epithelial-mesenchymal transition
Endo endodermal cells
eNOS endothelial NO synthase
Epi epithelial cells
EXIT ex-utero intrapartum treatment
FC control fi broblasts
FN nitrofen fi broblasts
FACS fl uorescence-activated cell sorting
FCS fetal calf serum
FETO fetoscopic endoluminal tracheal occlusion
FGF fi broblast growth factor
FGFRL1 FGF receptor L1
Fib fi broblasts
FITC fl uorescein isothiocyanate
FOG2 friend of GATA2
GA gestational age
GATA GATA-binding protein
GFP green fl uorescent protein
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GNZ GFP and LacZ
H&E hematoxylin and eosin
HBSS Hanks’ Balanced Salt Solution
HFO high frequency oscillation
HIF1α hypoxia-inducible factor 1-alpha
IF immunofl uorescence
iPS cell induced pluripotent stem cell
IRDS infant respiratory distress syndrome
LacZ beta-galactosidase fusion protein
LHLBR lung hypoplasia based on lung weight : body weight-ratio
LHR lung area to head circumference-ratio
LHW lung hypoplasia based on lung weight versus GA normal values
LRAT lecithin : retinol acyltransferase
Mes mesenchymal cells
MET mesenchymal-epithelial transition
MOF multi-organ failure
NGS normal goat serum
nitrofen 2,4-dichlorophenyl-p-nitrophenyl ether
NO nitric oxide
PBS phosphate buffered saline
PBST phosphate buffered saline with tween
PCNA proliferating cell nuclear antigen
PCR polymerase chain reaction
PDGFR platelet-derived growth factor receptor
PECAM platelet endothelial cell adhesion molecule
PGE2 prostaglandin E2
pH3 phosphohistone H3
PHD prolyl hydroxylase
PLUG ‘plug the lung until it grows’
PPF pleuroperitoneal fold
PPHN persistent pulmonary hypertension of the neonate
PROM premature rupture of membranes
pro-SFTPC pro-surfactant protein-C
RA retinoic acid
RALDH retinal dehydrogenase
RAR RA receptor
RARE RA response element
RBP retinol binding protein
RE retinyl ester
RXR retinoid X receptor
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Shh sonic hedgehog
STRA6 membrane receptor for retinol
T3 triiodothyronine
T4 thyroxine
TGFβ transforming growth factor beta
TH thyroid hormone
THT TH transporters
TOTAL-trial TO to accelerate lung growth-trial
TR thyroid hormone receptor
TRE thyroid response element
TRH thyrotropin-releasing hormone
TITF-1 thyroid transcription factor-1
TUNEL Terminal Deoxynucleotidyl Transferase dUTP Nick-End labeling
VEGF vascular endothelial growth factor
VHL Von Hippel-Lindau
Vim vimentin
VSD ventricular septal defect
Wt1 Wilm’s tumor 1
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- Transplant Rounds, Hospital for Sick Children [oral] 2010
- P.E.M. retreat, Hospital for Sick Children [poster] 2010
- Research Institute retreat, Hospital for Sick Children [poster] 2009
- Research Institute retreat, Hospital for Sick Children [poster] 2008
- American Thoracic Society (ATS) conference [poster discussion] 2008
- Research Institute retreat, Hospital for Sick Children [poster] 2007
- Summer Programme, Hospital for Sick Children [poster] 2007
Seminars & Workshops
- TULIPS PhD Clinician-Scientist Programme 2011 – 2012
- Lab Meetings Cell Biology 2010 – 2012
- CCHCSP Canadian Clinician-Scientist Programme 2008 – 2010
- Lab Meetings Lung Biology 2007 – 2010
PhD Portfolio
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- Seminars P.E.M. Programme 2007 – 2010
- Seminars University of Toronto 2007 – 2010
- ATS Course Stem Cells in Lung Development 2007
Master of Science in Clinical Epidemiology 2003 – 2005
Erasmus University Rotterdam, Rotterdam, the Netherlands
- Emerging Infectious Diseases
- Genetic Epidemiology
- Causal Modelling
- History of Epidemiologic Ideas
- Maternal and Child Health
- Advanced Topics in Clinical Trials
- Seminars in Clinical Research
- Introduction to Data-analysis
- Regression Analysis
- Survival Analysis
- Introduction to Clinical Research
- Intervention Research and Clinical Trials
- Diagnostic Research
- Advances in Prognostic Research
- Decision Making in Medicine
- Pharmaco-epidemiology
- Erasmus Course Study Design
- Principles of Research in Medicine and Epidemiology
- Clinical Decision Analysis
- Methods of Clinical Research
- Methods of Health Services Research
- Prevention Research
- Topics in Evidence Based Medicine
University Medical Center Utrecht, Utrecht, the Netherlands
- Advanced Diagnostic Research
Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA
- Intermediate Epidemiology
- Epidemiology in Evidence-Based Decisions
- Social Epidemiology
Cambridge University, Cambridge, United Kingdom
- Cardiovascular Module
- Diabetes Module
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